<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Corticosteroids for the treatment of Duchenne muscular dystrophy - Matthews, E - 2016 | Cochrane Library</title> <meta content="Corticosteroids for the treatment of Duchenne muscular dystrophy - Matthews, E - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003725.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Corticosteroids for the treatment of Duchenne muscular dystrophy - Matthews, E - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003725.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003725.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Corticosteroids for the treatment of Duchenne muscular dystrophy" name="citation_title"/> <meta content="Emma Matthews" name="citation_author"/> <meta content="National Hospital for Neurology and Neurosurgery" name="citation_author_institution"/> <meta content="emma.matthews@ucl.ac.uk" name="citation_author_email"/> <meta content="Ruth Brassington" name="citation_author"/> <meta content="National Hospital for Neurology and Neurosurgery" name="citation_author_institution"/> <meta content="Thierry Kuntzer" name="citation_author"/> <meta content="CHU Vaudois and University of Lausanne" name="citation_author_institution"/> <meta content="Fatima Jichi" name="citation_author"/> <meta content="Joint Research Office, University College London" name="citation_author_institution"/> <meta content="Adnan Y Manzur" name="citation_author"/> <meta content="Great Ormond Street Hospital for Children NHS Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD003725.pub4" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/05/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003725.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003725.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003725.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adrenal Cortex Hormones [administration &amp; dosage, adverse effects, *therapeutic use]; Glucocorticoids [administration &amp; dosage, adverse effects, *therapeutic use]; Muscle Strength [*drug effects]; Muscular Dystrophy, Duchenne [*drug therapy]; Prednisolone [therapeutic use]; Prednisone [therapeutic use]; Pregnenediones [administration &amp; dosage, therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic; Walking" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003725.pub4&amp;doi=10.1002/14651858.CD003725.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003725\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003725\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003725.pub4",title:"Corticosteroids for the treatment of Duchenne muscular dystrophy",firstPublishedDate:"May 5, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003725.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003725.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003725.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003725.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003725.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003725.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003725.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003725.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003725.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003725.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15684 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003725.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-sec-0196"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-sec-0156"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/appendices#CD003725-sec-0201"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/table_n/CD003725StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/table_n/CD003725StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Corticosteroids for the treatment of Duchenne muscular dystrophy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information#CD003725-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Emma Matthews</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information#CD003725-cr-0003">Ruth Brassington</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information#CD003725-cr-0004">Thierry Kuntzer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information#CD003725-cr-0005">Fatima Jichi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information#CD003725-cr-0006">Adnan Y Manzur</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information/en#CD003725-sec-0218">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 May 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003725.pub4">https://doi.org/10.1002/14651858.CD003725.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003725-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003725-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003725-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003725-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003725-abs-0001" lang="en"> <section id="CD003725-sec-0001"> <h3 class="title" id="CD003725-sec-0001">Background</h3> <p>Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy of childhood. Untreated, this incurable disease, which has an X‐linked recessive inheritance, is characterised by muscle wasting and loss of walking ability, leading to complete wheelchair dependence by 13 years of age. Prolongation of walking is a major aim of treatment. Evidence from randomised controlled trials (RCTs) indicates that corticosteroids significantly improve muscle strength and function in boys with DMD in the short term (six months), and strength at two years (two‐year data on function are very limited). Corticosteroids, now part of care recommendations for DMD, are largely in routine use, although questions remain over their ability to prolong walking, when to start treatment, longer‐term balance of benefits versus harms, and choice of corticosteroid or regimen. </p> <p>We have extended the scope of this updated review to include comparisons of different corticosteroids and dosing regimens. </p> </section> <section id="CD003725-sec-0002"> <h3 class="title" id="CD003725-sec-0002">Objectives</h3> <p>To assess the effects of corticosteroids on prolongation of walking ability, muscle strength, functional ability, and quality of life in DMD; to address the question of whether benefit is maintained over the longer term (more than two years); to assess adverse events; and to compare efficacy and adverse effects of different corticosteroid preparations and regimens. </p> </section> <section id="CD003725-sec-0003"> <h3 class="title" id="CD003725-sec-0003">Search methods</h3> <p>On 16 February 2016 we searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, EMBASE, CINAHL Plus, and LILACS. We wrote to authors of published studies and other experts. We checked references in identified trials, handsearched journal abstracts, and searched trials registries. </p> </section> <section id="CD003725-sec-0004"> <h3 class="title" id="CD003725-sec-0004">Selection criteria</h3> <p>We considered RCTs or quasi‐RCTs of corticosteroids (e.g. prednisone, prednisolone, and deflazacort) given for a minimum of three months to patients with a definite DMD diagnosis. We considered comparisons of different corticosteroids, regimens, and corticosteroids versus placebo. </p> </section> <section id="CD003725-sec-0005"> <h3 class="title" id="CD003725-sec-0005">Data collection and analysis</h3> <p>The review authors followed standard Cochrane methodology.</p> </section> <section id="CD003725-sec-0006"> <h3 class="title" id="CD003725-sec-0006">Main results</h3> <p>We identified 12 studies (667 participants) and two new ongoing studies for inclusion. Six RCTs were newly included at this update and important non‐randomised cohort studies have also been published. Some important studies remain unpublished and not all published studies provide complete outcome data. </p> <p>Primary outcome measure: one two‐year deflazacort RCT (n = 28) used prolongation of ambulation as an outcome measure but data were not adequate for drawing conclusions. </p> <p>Secondary outcome measures: meta‐analyses showed that corticosteroids (0.75 mg/kg/day prednisone or prednisolone) improved muscle strength and function versus placebo over six months (moderate quality evidence from up to four RCTs). Evidence from single trials showed 0.75 mg/kg/day superior to 0.3 mg/kg/day on most strength and function measures, with little evidence of further benefit at 1.5 mg/kg/day. Improvements were seen in time taken to rise from the floor (Gowers' time), timed walk, four‐stair climbing time, ability to lift weights, leg function grade, and forced vital capacity. One new RCT (n = 66), reported better strength, function and quality of life with daily 0.75 mg/kg/day prednisone at 12 months. One RCT (n = 28) showed that deflazacort stabilised muscle strength versus placebo at two years, but timed function test results were too imprecise for conclusions to be drawn. </p> <p>One double‐blind RCT (n = 64), largely at low risk of bias, compared daily prednisone (0.75 mg/kg/day) with weekend‐only prednisone (5 mg/kg/weekend day), finding no overall difference in muscle strength and function over 12 months (moderate to low quality evidence). Two small RCTs (n = 52) compared daily prednisone 0.75 mg/kg/day with daily deflazacort 0.9 mg/kg/day, but study methods limited our ability to compare muscle strength or function. </p> <p>Adverse effects: excessive weight gain, behavioural abnormalities, cushingoid appearance, and excessive hair growth were all previously shown to be more common with corticosteroids than placebo; we assessed the quality of evidence (for behavioural changes and weight gain) as moderate. Hair growth and cushingoid features were more frequent at 0.75 mg/kg/day than 0.3 mg/kg/day prednisone. Comparing daily versus weekend‐only prednisone, both groups gained weight with no clear difference in body mass index (BMI) or in behavioural changes (low quality evidence for both outcomes, one study); the weekend‐only group had a greater linear increase in height. Very low quality evidence suggested less weight gain with deflazacort than with prednisone at 12 months, and no difference in behavioural abnormalities. Data are insufficient to assess the risk of fractures or cataracts for any comparison. </p> <p>Non‐randomised studies support RCT evidence in showing improved functional benefit from corticosteroids. These studies suggest sustained benefit for up to 66 months. Adverse effects were common, although generally manageable. According to a large comparative longitudinal study of daily or intermittent (10 days on, 10 days off) corticosteroid for a mean period of four years, a daily regimen prolongs ambulation and improves functional scores over the age of seven, but with a greater frequency of side effects than an intermittent regimen. </p> </section> <section id="CD003725-sec-0007"> <h3 class="title" id="CD003725-sec-0007">Authors' conclusions</h3> <p>Moderate quality evidence from RCTs indicates that corticosteroid therapy in DMD improves muscle strength and function in the short term (twelve months), and strength up to two years. On the basis of the evidence available for strength and function outcomes, our confidence in the effect estimate for the efficacy of a 0.75 mg/kg/day dose of prednisone or above is fairly secure. There is no evidence other than from non‐randomised trials to establish the effect of corticosteroids on prolongation of walking. In the short term, adverse effects were significantly more common with corticosteroids than placebo, but not clinically severe. A weekend‐only prednisone regimen is as effective as daily prednisone in the short term (12 months), according to low to moderate quality evidence from a single trial, with no clear difference in BMI (low quality evidence). Very low quality evidence indicates that deflazacort causes less weight gain than prednisone after a year's treatment. We cannot evaluate long‐term benefits and hazards of corticosteroid treatment or intermittent regimens from published RCTs. Non‐randomised studies support the conclusions of functional benefits, but also identify clinically significant adverse effects of long‐term treatment, and a possible divergence of efficacy in daily and weekend‐only regimens in the longer term. These benefits and adverse effects have implications for future research and clinical practice. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003725-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003725-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003725-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003725-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003725-abs-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003725-abs-0008">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003725-abs-0003" lang="en"> <h3>Corticosteroid therapy for Duchenne muscular dystrophy</h3> <p><b>Review question</b> </p> <p>Is there new evidence for benefit from corticosteroids for prolongation of walking, and improving muscle strength and functional abilities in Duchenne muscular dystrophy (DMD), particularly over the long term (more than two years)? Are different corticosteroids, or different regimens equally effective, with similar side effect profiles? </p> <p><b>Background</b> </p> <p>DMD is an incurable disease beginning in childhood that almost exclusively affects boys. Muscle wasting and loss of walking lead to wheelchair dependence and early death. Randomised controlled trials (RCTs) have shown that corticosteroids improve muscle strength and function for up to six months and strength up to two years (evidence on function at two years is limited). Data from other study types suggest that corticosteroids produce better function over a five‐year period in many patients. Overall, long‐term benefit remains unclear, and has to be weighed against long‐term side effects. It is also unclear whether different corticosteroids differ greatly in side effects. Earlier versions of this review found insufficient evidence to determine whether an intermittent regimen is as effective as a daily regime, or produces fewer side effects. </p> <p><b>Study characteristics</b> </p> <p>We found 12 studies of corticosteroid treatment in DMD, involving a total of 667 randomised boys; two other studies are ongoing. Among the 12 completed studies, the treatments were: a corticosteroid versus inactive medicine (placebo) (in nine trials); daily versus weekend‐only prednisone (in one trial); and deflazacort versus prednisone (in three trials). Some studies included more than one comparison; some were not fully reported or provided results that could not be analysed. </p> <p><b>Key results and quality of the evidence</b> </p> <p>One trial, a two‐year study comparing a corticosteroid (deflazacort) with placebo, assessed the effects of corticosteroids on the ability to continue walking, but the data were not suitable for analysis. Most studies did not report ability to continue walking. </p> <p>At the usual 0.75 mg/kg/day dose, corticosteroids improved muscle strength and function over six months compared to placebo. These results are based on combined data (up to 152 participants) from four trials, which provided moderate quality evidence. Improvements were seen in timed tests (eg. timed walk or run, time to stand, stair climb), ability to lift weights, a leg function grade, and a measure of the strength of muscles used in breathing. Evidence from single trials showed 0.75 mg/kg/day prednisone to be superior to 0.3 mg/kg/day on most strength and function tests, with little evidence of greater benefit at 1.5 mg/kg/day. Changes in appearance and hair growth were more common at 0.75 mg/kg/day than 0.3 mg/kg/day. </p> <p>One RCT (n = 66) also reported better strength, function and quality of life at 12 months with daily 0.75 mg/kg/day prednisone. The two‐year RCT, which had 28 participants, showed that deflazacort stabilised muscle strength for up to two years compared to placebo. This study did not show benefit on timed tests at two years; however, these results are imprecise and at high risk of bias, with less than half the original participants contributing data. </p> <p>One trial found that changes in muscle strength and function were similar with daily and weekend‐only prednisone regimens over a 12‐month period (low to moderate quality evidence). </p> <p>Two small RCTs compared daily prednisone 0.75 mg/kg/day with daily deflazacort 0.9 mg/kg/day, but trial methods did not allow comparisons of muscle strength or function. </p> <p>Previous versions of this review have found adverse events such as excessive weight gain, abnormal behaviour, changes in appearance, and abnormal hair growth to be more common with corticosteroids than with placebo. We assessed the quality of evidence for abnormal behaviour and weight gain for this review and found it to be moderate. The newer study of daily versus weekend‐only prednisone showed that both groups gained weight. The body mass index (BMI; a measure of weight for height) did not show any clear difference between the regimens (low quality evidence). The weekend‐only group had a greater increase in height. According to very low quality evidence from two studies, deflazacort appeared to cause less weight gain at one year than prednisone, and no significant difference in numbers with behaviour change. Data were insufficient to assess the risk of fractures or cataracts. </p> <p>The evidence is up to date to February 2016.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003725-sec-0196" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003725-sec-0196">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003725-sec-0298">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003725-sec-0196"></div> <h3 class="title" id="CD003725-sec-0197">Implications for practice</h3> <section id="CD003725-sec-0197"> <p>Randomised controlled trials (RCTs) provide moderate quality evidence that treatment with corticosteroids in Duchenne muscular dystrophy (DMD) compared with placebo improves muscle strength and function, including respiratory muscle strength and function, for six months. There is evidence of continuing benefit on muscle strength and function at one year. On the basis of the evidence available, our confidence in the effect estimate for the efficacy of a 0.75 mg/kg/day dose of prednisolone or above is fairly secure. Little RCT evidence is available on longer‐term effects of corticosteroids versus placebo; one small longer‐term RCT found an improvement in muscle strength at two years with deflazacort, with imprecise results on function at two years. Not enough data were available to adequately compare the efficacy of prednisone and deflazacort, although there is very low quality data favouring deflazacort for less weight gain. In the short term (12 months), a weekend‐only prednisolone regimen is as effective as daily prednisolone according to low to moderate quality evidence from a single trial. Low quality evidence did not show a difference between the regimens on change in body mass index (BMI). A greater increase in linear height occurred in the weekend‐only regimen, but no appreciable difference in other side effects. The long‐term benefits and harms of daily corticosteroids or daily versus intermittent regimens are not clear. Non‐randomised studies suggest that clinically significant prolongation of time to loss of ambulation is possible with daily corticosteroids, though potential harms, including weight gain, behavioural changes, vertebral fractures, and cataracts, are significant. Non‐randomised studies also suggest there may be a divergence in efficacy between daily and intermittent prednisolone regimens beyond the age of seven years, with greater side effects from daily regimens in the longer term. </p> </section> <h3 class="title" id="CD003725-sec-0198">Implications for research</h3> <section id="CD003725-sec-0198"> <p>Many issues, including the ideal age or functional stage for initiation of treatment, the optimal corticosteroid type, regimen and dose, strategies for prevention of osteoporosis, and the age for discontinuation of corticosteroid treatment still need to be clarified with RCTs. This will require national and international collaboration, standardised and comparable protocols of assessment, timely publication of studies and the facility of sharing anonymised individual patient data. While previous studies have focused mainly on muscle strength, walking, and motor aspects, studies are now beginning to address respiratory, cardiac, and quality of life issues; this review or separate Cochrane reviews will examine these outcomes in future. The Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society emphasised the need for studies to be long term to evaluate the effect of corticosteroids on ambulation, respiratory function, cardiac function, and quality of life. There is a need to identify and evaluate strategies to prevent the predictable adverse effects of long‐term corticosteroid treatment, particularly excessive weight gain, osteoporosis, and growth retardation. The incorporation of patient and caregiver evaluations of the beneficial and adverse effects of treatment, as additional outcome measures, should be considered. The impact of corticosteroid therapy on quality of life of the patient and the family, in relation both to benefits and adverse effects, should also be evaluated. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003725-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003725-sec-0022"></div> <div class="table" id="CD003725-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Corticosteroids versus placebo for Duchenne muscular dystrophy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Corticosteroids versus placebo for Duchenne muscular dystrophy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with Duchenne muscular dystrophy<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> corticosteroids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk or score/value with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk or score/value with corticosteroids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolongation of time to loss of ambulation ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An outcome measure in one 2‐year trial (n = 28). The trial reported a 13‐month prolongation of walking with deflazacort among boys who became wheelchair‐dependent, but statistical analysis was flawed as it did not take account of participants still walking at study end </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in average muscle score: prednisone ‐ daily dose regimen (0.75 mg/kg/day)</p> <p>Assessed with: MRC scale (higher indicates stronger)</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in average muscle score was 4.73 units<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in average muscle score in the intervention group was 0.52 units more (0.33 more to 0.71 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (3 RCTs)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The average muscle score (MRC scale) also showed a clear difference in favour of corticosteroid at 0.3 mg/kg/day and 1.5 mg/kg/day. For other strength outcomes see text </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nine‐metre walking/running time: prednisone ‐ daily dose regimen (0.75 mg/kg/day)</p> <p>Assessed with: seconds</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean nine‐metre walking/running time was 9.1 seconds<sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean nine‐metre walking/running time in the intervention group was 2.73 seconds quicker (3.97 quicker to 1.50 quicker) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> <p>(3 RCTs)<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For other functional outcomes and corticosteroid doses, see text.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐stair climbing time: prednisone ‐ daily dose regimen (0.75 mg/kg/day)</p> <p>Assessed with: seconds</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean 4‐stair climbing time was 7.40 seconds</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean 4‐stair climbing time in the intervention group was 3.09 seconds quicker (4.33 quicker to 1.85 quicker) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> <p>(4 RCTs)<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For other functional outcomes and corticosteroid doses, see text</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean % weight gain: prednisone ‐ daily dose regimen (0.75 mg/kg/day)<br/> Follow‐up: 6 months<sup>8</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % weight gain was 6.95 %</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % weight gain in the intervention group was 9.27% more (6.87% more to 11.68% more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (2 RCTs)<sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For other prednisone doses, see text. 1.09% more weight gain reported with deflazacort (2 mg/kg alternate days) than with placebo (mean gain 25.5%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavioural changes ‐ prednisone (0.75 mg/kg/day)</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>695 per 1000<br/> (470 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.39<br/> (0.94 to 2.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For other doses, see text</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractures</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 participant receiving deflazacort had a pathological fracture of tibia. An arm fracture occurred in the placebo group of a prednisone trial and a traumatic fracture of femur occurred in the placebo phase of a cross‐over prednisone trial </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies measured bone densitometry. A 6‐month trial is too short to adequately assess long‐term side effects. Other trials did not comment on the occurrence of fractures </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MRC</b> : Medical Research Council; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Mean of mean control group values.<br/> <sup>2</sup>Two additional trials (6 and 12 months' duration), which could not be included in the meta‐analysis, also demonstrated improvements in muscle strength over placebo with daily or intermittent prednisone 0.75 mg/kg/day ‐ see text for details (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>).<br/> <sup>3</sup>Single downgrading for unclear risk of allocation bias and possible publication bias.<br/> <sup>4</sup>Mean of the mean control group values at 6 months from <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> and <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> (data are not provided in <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> report).<br/> <sup>5</sup>Two additional trials (6 and 12 months' duration), which could not be included in the meta‐analysis, also demonstrated improvements in timed walk over placebo with daily or intermittent prednisone 0.75 mg/kg/day ‐ see text for details (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>).<br/> <sup>6</sup>An additional 6‐month trial, which could not be included in the meta‐analysis, also demonstrated improvements in 4‐stair climb over placebo with intermittent prednisone (0.75 mg/kg/day given for the first 10 days of every month for six months) ‐ see text for details (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>).<br/> <sup>7</sup>Two additional trials (6 and 12 months' duration), which could not be included in the meta‐analysis, monitored weight during daily or intermittent prednisone 0.75 mg/kg/day; no clear difference was present between groups at six months (intermittent dosing) or a year; however these results were imprecise ‐ see text for details (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>).<br/> <sup>8</sup>For details of other dosages and the deflazacort versus placebo comparison see the review text. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003725-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Weekend‐only versus daily prednisone for Duchenne muscular dystrophy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Weekend‐only versus daily prednisone for Duchenne muscular dystrophy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with Duchenne muscular dystrophy<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> weekend prednisone<br/> <b>Comparison:</b> daily prednisone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Score/value with daily prednisone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Score/value with weekend‐only prednisone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolongation of time to loss of ambulation ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not an outcome in the single included study for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in muscle strength ‐ QMT arm score (lb)</p> <p>follow‐up: 12 months</p> <p>(higher indicates stronger)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in QMT arm score in the control group was 1.3 lb</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in QMT arm score in the intervention group was 0.6 lb lower (1.67 lower to 0.47 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Moderate</b> </p> <p><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in muscle strength ‐ QMT leg score (lb)</p> <p>follow‐up: 12 months</p> <p>(higher indicates stronger)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in QMT leg score in the control group was 3.4 lb</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in QMT leg score in the intervention group was 0.1 lb more (1.75 lower to 1.95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in muscle strength ‐ MMT score</p> <p>Follow‐up: 12 months</p> <p>(higher indicates stronger)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in MMT score in the control group was ‐0.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in MMT score in the intervention group was 4.6 higher (8.07 lower to 17.27 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in 10‐metre walking time</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 10‐metre walking time in the control group was 0.1 seconds</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 10‐metre walking time in the intervention group was 0 (0.21 quicker to 0.21 slower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Moderate<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in 4‐stair climbing time</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 4‐stair climbing time in the control group was ‐0.06 seconds</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 4‐stair climbing time in the intervention group was 0 (0.22 quicker to 0.22 slower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Moderate<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) at end of study </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI (kg/m<sup>2</sup>) in the control group was 19.6 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI kg/m<sup>2</sup> in the intervention group was 1.8 lower (3.74 lower to 0.14 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean % weight gain not reported. Mean difference in weight (kg) did not show a clear difference at 12 months, being 2.5 kg lower; 7.54 lower to 2.54 higher with weekend‐only dosing </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavioural changes<br/> assessed with Child Behaviour Checklist total problems (higher scores indicate more severe behavioural changes) </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean behavioural change score in the control group was 48</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean behavioural change score in the intervention group was 1 higher (4.34 lower to 6.34 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractures ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No fractures reported. Change in lumbar spine Z scores favoured weekend‐only dosing (increase in the weekend group +0.26, compared with ‐0.30 decline with daily prednisolone </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BMI</b> : body mass index; <b>CI:</b> confidence interval; <b>MMT</b> : manual muscle testing; <b>QMT</b> : quantitative muscle testing; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Trial authors defined equivalence limits (limits within which the regimens can be considered of equivalent efficacy) of ± 2 lb for QMT. We downgraded once as although serious imprecision is present, the CIs fall within the equivalence limits. </p> <p><sup>2</sup>We downgraded the quality of evidence twice for serious imprecision due to small sample size; trial authors defined equivalence limits (limits within which the regimens can be considered of equivalent efficacy) of ± 17 points and the CIs allow for the possibility of non‐equivalence. </p> <p><sup>3</sup>Trial authors defined equivalence limits (limits within which the regimens can be considered of equivalent efficacy) of ± 0.4 seconds for timed tests. We downgraded once; although serious imprecision is present, the CIs fall within the equivalence limits. </p> <p><sup>4</sup> We downgraded the evidence for very serious imprecision (due to small sample sizes, plus the CI includes appreciable differences in favour of either intervention). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003725-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Deflazacort versus prednisone for Duchenne muscular dystrophy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deflazacort versus prednisone for Duchenne muscular dystrophy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with Duchenne muscular dystrophy<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> deflazacort<br/> <b>Comparison:</b> prednisone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk or score/value with prednisone or prednisolone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk or score/value with deflazacort</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolongation of time to loss of ambulation ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies investigating this comparison assessed prolongation of time to loss of ambulation </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Muscle strength ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study measured summed MRC scores from 4 muscles at 3, 6, 9, and 12 months, but presented data graphically without measures of variability </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in 10‐metre walking time</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies (n = 43) reported composite scores of timed function tests, but did not report the scores for each test separately </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in 4‐stair climbing time</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies (n = 43) reported composite scores of timed function tests, but did not report the scores for each test separately </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain (%)</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean weight gain (%) was 21.48%</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean weight gain (%) in the intervention group was 9.52% lower (14.91 lower to 4.12 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavioural changes</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>445 per 1000 (160 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07 (0.53 to 2.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractures</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 traumatic fracture occurred after 4 months' deflazacort treatment in one study (n = 26). No other fractures reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MRC</b> : Medical Research Council; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence twice for a high risk of bias in most domains.<br/> <sup>2</sup>We downgraded the quality of evidence once for possible publication bias ‐ a large study remains unpublished (<a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>).<br/> <sup>3</sup>Analysis involved some statistical assumptions in calculating SD.<br/> <sup>4</sup>CIs include the possibility of both a large effect and a clinically unimportant effect (i.e. imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003725-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003725-sec-0023">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003725-sec-0228">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD003725-sec-0023"></div> <section id="CD003725-sec-0024"> <h3 class="title" id="CD003725-sec-0024">Description of the condition</h3> <p>Duchenne muscular dystrophy (DMD), which has an incidence of 1 in 3500 to 1 in 5000 male live births (<a href="./references#CD003725-bbs2-0101" title="EmeryAEH . Population frequencies of inherited neuromuscular diseases: a world survey. Neuromuscular Disorders1991;1(1):19‐29. ">Emery 1991</a>; <a href="./references#CD003725-bbs2-0123" title="MendellJR , ShillingC , LeslieND , FlaniganKM , al‐DahhakR , Gastier‐FosterJ , et al. Evidence‐based path to newborn screening for Duchenne muscular dystrophy. Annals of Neurology2012;71(3):304–13. ">Mendell 2012</a>), is the most common muscular dystrophy of childhood. </p> <p>Boys with DMD present in the first five years of life with abnormal gait, inability to run, and difficulty in rising from the floor. Untreated, the combination of muscle weakness and contractures of the tendo Achilles and iliotibial bands leads to loss of independent walking at a mean age of 9.5 years (range 7 to 13 years). Before corticosteroids were routinely used, once these boys become constant wheelchair users, over 50% developed scoliosis. Subclinical cardiomyopathy is very common, but this becomes symptomatic only in about 20% of patients, often in the second decade of life (<a href="./references#CD003725-bbs2-0105" title="FrankelK , RosserR . The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Human Pathology1976;7(4):375‐86. ">Frankel 1976</a>; <a href="./references#CD003725-bbs2-0114" title="IshikawaY , BachJR , IshikawaY , MinamiR . A management trial for Duchenne cardiomyopathy. American Journal of Physical Medicine and Rehabilitation1995;74(5):345‐50. ">Ishikawa 1995</a>; <a href="./references#CD003725-bbs2-0115" title="IshikawaY , BachJR , MinamiR . Cardioprotection for Duchenne's muscular dystrophy. American Heart Journal1999;137(5):895‐902. ">Ishikawa 1999</a>; <a href="./references#CD003725-bbs2-0130" title="MuntoniF . Cardiomyopathy in muscular dystrophies. Current Opinion in Neurology2003;16(5):577‐83. ">Muntoni 2003</a>). The late teen years are marked by progression of respiratory muscle weakness, nocturnal hypoventilation, respiratory failure, and death in late teens or twenties in untreated patients. No curative treatment for DMD is known, but the quality of life and comfort of the patient can be improved by symptomatic physiotherapeutic and medical treatments (<a href="./references#CD003725-bbs2-0084" title="BushbyK , MuntoniF , BourkeJP . 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th‐9th June 2002, Naarden, the Netherlands. Neuromuscular Disorders2003;13(2):166‐72. ">Bushby 2003</a>; <a href="./references#CD003725-bbs2-0093" title="DubowitzV . Muscle Disorders in Childhood. 2nd Edition. London: Saunders, 1995. ">Dubowitz 1995</a>; <a href="./references#CD003725-bbs2-0103" title="EmeryAEH , MuntoniF . Duchenne muscular dystrophy. Oxford Monographs on Medical Genetics. 3rd Edition. Oxford: Oxford Medical Publications, 2003. ">Emery 2003</a>; <a href="./references#CD003725-bbs2-0111" title="HeckmattJZ , RodilloE , DubowitzV . Management of children: pharmacological and physical. British Medical Bulletin1989;45(3):788‐801. ">Heckmatt 1989</a>). Provision of respiratory support, with ventilator use at the appropriate stage, can prolong survival into the fourth decade (<a href="./references#CD003725-bbs2-0098" title="EagleM , BaudouinSV , ChandlerC , GiddingsDR , BullockR , BushbyK . Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscular Disorders2002;12(10):926‐9. ">Eagle 2002</a>; <a href="./references#CD003725-bbs2-0099" title="EagleM , BourkeJ , BullockR , GibsonM , MehtaJ , GiddingsD , et al. Managing Duchenne muscular dystrophy ‐ the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscular Disorders2007;17(6):470‐5. ">Eagle 2007</a>; <a href="./references#CD003725-bbs2-0109" title="Gomez‐MerinoE , BachJR . Duchenne muscular dystrophy: prolongation of life by noninvasive ventilation and mechanically assisted coughing. American Journal of Physical and Medical Rehabilitation2002;81(6):411‐5. ">Gomez‐Merino 2002</a>; <a href="./references#CD003725-bbs2-0117" title="JeppesenJ , GreenA , SteffensenBF , RahbekJ . The Duchenne muscular dystrophy population in Denmark, 1977‐2001: prevalence, incidence and survival in relation to the introduction of ventilator use. Neuromuscular Disorders2003;13(10):804‐12. ">Jeppesen 2003</a>). </p> <p>The DMD gene locus is at Xp21 and codes for a protein named dystrophin (<a href="./references#CD003725-bbs2-0113" title="HoffmanEP , BrownRHJr , KunkelLM . Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell1987;51(6):919‐28. ">Hoffman 1987</a>). Depending on the type of mutation in the dystrophin gene, there may be a severe reduction or absence of dystrophin in muscle, resulting in DMD (<a href="./references#CD003725-bbs2-0119" title="KoenigM , BeggsAH , MoyerM , ScherpfS , HeindrichK , BetteckenT , et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. American Journal of Human Genetics1989;45(4):498‐506. ">Koenig 1989</a>). Dystrophin localises at the cytoplasmic side of the sarcolemma and binds to a glycoprotein complex (<a href="./references#CD003725-bbs2-0120" title="MatsumuraK , OhlendieckK , IonasescuVV , TomeFM , NonakaI , BurghesAH , et al. The role of the dystrophin‐glycoprotein complex in the molecular pathogenesis of muscular dystrophies. Neuromuscular Disorders1993;3(5):533‐5. ">Matsumura 1993</a>; <a href="./references#CD003725-bbs2-0121" title="MatsumuraK , CampbellKP . Dystrophin‐glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Muscle &amp; Nerve1994;17(1):2‐15. ">Matsumura 1994</a>; <a href="./references#CD003725-bbs2-0122" title="MendellJR , SahenkZ , PriorTW . The childhood muscular dystrophies: diseases sharing a common pathogenesis of membrane instability. Journal of Child Neurology1995;10(2):150‐9. ">Mendell 1995</a>). This dystrophin‐glycoprotein complex provides a link between the cytoskeleton of the muscle fibre and the extracellular matrix. Lack of dystrophin compromises this link and is postulated to lead to muscle fibre degeneration (<a href="./references#CD003725-bbs2-0090" title="DeconinckN , DanB . Pathophysiology of Duchenne muscular dystrophy: Current hypotheses. Pediatric Neurology2007;36(1):1‐7. ">Deconinck 2007</a>; <a href="./references#CD003725-bbs2-0136" title="PetrofBJ , ShragerJB , StedmanHH , KellyAM , SweeneyHL . Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proceedings of the National Academy of Sciences, USA1993;90(8):3710‐4. ">Petrof 1993</a>; <a href="./references#CD003725-bbs2-0137" title="PetrofBJ . The molecular basis of activity‐induced muscle injury in Duchenne muscular dystrophy. Molecular Cell Biochemistry1998;179(1‐2):111‐23. [MEDLINE: 98202355] ">Petrof 1998</a>). </p> <p>Although DMD is not primarily an immune‐mediated disease, some evidence raises the possibility that humoral and cellular immune responses contribute to the pathological processes. This includes invasion of necrotic muscle fibres by macrophages and cytotoxic T‐cells (<a href="./references#CD003725-bbs2-0075" title="ArahataK , EngelAG . Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Annals of Neurology1984;16(2):193‐208. ">Arahata 1984</a>), complement activation with deposition of membrane attack complexes on necrotic fibres, and expression of HLA class I antigens on the dystrophic muscle fibres (<a href="./references#CD003725-bbs2-0104" title="EngelAG , BieseckerG . Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Annals of Neurology1982;12(3):289‐96. ">Engel 1982</a>), making them susceptible to T‐cell mediated damage. Initial empirical studies of prednisone in DMD (e.g. <a href="./references#CD003725-bbs2-0031" title="DrachmanDB , ToykaKV , MyerE . Prednisone in Duchenne muscular dystrophy. Lancet1974;2(7894):1409‐12. ">Drachman 1974</a>) and the above histopathological observations led to trials of immunomodulation therapy with corticosteroids (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>; <a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a>; <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>; <a href="./references#CD003725-bbs2-0032" title="DubowitzV , KinaliM , MainM , MercuriE , MuntoniF . Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low‐dosage prednisolone therapy. European Journal of Paediatric Neurology2002;6(3):153‐9. ">Dubowitz 2002</a>; <a href="./references#CD003725-bbs2-0034" title="FenichelGM , MendellJR , MoxleyRT , GriggsRC , BrookeMH , MillerJP . A comparison of daily and alternate‐day prednisone therapy in the treatment of Duchenne muscular dystrophy. Archives of Neurology1991;48(6):575‐9. ">Fenichel 1991a</a>; <a href="./references#CD003725-bbs2-0035" title="FenichelGM , FlorenceJM , PestronkA , MendellJR , MoxleyRT3rd , GriggsRC , et al. Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology1991;41(12):1874‐7. ">Fenichel 1991b</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0037" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology1993;43(3 Pt 1):520‐7. ">Griggs 1993</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0049" title="MesaLE , DubrovskyAL , CorderiJ , MarcoP , FloresD . Steroids in Duchenne muscular dystrophy ‐ deflazacort trial. Neuromuscular Disorders1991;1(4):261‐6. ">Mesa 1991</a>; <a href="./references#CD003725-bbs2-0056" title="SansomeA , RoystonP , DubowitzV . Steroids in Duchenne muscular dystrophy; pilot study of a new low‐dosage schedule. Neuromuscular Disorders1993;3(5‐6):567‐9. ">Sansome 1993</a>), azathioprine (<a href="./references#CD003725-bbs2-0037" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology1993;43(3 Pt 1):520‐7. ">Griggs 1993</a>), and ciclosporin (<a href="./references#CD003725-bbs2-0148" title="SharmaKR , MynhierMA , MillerRG . Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology1993;43(3):527‐32. ">Sharma 1993</a>). Complimentary DNA (cDNA) microarray studies on the mdx mouse demonstrated a differential gene expression in affected and non‐affected muscles (<a href="./references#CD003725-bbs2-0139" title="PorterJD , MerriamAP , LeahyP , GongB , KhannaS . Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin‐deficient (mdx) mice. Human Molecular Genetics2003;12(15):1813‐21. ">Porter 2003</a>), and a "skeletal muscle molecular signature" dominated by chronic inflammatory response (<a href="./references#CD003725-bbs2-0138" title="PorterJD , KhannaS , KaminskiHJ , RaoJS , MerriamAP , RichmondsCR , et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin‐deficient mdx mice. Human Molecular Genetics2002;11(3):263‐72. ">Porter 2002</a>). A study of cDNA microarray analysis of skeletal muscle from DMD patients reported a variable gene expression pattern that correlated with the severity of dystrophic changes on histological examination (<a href="./references#CD003725-bbs2-0132" title="NoguchiS , TsukaharaT , FujitaM , KurokawaR , TachikawaM , TodaT , et al. cDNA microarray analysis of individual Duchenne muscular dystrophy patients. Human Molecular Genetics2003;12(6):595‐600. ">Noguchi 2003</a>). <a href="./references#CD003725-bbs2-0135" title="PescatoriM , BroccoliniA , MinettiC , BertiniE , BrunoC , D'amicoA . Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. The FASEB Journal2007;21(4):1210‐26. ">Pescatori 2007</a> undertook gene expression profiling of skeletal muscle from DMD patients and reported induction of genes involved in the inflammatory response, extracellular matrix remodeling and muscle regeneration, and reduced transcription of genes involved in energy metabolism. <a href="./references#CD003725-bbs2-0097" title="DudleyRWR , DanialouG , GovindarajuK , LandsL , EidelmanDE , PetrovBJ . Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stresses. American Journal of Pathology2006;168(4):1276‐87. ">Dudley 2006</a> investigated the interactive effect of mechanical and oxidative stresses in pathogenesis of muscle fibre damage in dystrophin‐deficient mdx mice and normal wild‐type control mice. Their experiments suggested that sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative stresses. Taken together, these quoted studies provide further evidence that the absence of dystrophin, though necessary, is not sufficient to cause the pattern of fibrosis, inflammation, and muscle degeneration and regeneration, characteristic of DMD. </p> </section> <section id="CD003725-sec-0025"> <h3 class="title" id="CD003725-sec-0025">Description of the intervention</h3> <p>Over the last three decades, many studies of the use of prednisone, prednisolone and deflazacort in DMD have been published. In the neuromuscular literature, authors often described these medications as "steroids" (e.g. <a href="./references#CD003725-bbs2-0096" title="DubrovskyAL , AngeliniC , BonifatiDM , PegoraroE , MesaL . Steroids in muscular dystrophy: Where do we stand?. Neuromuscular Disorders1998;8(6):380‐4. ">Dubrovsky 1998</a>) or "corticosteroids" (e.g. <a href="./references#CD003725-bbs2-0085" title="BushbyK , MuntoniF , Urtizberea , HughesR , GriggsR . Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2‐4 April 2004, Naarden, The Netherlands. Neuromuscular Disorders2004;14(8‐9):526‐34. ">Bushby 2004</a> and <a href="./references#CD003725-bbs2-0127" title="MoxleyRT3rd , AshwalS , PandyaS , ConnollyA , FlorenceJ , MathewsK , et al. Practice Parameter: corticosteroid treatment of Duchenne dystrophy, report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology2005;64(1):13‐20. ">Moxley 2005</a>). Corticosteroids (the steroids produced by the adrenal cortex) may have a predominant glucocorticoid or mineralocorticoid activity. The relevant corticosteroids in neuromuscular practice (prednisone, prednisolone, and deflazacort) have a predominant glucocorticoid action, and their dose equivalence, toxicity and possibly, at least one mode of action relates to this glucocorticoid activity. </p> <p>The commonly used corticosteroids in published trials are prednisone, prednisolone, and deflazacort. The corticosteroid dose used in various trials for prednisolone or its equivalent ranges from 0.3 mg/kg/day to 1.5 mg/kg/day, given daily or on alternate days, or in an intermittent (10 days on, 10 or 20 days off) regimen (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0032" title="DubowitzV , KinaliM , MainM , MercuriE , MuntoniF . Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low‐dosage prednisolone therapy. European Journal of Paediatric Neurology2002;6(3):153‐9. ">Dubowitz 2002</a>). </p> </section> <section id="CD003725-sec-0026"> <h3 class="title" id="CD003725-sec-0026">How the intervention might work</h3> <p>The precise mechanism by which corticosteroids increase strength in DMD is not known, but their potential beneficial effects include inhibition of muscle proteolysis (<a href="./references#CD003725-bbs2-0100" title="EliaM , CarterA , BaconS , WinearlsCG , SmithR . Clinical usefulness of urinary 3‐methylhistidine excretion in indicating muscle protein breakdown. British Medical Journal (Clinical Research Ed)1981;282(6261):351‐4. ">Elia 1981</a>; <a href="./references#CD003725-bbs2-0144" title="RifaiZ , WelleE , MoxleyRT3rd , LorensonM , GriggsRC . Effect of prednisone on protein metabolism in Duchenne muscular dystrophy. American Journal of Physiology1995;268(1 pt 1):E67‐E74. ">Rifai 1995</a>), stimulation of myoblast proliferation (<a href="./references#CD003725-bbs2-0077" title="BalE , SanwallW . A synergistic effect of glucocorticosteroids and insulin on the differentiation of myoblasts. Journal of Cell Physiology1980;102:27‐36. ">Bal 1980</a>), stabilisation of muscle fibre membranes (<a href="./references#CD003725-bbs2-0116" title="JacobsSC , BootsmaAL , WillemsPW , BarPR , WokkeJH . Prednisolone can protect against exercise‐induced muscle damage. Journal of Neurology1996;243(5):410‐6. ">Jacobs 1996</a>), increase in myogenic repair (<a href="./references#CD003725-bbs2-0074" title="AndersonJE , WeberM , VargusC . Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy. Cell Transplantation2000;9(4):551‐64. ">Anderson 2000</a>), anti‐inflammatory or immunosuppressive effect (<a href="./references#CD003725-bbs2-0118" title="KisselJT , BurrowK , RammohanKW , MendellJR . Mononuclear cell analysis of muscle biopsies in prednisone‐treated and untreated Duchenne muscular dystrophy. CIDD Study Group. Neurology1991;41(5):667‐72. ">Kissel 1991</a>), reduction of cytosolic calcium concentrations (<a href="./references#CD003725-bbs2-0124" title="MetzingerL , PassaquinAC , LeijendekkerWJ , PoindronP , RueggUT . Modulation by prednisolone of calcium handling in skeletal muscle cells. British Journal of Pharmacology1995;116(7):2811‐6. ">Metzinger 1995</a>; <a href="./references#CD003725-bbs2-0134" title="PassaquinAC , LhoteP , RueggUT . Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. British Journal of Pharmacology1998;124(8):1751‐9. ">Passaquin 1998</a>; <a href="./references#CD003725-bbs2-0150" title="VandebrouckC , ImbertN , DupontG , CognardC , RaymondG . The effect of methylprednisone on intracellular calcium of normal and dystrophic human skeletal muscle cells. Neuroscience Letters1999;269(2):110‐4. ">Vandebrouck 1999</a>), up‐regulation of utrophin (<a href="./references#CD003725-bbs2-0133" title="PasquiniF , GuerinC , BlakeD , DaviesK , KarpatiG , HollandP . The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells. Neuromuscular Disorders1995;5(2):105‐14. ">Pasquini 1995</a>), and differential regulation of genes in muscle fibres (<a href="./references#CD003725-bbs2-0129" title="MuntoniF , FisherI , MorganJE , AbrahamD . Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research. Neuromuscular Disorders2002;12(Suppl 1):S162‐5. ">Muntoni 2002</a>). </p> </section> <section id="CD003725-sec-0027"> <h3 class="title" id="CD003725-sec-0027">Why it is important to do this review</h3> <p>Evaluation of the role of corticosteroids in DMD by systematic reviews, such as <a href="./references#CD003725-bbs2-0066" title="WongBL , ChristopherC . Corticosteroids in Duchenne muscular dystrophy: a reappraisal. Journal of Child Neurology2002;17(3):183‐9. ">Wong 2002</a>, <a href="./references#CD003725-bbs2-0026" title="CampbellC , JacobP . Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurology2003; Vol. 3, issue 1:7. ">Campbell 2003</a>, and <a href="./references#CD003725-bbs2-0127" title="MoxleyRT3rd , AshwalS , PandyaS , ConnollyA , FlorenceJ , MathewsK , et al. Practice Parameter: corticosteroid treatment of Duchenne dystrophy, report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology2005;64(1):13‐20. ">Moxley 2005</a>, helped the development of clinical practice parameters (<a href="./references#CD003725-bbs2-0127" title="MoxleyRT3rd , AshwalS , PandyaS , ConnollyA , FlorenceJ , MathewsK , et al. Practice Parameter: corticosteroid treatment of Duchenne dystrophy, report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology2005;64(1):13‐20. ">Moxley 2005</a>), and international workshops establishing standards for use of corticosteroids in DMD (<a href="./references#CD003725-bbs2-0085" title="BushbyK , MuntoniF , Urtizberea , HughesR , GriggsR . Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2‐4 April 2004, Naarden, The Netherlands. Neuromuscular Disorders2004;14(8‐9):526‐34. ">Bushby 2004</a>). Although many observers claimed a beneficial effect on muscle strength, the long‐term functional benefit remained unclear, and had to be weighed against the short‐term and long‐term side effects and tolerability of these drugs. </p> <p>The previous version of this review examined RCT evidence that showed corticosteroid therapy in DMD improved muscle strength and function in the short term (six months), and evidence exists for benefit on strength at two years, although no conclusions can be drawn from two‐year timed function data, which are very limited. The most effective prednisone regimen appeared to be 0.75 mg/kg/day given daily. In the short term, adverse effects were significantly more common with corticosteroids than placebo, but not clinically severe. Long‐term benefits and hazards of corticosteroid treatment could not be evaluated from the published RCTs at that time. Since the last review, care recommendations for DMD have been published that recommend the use of corticosteroids (<a href="./references#CD003725-bbs2-0087" title="BushbyK , FinkelR , BirnkrantDJ , CaseLE , ClemensPR , CripeL , et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurology2010;9(1):77‐93. ">Bushby 2010a</a>; <a href="./references#CD003725-bbs2-0088" title="BushbyK , FinkelR , BirnkrantDJ , CaseLE , ClemensPR , CripeL , et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurology2010;9(2):177‐89. ">Bushby 2010b</a>). However, additional questions important to clinical practice about the choice of corticosteroid, optimal dosage regimens, long‐term outcomes, and age of initiation or discontinuation of treatment remain (<a href="./references#CD003725-bbs2-0085" title="BushbyK , MuntoniF , Urtizberea , HughesR , GriggsR . Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2‐4 April 2004, Naarden, The Netherlands. Neuromuscular Disorders2004;14(8‐9):526‐34. ">Bushby 2004</a>; <a href="./references#CD003725-bbs2-0086" title="KBushby , RGriggs , MSG/ENMC for DMD Trial Study Group. 145th ENMC International Workshop: Planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD). 22‐24th October 2006, Naarden, The Netherlands. Neuromuscular Disorders2007;17(5):423‐8. ">Bushby 2007</a>). Updating systematic reviews such as this one is essential to answer these questions and plan further studies. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003725-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003725-sec-0028">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003725-sec-0233">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003725-sec-0028"></div> <p>To assess the effects of corticosteroids on prolongation of walking ability, muscle strength, functional ability, and quality of life in DMD; to address the question of whether benefit is maintained over the longer term (more than two years); to assess adverse events; and to compare efficacy and adverse effects of different corticosteroid preparations and regimens. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003725-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003725-sec-0029">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003725-sec-0234">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003725-sec-0029"></div> <section id="CD003725-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003725-sec-0031"> <h4 class="title">Types of studies</h4> <p>We considered all randomised or quasi‐randomised trials of corticosteroids such as prednisone, prednisolone, deflazacort, or others, with a minimum treatment period of three months. (Quasi‐randomised trials use a method of allocating participants to different interventions that is not truly random, such as by date of birth, day of the week, or medical record number). </p> </section> <section id="CD003725-sec-0032"> <h4 class="title">Types of participants</h4> <p>We considered trials involving patients with a definite diagnosis of Duchenne muscular dystrophy (DMD), based on either of the following. </p> <p> <ol id="CD003725-list-0001"> <li> <p>The definition of <a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a>. </p> <ul id="CD003725-list-0002"> <li> <p>Male patient with onset of proximal weakness by five years and elevated serum creatine kinase (CK), together with two of the following minor criteria: </p> <ul id="CD003725-list-0003"> <li> <p>muscle hypertrophy/lower limb contractures/toe walking, electrocardiogram (ECG) changes, myopathic electromyogram (EMG) changes, and dystrophic change on muscle biopsy. </p> </li> </ul> </li> </ul> </li> <li> <p>The European Neuromuscular Centre (ENMC) DMD diagnostic criteria (<a href="./references#CD003725-bbs2-0102" title="EmeryAEH . Diagnostic Criteria for Neuromuscular Disorders. 2nd Edition. London: Royal Society of Medicine Press, 1997. ">Emery 1997</a>). </p> <ul id="CD003725-list-0004"> <li> <p>Onset of proximal weakness by five years of age, loss of unassisted walking by 13 years, 10‐fold or greater elevation of serum CK, dystrophic muscle biopsy, absent or minimal dystrophin on muscle biopsy, and/or Duchenne‐type mutation in the dystrophin gene. </p> </li> </ul> </li> </ol> </p> </section> <section id="CD003725-sec-0033"> <h4 class="title">Types of interventions</h4> <p>We considered trials examining the effects of any corticosteroid, including prednisone, prednisolone, and deflazacort, compared with placebo or another corticosteroid, or comparing regimens. The minimum treatment period was three months. For placebo comparisons, to analyse the effect of corticosteroids on patients with DMD, we considered the three drugs together as a group. The corticosteroids were reviewed on the basis of their dose equivalence, which is well known (<a href="./references#CD003725-bbs2-0081" title="Joint Formulary Committee. British National Formulary (online). www.medicinescomplete.com (accessed 4 April 2016). ">BNF 2016</a>; <a href="./references#CD003725-bbs2-0106" title="FreyBM , FreyFJ . Clinical pharmacokinetics of prednisone and prednisolone. Clinical Pharmacokinetics1990;19(2):126‐46. ">Frey 1990</a>). </p> </section> <section id="CD003725-sec-0034"> <h4 class="title">Types of outcome measures</h4> <section id="CD003725-sec-0035"> <h5 class="title">Primary outcomes</h5> <p>Prolongation of time to loss of ambulation (independent walking without long leg calipers) (<a href="./references#CD003725-bbs2-0110" title="HeckmattJZ , DubowitzV , HydeSA , FlorenceJ , GabainAC , ThompsonN . Prolongation of walking in Duchenne Muscular Dystrophy with lightweight orthoses; review of 57 cases. Developmental Medicine and Child Neurology1985;27(2):149‐54. ">Heckmatt 1985</a>; <a href="./references#CD003725-bbs2-0149" title="SpencerGE , VignosPJ . Bracing for ambulation in childhood progressive muscular dystrophy. Journal of Bone and Joint Surgery1962;44A:234‐42. ">Spencer 1962</a>). </p> </section> <section id="CD003725-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD003725-list-0005"> <li> <p>Strength outcome measures (performed after an intervention period of at least three months) assessed by manual muscle strength testing using Medical Research Council (MRC) strength scores (<a href="./references#CD003725-bbs2-0128" title="Medical Research Council. Aids to the Investigation of Peripheral Nerve Injuries. London: HMSO, 1976. ">MRC 1976</a>), ability to lift weights, or hand‐held dynamometry (<a href="./references#CD003725-bbs2-0078" title="BeenakkerEAC , van derHoevenJH , FockJM , MauritsNM . Reference values of maximum isometric muscle force obtained in 270 children aged 4 ‐16 years by hand‐held dynamometry. Neuromuscular Disorders2001;11(5):441‐6. ">Beenakker 2001</a>). </p> </li> <li> <p>Functional outcome measures, assessed by functional rating scores such as Motor Ability Score (<a href="./references#CD003725-bbs2-0146" title="ScottOM , HydeSA , GoddardC , DubowitzV . Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle &amp; Nerve1982;5(4):291‐301. ">Scott 1982</a>), Functional Grade (leg function grade) (<a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a>; <a href="./references#CD003725-bbs2-0083" title="BrookeMH , FenichelGM , GriggsRC , MendellJR , MoxleyR , ProvinceMA . Clinical investigation in Duchenne dystrophy. 2. Determination of the 'power' of therapeutic trials based on natural history. Muscle &amp; Nerve1983;6(2):91‐103. ">Brooke 1983</a>), and North Star Ambulatory Assessment score (<a href="./references#CD003725-bbs2-0143" title="RicottiV , RidoutDA , PaneM , MainM , MayhewA , MercuriE , et al. The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. Journal of Neurology, Neurosurgery, &amp; Psychiatry2016;87(2):149‐55. ">Ricotti 2016</a>; <a href="./references#CD003725-bbs2-0147" title="ScottE , EagleM , MayhewA , FreemanJ , MainM , SheehanJ , et al. North Star Clinical Network for Paediatric Neuromuscular Disease. Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiotherapy Research International2012;17(2):101‐9. ">Scott 2012</a>), or functional tests, such as timed walk, time taken to rise from the floor (Gowers’ time), and four‐stair climbing time (<a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a>; <a href="./references#CD003725-bbs2-0083" title="BrookeMH , FenichelGM , GriggsRC , MendellJR , MoxleyR , ProvinceMA . Clinical investigation in Duchenne dystrophy. 2. Determination of the 'power' of therapeutic trials based on natural history. Muscle &amp; Nerve1983;6(2):91‐103. ">Brooke 1983</a>; <a href="./references#CD003725-bbs2-0146" title="ScottOM , HydeSA , GoddardC , DubowitzV . Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle &amp; Nerve1982;5(4):291‐301. ">Scott 1982</a>). </p> </li> <li> <p>Pulmonary function ‐ forced vital capacity (FVC)</p> </li> <li> <p>Quality of life, assessed by a validated measure, such as the Pediatric Quality of Life Inventory (PedsQL) Neuromuscular Model (<a href="./references#CD003725-bbs2-0089" title="DavisSE , HynanLS , LimbersCA , AndersenCM , GreeneMC , VarniJW , et al. The PedsQL in pediatric patients with Duchenne muscular dystrophy: feasibility, reliability, and validity of the Pediatric Quality of Life Inventory Neuromuscular Module and Generic Core Scales. Journal of Clinical Neuromuscular Disease2010;11(3):97‐109. ">Davis 2010</a>) </p> </li> <li> <p>Adverse events (noted during treatment or up to one year after cessation of treatment), including: </p> </li> </ol> <ul class="plain" id="CD003725-list-0006"> <li> <ul id="CD003725-list-0007"> <li> <p>deaths;</p> </li> <li> <p>life‐threatening infections;</p> </li> <li> <p>abnormal behaviour, e.g. irritability, hyperactivity, euphoria, mood lability, depression;</p> </li> <li> <p>cushingoid appearance;</p> </li> <li> <p>fractures (if data were available beyond one year after cessation of treatment they were collected); </p> </li> <li> <p>hyperglycaemia, glycosuria;</p> </li> <li> <p>hypertension;</p> </li> <li> <p>weight gain;</p> </li> <li> <p>height restriction;</p> </li> <li> <p>cataracts</p> </li> </ul> </li> </ul> </p> </section> </section> </section> <section id="CD003725-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003725-sec-0038"> <h4 class="title">Electronic searches</h4> <p>On 16 February 2016, we searched for eligible trials in the Cochrane Neuromuscular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Register of Studies Online (16 February 2016), MEDLINE (January 1966 to February 2016), EMBASE (January 1980 to February 2016), CINAHL Plus (January 1937 to February 2016), and LILACS (January 1982 to February 2016). </p> <p>On 26 April 2016 we searched ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp/en/" target="_blank">http://www.who.int/ictrp/en/</a>). </p> <p>The detailed search strategies are in the appendices: <a href="./appendices#CD003725-sec-0202">Appendix 1</a> (Cochrane Neuromuscular Specialised Register), <a href="./appendices#CD003725-sec-0203">Appendix 2</a> (CENTRAL), <a href="./appendices#CD003725-sec-0204">Appendix 3</a> (MEDLINE), <a href="./appendices#CD003725-sec-0205">Appendix 4</a> (EMBASE), <a href="./appendices#CD003725-sec-0206">Appendix 5</a> (CINAHL Plus), <a href="./appendices#CD003725-sec-0207">Appendix 6</a> (LILACS), and <a href="./appendices#CD003725-sec-0208">Appendix 7</a> (clinical trials registers). </p> </section> <section id="CD003725-sec-0039"> <h4 class="title">Searching other resources</h4> <p>We wrote to authors of published studies and other experts in this disease to help identify other trials. We checked all references in the identified trials and contacted trial authors to identify any additional published or unpublished data, or other trials. </p> </section> </section> <section id="CD003725-sec-0040"> <h3 class="title" id="CD003725-sec-0040">Data collection and analysis</h3> <section id="CD003725-sec-0041"> <h4 class="title">Selection of studies</h4> <p>One review author (EM) independently screened the initial search of all the databases and reference lists to identify citations with potential relevance to the review. EM obtained the full text of selected articles (translated into English where required) and using predefined eligibility criteria, selected trials for inclusion in the review. AM and TK checked and agreed study selection. Review authors were not blinded to trial authors, journal or results. Discussion between the review authors and, if necessary, the involvement of a third party (editor in charge of the review) resolved disagreements when they occurred. </p> <p>We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD003725-bbs2-0125" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. ">Moher 2009</a>), and 'Characteristics of excluded studies' table. </p> </section> <section id="CD003725-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>For the earlier versions of this review, one review author entered data into Review Manager 5 (RevMan) (<a href="./references#CD003725-bbs2-0142" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) and the then Review Group Co‐ordinator checked the data entry. For this update two review authors (EM and RB) extracted data for the newly included studies and RB entered data into RevMan. EM checked the data entry. </p> </section> <section id="CD003725-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (EM and RB) independently assessed the risk of bias in each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003725-bbs2-0112" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreements by discussion. We assessed the risk of bias according to the following domains. </p> <p> <ul id="CD003725-list-0008"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We graded each potential source of bias as high, low, or unclear and provided a quote from the study report together with a justification for our judgment in the 'Risk of bias' table. We summarised the risk of bias judgements across different studies for each of the domains listed. Where information on risk of bias relates to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contribute to that outcome. </p> </section> <section id="CD003725-sec-0044"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes we reported risk ratios (RRs) with a 95% confidence interval (CI). For continuous outcomes we reported mean differences (MDs) with a corresponding 95% CI when the outcomes were measured in the same units in each trial. We reported calculations of MD and 95% CI from Review Manager 5 in preference to values given in trial reports, where different (e.g. because of rounding), for consistency of approach across the review </p> </section> <section id="CD003725-sec-0045"> <h4 class="title">Unit of analysis issues</h4> <p>We used the generic inverse variance (GIV) method in RevMan when analyses included cross‐over studies. </p> </section> <section id="CD003725-sec-0046"> <h4 class="title">Dealing with missing data</h4> <p>We sought full reports from authors where trials were published in abstract form, presented at meetings or presented as posters, and we contacted trial authors to obtain missing or ambiguously reported data. Because a number of the published papers gave only P values and means or differences (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>), we inferred the standard deviations (SDs) and other quantities required for the RevMan meta‐analysis by inverting the P value calculations. Care was required by a statistician to obtain reasonable values from what were sometimes very small and 'rounded' P values. One study reported the difference (and P values) in responses as daily rate of change, obtained from a regression using data from a six‐month follow‐up period (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>). We scaled up the response to 24 weeks (six months) equivalent, and deduced the standard error (SE) from the P values, assuming they had been obtained using a normal (the 1.96 cut‐off) rather than a t‐test, because RevMan assumes normality, and any other approach would give conflicting results. However, the P values were sometimes very small and rounding errors may make the results very approximate, so results using these inferred SEs have to be interpreted cautiously. </p> </section> <section id="CD003725-sec-0047"> <h4 class="title">Assessment of heterogeneity</h4> <p>We conducted meta‐analysis only when clinically appropriate. We assessed statistical heterogeneity using the I<sup>2</sup> statistic (<a href="./references#CD003725-bbs2-0112" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We used a random‐effects meta‐analysis in all cases, even when the heterogeneity was low. </p> </section> <section id="CD003725-sec-0048"> <h4 class="title">Assessment of reporting biases</h4> <p>The review included too few trials in any one analysis to reliably assess small study effects using funnel plots. The <i>Cochrane Handbook for Systematic Reviews of Interventions</i> recommends that tests for funnel plot asymmetry are only used when at least 10 studies are included in a meta‐analysis (<a href="./references#CD003725-bbs2-0112" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD003725-sec-0049"> <h4 class="title">Data synthesis</h4> <p>Where appropriate, we pooled estimates from individual studies to obtain overall estimates and 95% CIs. For continuous outcome measures we did this using the MD with corresponding 95% CIs. The MD is a method of meta‐analysis used to combine differences between treatment effects from different studies when the outcomes are measured in the same units in each trial. It averages the differences from the studies involved in the meta‐analysis, weighting them according to precision of the effect estimate. </p> <p>If any of the studies using a common outcome measure did not report the SD or we could not deduce it, we deduced the SE and pooled estimates from the individual studies using the Revman GIV facility to obtain overall estimates and 95% CIs. By this method, the weight given to each study is chosen to be the inverse of the variance of the effect estimate (i.e. one over the square of its standard error). Thus, larger studies, which have smaller SEs, receive more weight than smaller studies, which have larger SEs. This choice of weight minimises the imprecision (uncertainty) of the pooled effect estimate. For dichotomous outcomes, we used RRs with corresponding 95% CI. To include an additional study in GIV meta‐analyses at this update, we entered available data into the calculator tool available in RevMan to produce a mean and SE with 95% CI. </p> <section id="CD003725-sec-0050"> <h5 class="title">'Summary of findings' tables</h5> <p>We included 'Summary of findings' tables for each main comparison. We assessed the evidence for key outcomes using the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias). We graded the evidence as high, moderate, low, or very low quality using these criteria, providing a rationale for any decisions to downgrade the evidence. We included the following outcomes in these tables. </p> <p> <ol id="CD003725-list-0009"> <li> <p>Prolongation of time to loss of ambulation (independent walking without long leg calipers).</p> </li> <li> <p>Strength outcome measures (performed after an intervention period of at least three months). </p> </li> <li> <p>Functional outcome measures: walking times, such as time taken to walk 30 feet (<a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a>; <a href="./references#CD003725-bbs2-0083" title="BrookeMH , FenichelGM , GriggsRC , MendellJR , MoxleyR , ProvinceMA . Clinical investigation in Duchenne dystrophy. 2. Determination of the 'power' of therapeutic trials based on natural history. Muscle &amp; Nerve1983;6(2):91‐103. ">Brooke 1983</a>; <a href="./references#CD003725-bbs2-0146" title="ScottOM , HydeSA , GoddardC , DubowitzV . Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle &amp; Nerve1982;5(4):291‐301. ">Scott 1982</a>), and four‐stair climbing time. </p> </li> <li> <p>Adverse events:</p> <ul id="CD003725-list-0010"> <li> <p>weight gain;</p> </li> <li> <p>fractures (if data were available beyond one year after cessation of treatment they were collected); </p> </li> <li> <p>abnormal behaviour such as irritability, hyperactivity, euphoria, mood lability, and depression. </p> </li> </ul> </li> </ol> </p> <p>Where data for several prednisolone/prednisone doses were reported, we reported the data for 0.75 mg/kg/day daily in the 'Summary of findings' tables, as this dose is most commonly used in clinical practice. We limited the adverse events reported in the 'Summary of findings' tables to those that commonly cause patients to cease treatment with corticosteroids. For efficacy outcomes, in addition to the primary outcome (prolongation of walking), we chose strength and functional outcomes that reflect daily activities most closely (speed of walking and climbing stairs). </p> </section> </section> <section id="CD003725-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We investigated the possibility of heterogeneity of treatment effect differences among studies with appropriate tests. </p> <p>It was not possible to carry out subgroup analyses (e.g. for age at initiation of corticosteroid: less than seven years old or seven years or older) as these data were not available for individual studies. </p> </section> <section id="CD003725-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis removing trials assessed at high risk of bias for any domain. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003725-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003725-sec-0053"></div> <section id="CD003725-sec-0054"> <h3 class="title">Description of studies</h3> <section id="CD003725-sec-0055"> <h4 class="title">Results of the search</h4> <p>The number of papers found by the first electronic searches for this update in April 2015 were: Cochrane Neuromuscular Specialised Register 57, CENTRAL 68, MEDLINE 221 (65 new papers), EMBASE 95 (36 new papers), CINAHL Plus 39 (16 new papers), and LILACS 3, with a further 84 references (57 after removal of duplicates) from a late search in February 2016 (Register 17, CENTRAL 18, MEDLINE 10, EMBASE 29, CINAHL 10, and LILACS 0). We identified two additional records from reference lists of included studies. </p> <p>Simple searches of clinical trials registries in April 2016 revealed 13 references in ClinicalTrials.gov and 16 references in the International Clinical Trials Registry Platform. From these we identified two trial reports: <a href="./references#CD003725-bbs2-0071" title="CTRI/2009/091/000738 . A clinical trial to compare the two ways of giving steroids (daily versus intermittent) in ambulatory patients with Duchenne muscular dystrophy. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000605 accessed 28 April 2016. ">CTRI/2009/091/000738</a>, which is an ongoing trial, and <a href="./references#CD003725-bbs2-0068" title="ACTRN12605000075684 . A randomized phase III study to evaluate the effectiveness of two different dosing regimens (high dose vs daily) of prednisone for boys with Duchenne muscular dystrophy in improving muscle strength and function and minimising side effects. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12605000075684 (accessed 26 April 2016). ">ACTRN12605000075684</a>, which did not provide enough information for eligibility to be assessed. Although listed as recruiting (as of April 2016), this trial was registered on ICTRP in 2005. </p> <p>After deduplicating the new references above in the Cochrane Register of Studies software or manually, we obtained 163 new references. </p> <p>For the previous version of the review, six studies met the inclusion criteria and had been published in full in peer reviewed journals (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>; <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). All six trials randomised participants to corticosteroids against placebo (five to prednisolone or prednisone for six months and one to deflazacort for two years). </p> <p>In this update, we identified six additional trials for inclusion:</p> <p> <ul id="CD003725-list-0011"> <li> <p>three new randomised studies published since the last version of the review (<a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>); </p> </li> <li> <p>one previously excluded study comparing deflazacort and prednisone (<a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>), now eligible because of the expanded scope of the review to evaluate evidence from comparative trials of corticosteroids; </p> </li> <li> <p>two previously excluded studies published only as abstracts, as this is current Cochrane practice (<a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>; <a href="./references#CD003725-bbs2-0012" title="TodorovicSM . High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Muscle &amp; Nerve. 1998; Vol. 7 Suppl:72. ">Todorovic 1998</a>). However, we were unable to obtain further data from the trial authors. </p> </li> </ul> </p> <p>Two additional studies are ongoing (<a href="./references#CD003725-bbs2-0071" title="CTRI/2009/091/000738 . A clinical trial to compare the two ways of giving steroids (daily versus intermittent) in ambulatory patients with Duchenne muscular dystrophy. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000605 accessed 28 April 2016. ">CTRI/2009/091/000738</a>; <a href="./references#CD003725-bbs2-0072" title="GuglieriM , VanRuitenHJA , SpeedC , HartK , WatsonG , McCollE , et al. FOR‐DMD: Double‐blind randomised trial to optimise corticosteroid regime in Duchenne muscular dystrophy (DMD). Developmental Medicine and Child Neurology2015; Vol. 57, issue Suppl s1:25‐6. NCT01603407 . Finding the optimum regimen for Duchenne muscular dystrophy (FOR‐DMD). www.clinicaltrials.gov/ct2/show/NCT01603407 (accessed 14 December 2015). ">Guglieri 2015</a>). </p> <p>In summary therefore, we included 12 studies (667 participants) at this update (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>; <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>; <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>; <a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>; <a href="./references#CD003725-bbs2-0012" title="TodorovicSM . High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Muscle &amp; Nerve. 1998; Vol. 7 Suppl:72. ">Todorovic 1998</a>), additionally listing <a href="./references#CD003725-bbs2-0071" title="CTRI/2009/091/000738 . A clinical trial to compare the two ways of giving steroids (daily versus intermittent) in ambulatory patients with Duchenne muscular dystrophy. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000605 accessed 28 April 2016. ">CTRI/2009/091/000738</a> and <a href="./references#CD003725-bbs2-0072" title="GuglieriM , VanRuitenHJA , SpeedC , HartK , WatsonG , McCollE , et al. FOR‐DMD: Double‐blind randomised trial to optimise corticosteroid regime in Duchenne muscular dystrophy (DMD). Developmental Medicine and Child Neurology2015; Vol. 57, issue Suppl s1:25‐6. NCT01603407 . Finding the optimum regimen for Duchenne muscular dystrophy (FOR‐DMD). www.clinicaltrials.gov/ct2/show/NCT01603407 (accessed 14 December 2015). ">Guglieri 2015</a> as ongoing. </p> <p>See <a href="#CD003725-fig-0001">Figure 1</a> for a flow chart illustrating the study selection process. </p> <div class="figure" id="CD003725-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003725-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003725-sec-0056"> <h4 class="title">Included studies</h4> <section id="CD003725-sec-0057"> <h5 class="title">Corticosteroids versus placebo</h5> <p>See <a href="./references#CD003725-sec-0224" title="">Characteristics of included studies</a>. </p> <p>We included data from five randomised, parallel‐group, double‐blind studies of corticosteroids versus placebo (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>), and one randomised, placebo‐controlled, cross‐over trial (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>). Overall, these studies comprised 332 participants. The 315 participants in the randomised parallel‐group trials involved 88 in the placebo groups and 161 in the corticosteroid treatment groups (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). One hundred and one of the 218 participants in the control groups and 164 of the 197 in the corticosteroid groups were walking, either independently or with the help of long leg braces. The corticosteroid treatment groups included prednisone (n = 170), prednisolone (n = 10), and deflazacort (n = 17). <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> was a cross‐over study comprising 17 boys, all walking independently, who received prednisone during the six‐month active treatment period. </p> <p>In three of the included studies, all lasting six months, treatment groups received prednisone or prednisolone in a daily dose regimen (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). These studies included a total of 144 participants in the treatment group and 77 in the placebo group. Prednisone is broken down in the body to prednisolone and they are equipotent in glucocorticoid effect (<a href="./references#CD003725-bbs2-0076" title="AzarnoffDL . Steroid Therapy. 1st Edition. Philadelphia: Saunders, 1975. ">Azarnoff 1975</a>; <a href="./references#CD003725-bbs2-0106" title="FreyBM , FreyFJ . Clinical pharmacokinetics of prednisone and prednisolone. Clinical Pharmacokinetics1990;19(2):126‐46. ">Frey 1990</a>). </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>, used an intermittent regimen, prednisone 0.75 mg/kg/day given for the first 10 days of every month, in the active treatment phase. The participants were 17 independently ambulant boys. One study (n = 28) used deflazacort (2 mg/kg body weight on alternate days for two years) in the treatment group (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>). This was the only study to address the primary outcome measure of prolongation of walking. </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> was a placebo‐controlled study of 66 independently ambulant boys and the only placebo‐controlled corticosteroid study published since the previous update of this review. The intervention was prednisone 0.75 mg/kg/day given daily for a year. </p> <p>The secondary outcome measures of this review were assessed by different parameters and assessment tools in the five prednisolone/prednisone studies that were published in full and which provided data for our secondary outcomes. However, <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> and <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, the two studies that comprised 80% of the participants for all the four included and analysed studies, used the same outcome measures, as described in <a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a> (see <a href="./references#CD003725-sec-0224" title="">Characteristics of included studies</a>). <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>, <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>, and <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>, the other three published studies of prednisolone or prednisone, also used some of these outcome measures. </p> <p><a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>, a cross‐over trial, reported efficacy as the numbers improving (improved or unchanged across two‐thirds or more of the tested measures) and numbers deteriorating during treatment with prednisolone (0.35 mg/kg/day) or placebo. The participants were 37 boys with Duchenne muscular dystrophy (DMD) (22 of whom were ambulant) and four with Becker muscular dystrophy. Although outcome data were not adequate for inclusion in the review, the trial provided some adverse event data. </p> <p><a href="./references#CD003725-bbs2-0012" title="TodorovicSM . High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Muscle &amp; Nerve. 1998; Vol. 7 Suppl:72. ">Todorovic 1998</a> was a 20‐month study involving 34 boys, who received prednisone 2 mg/kg alternate days (high dose) or placebo. No results have been published. </p> <p><a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> was a 12‐month randomised, double‐blind comparative trial with four arms: placebo, prednisone 0.75 mg/kg, deflazacort 0.9 mg/kg, and deflazacort 1.2 mg/kg, published in abstract form. We presume, although the abstract does not specify, that these were daily doses. After three months, participants in the placebo group were randomised to one of the three active treatment arms and followed up for a further nine months. The abstract presents data for the average muscle score (the method of measurement is not defined), and for weight gain as a percentage of baseline weight. This study was large, at 196 randomised participants, but we were unable to obtain data to allow for any analysis. </p> </section> <section id="CD003725-sec-0058"> <h5 class="title">Weekend‐only versus daily prednisone</h5> <p>Only one randomised study provided data for a comparison of different prednisone dosing regimes. <a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a> performed a double‐blind placebo‐controlled randomised study comparing daily prednisone 0.75 mg/kg/day (and weekend placebo) with weekend‐only prednisone 5 mg/kg/weekend day (and daily placebo), taken over a 12‐month period. The study comprised 64 eligible participants with a mean age of 7.3 years (range 4 to 10), all of whom were ambulant at the start. The study did not measure the primary outcome of this review, prolongation of time to loss of ambulation, but assessed secondary outcomes at 12 months using multiple measures, including the change from baseline of quantitative muscle testing (QMT) arm and leg scores, and mean body mass index (BMI). </p> </section> <section id="CD003725-sec-0059"> <h5 class="title">Deflazacort versus prednisone</h5> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>, a double‐blind study, randomised 18 participants to treatment with 0.75 mg/kg/day prednisone (mean age 7.5 years, range, 5.1 to 10) or 0.9 mg/kg/day deflazacort (mean age 8.6 years, range 5.3 to 14.6) for 12 months. Investigators assessed muscle strength and function using a summed Medical Research Council (MRC) score of four muscles (two right upper limb, two right lower limb) and a summed functional score comprising several timed assessments including a 10‐metre walk, rise from chair and floor, and four‐stair climbing. Mean weight increase after 12 months was expressed as a percentage of initial weight. The trial authors presented outcome data for MRC scores, functional scores, and weight increase graphically, limiting full analysis. They tabulated adverse events. We requested further data but received no response from study authors. </p> <p><a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> initially randomised 34 participants to either prednisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day. Eight early dropouts occurred, but the trial continued for 12 months with 14 participants in the deflazacort group (mean age 7.1 years, range 3.2 to 10.5) and 12 in the prednisone group (mean age 7.37 years, range 6 to 10). In total, the study ran for 18 months, but at 12 months a further four participants were excluded from the prednisone group due to unacceptable weight gain; these four also had poor motor function scores. The report presented limited outcome data at 12 and 18 months. We contacted study authors for more data but did not receive a reply. </p> <p>As noted above, <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> also studied this comparison but did not provide data for analysis. </p> </section> </section> <section id="CD003725-sec-0060"> <h4 class="title">Excluded studies</h4> <section id="CD003725-sec-0061"> <h5 class="title">Non‐randomised excluded studies</h5> <p>See <a href="./references#CD003725-sec-0225" title="">Characteristics of excluded studies</a>. </p> <p>We excluded three RCTs. These were: a comparison of prednisone and azathioprine with no placebo group (<a href="./references#CD003725-bbs2-0037" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology1993;43(3 Pt 1):520‐7. ">Griggs 1993</a>), a study of deflazacort versus prednisolone in which the high dropout rate invalidated results (<a href="./references#CD003725-bbs2-0052" title="PradhanS , GhoshD , SrivastavaNK , KumarA , MittalB , PandeyCM , et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. Journal of Neurology2006;253(10):1309‐16. [DOI 10.1007/s00415‐006‐0212‐1] ">Pradhan 2006</a>), and a study of ayurvedic medicine, prednisone and placebo in which investigators modified the design mid‐trial (<a href="./references#CD003725-bbs2-0065" title="VasanthA , Gourie‐DeviM , RajaramP , TalyAB , VenkataramBS , RavishankarD , et al. Duchenne muscular dystrophy: therapeutic options and rehabilitation. European Journal of Neurology1996;3(Suppl 2):20. ">Vasanth 1996</a>). </p> <p>We also listed non‐randomised studies in the excluded studies. Thirty‐eight of these were fully published (<a href="./references#CD003725-bbs2-0014" title="AlmanBA , RazaNS , BiggarWD . Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. Journal of Bone and Joint Surgery. American Volume2004;86‐A(3):519‐24. ">Alman 2004</a>; <a href="./references#CD003725-bbs2-0019" title="BalabanB , MatthewsDJ , ClaytonGH , CarryT . Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long‐term effect. American Journal of Physical Medicine and Rehabilitation2005;84(11):843‐50. ">Balaban 2005</a>; <a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a>; <a href="./references#CD003725-bbs2-0021" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. ">Biggar 2004</a>; <a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a>; <a href="./references#CD003725-bbs2-0023" title="BonifatiDM , WitchelSF , ErmaniM , HoffmanEP , AngeliniC , PegoraroE . The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(10):1177‐9. ">Bonifati 2006</a>; <a href="./references#CD003725-bbs2-0024" title="BothwellJE , GordonKE , DooleyJM , MacSweenJ , CummingsEA , SalisburyS . Vertebral fractures in boys with Duchenne muscular dystrophy. Clinical Pediatrics2003;42(4):353‐6. ">Bothwell 2003</a>; <a href="./references#CD003725-bbs2-0025" title="BrookeMH , FenichelGM , GriggsRC , MendellJR , MoxleyRT3rd , MillerJP , et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Archives of Neurology1987;44(8):812‐7. ">Brooke 1987</a>; <a href="./references#CD003725-bbs2-0027" title="ConnollyAM , SchierbeckerJ , RennaR , FlorenceJ . High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscular Disorders2002;12(10):917‐25. ">Connolly 2002</a>; <a href="./references#CD003725-bbs2-0028" title="DaftaryAS , CrisantiM , KalraM , WongB , AminR . Effect of long‐term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics2007;119(2):e320‐4. ">Daftary 2007</a>; <a href="./references#CD003725-bbs2-0030" title="DeSilvaS , DrachmanDB , MellitsD , KunclR . Prednisone treatment in Duchenne muscular dystrophy. Long‐term benefit. Archives of Neurology1987;44(8):818‐22. ">DeSilva 1987</a>; <a href="./references#CD003725-bbs2-0031" title="DrachmanDB , ToykaKV , MyerE . Prednisone in Duchenne muscular dystrophy. Lancet1974;2(7894):1409‐12. ">Drachman 1974</a>; <a href="./references#CD003725-bbs2-0032" title="DubowitzV , KinaliM , MainM , MercuriE , MuntoniF . Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low‐dosage prednisolone therapy. European Journal of Paediatric Neurology2002;6(3):153‐9. ">Dubowitz 2002</a>; <a href="./references#CD003725-bbs2-0034" title="FenichelGM , MendellJR , MoxleyRT , GriggsRC , BrookeMH , MillerJP . A comparison of daily and alternate‐day prednisone therapy in the treatment of Duchenne muscular dystrophy. Archives of Neurology1991;48(6):575‐9. ">Fenichel 1991a</a>; <a href="./references#CD003725-bbs2-0035" title="FenichelGM , FlorenceJM , PestronkA , MendellJR , MoxleyRT3rd , GriggsRC , et al. Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology1991;41(12):1874‐7. ">Fenichel 1991b</a>; <a href="./references#CD003725-bbs2-0039" title="HenricsonEK , AbreschRT , CnaanA , HuF , DuongT , ArrietaA , et al. CINRG Investigators. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle &amp; Nerve2013;48(1):55–67. ">Henricson 2013</a>; <a href="./references#CD003725-bbs2-0040" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. ">Houde 2008</a>; <a href="./references#CD003725-bbs2-0041" title="KinaliM , MercuriE , MainM , MuntoniF , DubowitzV . An effective, low‐dosage, intermittent schedule of prednisolone in the long‐term treatment of early cases of Duchenne dystrophy. Neuromuscular Disorders2002;12(Suppl 1):S169‐74. ">Kinali 2002</a>; <a href="./references#CD003725-bbs2-0042" title="KinaliM , MainM , EliahooJ , MessinaS , KnightRK , LehovskyJ . Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. European Journal of Paediatric Neurology2007;11(3):160‐6. ">Kinali 2007</a>; <a href="./references#CD003725-bbs2-0043" title="KingWM , RuttencutterR , NagarajaHN , MatkovicV , LandollJ , HoyleC . Orthopedic outcomes of long‐term daily dose corticosteroid treatment in Duchenne muscular dystrophy. Neurology2007;68(19):1607‐13. ">King 2007</a>; <a href="./references#CD003725-bbs2-0044" title="MarkhamLW , SpicerRL , KhouryPR , WongBL , MathewsKD , CripeLH . Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatric Cardiology2005;26(6):768‐71. [10.1007/s00246‐005‐0909‐4] ">Markham 2005</a>; <a href="./references#CD003725-bbs2-0045" title="MayhewAG , CanoSJ , ScottE , EagleM , BushbyK , ManzurA , et al. Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Developmental Medicine and Child Neurology2013; Vol. 55, issue 11:1046‐52. ">Mayhew 2013</a>; <a href="./references#CD003725-bbs2-0046" title="MazzoneES , PaneM , SormaniMP , ScaliseR , BerardinelliA , MessinaS , et al. 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PloS One2013; Vol. 8, issue 1:e52512. [DOI: 10.1371/journal.pone.0052512] ">Mazzone 2013</a>; <a href="./references#CD003725-bbs2-0048" title="MerliniL , CicognaniA , MalaspinaE , GennariM , GnudiS , TalimB , et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle &amp; Nerve2003;27(2):222‐7. ">Merlini 2003</a>; <a href="./references#CD003725-bbs2-0049" title="MesaLE , DubrovskyAL , CorderiJ , MarcoP , FloresD . Steroids in Duchenne muscular dystrophy ‐ deflazacort trial. Neuromuscular Disorders1991;1(4):261‐6. ">Mesa 1991</a>; <a href="./references#CD003725-bbs2-0051" title="ParreiraSL , ResendeMB , Della Corte PedutoM , MarieSK , CarvalhoMS , ReedUC . Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arquivos de Neuro‐Psiquiatria2007;65(2A):245‐50. ">Parreira 2007</a>; <a href="./references#CD003725-bbs2-0053" title="ReitterB . Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain &amp; Development1995;17 Suppl:39‐43. ">Reitter 1995</a>; <a href="./references#CD003725-bbs2-0055" title="RicottiV , RidoutDA , ScottE , QuinlivanR , RobbSA , ManzurAY , et al. NorthStar Clinical Network. Long‐term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery &amp; Psychiatry2013;84(6):698‐705. ">Ricotti 2013</a>; <a href="./references#CD003725-bbs2-0056" title="SansomeA , RoystonP , DubowitzV . Steroids in Duchenne muscular dystrophy; pilot study of a new low‐dosage schedule. Neuromuscular Disorders1993;3(5‐6):567‐9. ">Sansome 1993</a>; <a href="./references#CD003725-bbs2-0057" title="ScharaU , MortierJ , MortierW . Long‐term steroid therapy in Duchenne muscular dystrophy‐positive results versus side effects. Journal of Clinical Neuromuscular Disease2001;2(4):179‐83. ">Schara 2001</a>; <a href="./references#CD003725-bbs2-0058" title="SchramG , FournierA , LeducH , DahdahN , TherienJ , VanasseM , et al. All‐cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. Journal of the American College of Cardiology2013; Vol. 61, issue 9:948‐54. ">Schram 2013</a>; <a href="./references#CD003725-bbs2-0059" title="SiegelIM , MillerJE , RayRD . Failure of corticosteroid in the treatment of Duchenne (pseudo‐hypertrophic) muscular dystrophy. Report of a clinically matched three year double‐blind study. Illinois Medical Journal1974;145(1):32‐3. ">Siegel 1974</a>; <a href="./references#CD003725-bbs2-0060" title="SilvaEC , MachadoDL , ResendeMB , SilvaRF , ZanoteliE , ReedUC . Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy. Arquivos de Neuro‐psiquiatria2012; Vol. 70, issue 3:191‐5. ">Silva 2012</a>; <a href="./references#CD003725-bbs2-0061" title="SilversidesCK , WebbGD , HarrisVA , BiggarDW . Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. American Journal of Cardiology2003;91(6):769‐72. ">Silversides 2003</a>; <a href="./references#CD003725-bbs2-0062" title="SimonVA , ResendeMB , SimonMA , ZanoteliE , ReedUC . Duchenne muscular dystrophy: quality of life among 95 patients evaluated using the Life Satisfaction Index for Adolescents. Arquivos de Neuro‐psiquiatria2011; Vol. 69, issue 1:19‐22. ">Simon 2011</a>; <a href="./references#CD003725-bbs2-0063" title="TakeuchiF , YonemotoN , NakamuraH , ShimizuR , KomakiH , Mori‐YoshimuraM , et al. Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. Journal of Neurology2013;260(12):3023‐9. ">Takeuchi 2013</a>; <a href="./references#CD003725-bbs2-0067" title="YilmazO , KaradumanA , ArasO , BasogluB , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Neuromuscular Disorders2004; Vol. 14:581. YilmazO , KaradumanA , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. European Journal of Neurology2004;11(8):541‐4. ">Yilmaz 2004</a>). Eight non‐randomised studies were published in abstract format only (<a href="./references#CD003725-bbs2-0013" title="AhlanderAC , KroksmarkAK , TuliniusM . Low‐dosage prednisolone in the long‐term treatment of Duchenne muscular dystrophy. Neuromuscular Disorders2003;13(7‐8):630. ">Ahlander 2003</a>; <a href="./references#CD003725-bbs2-0015" title="AngeliniC , PegoraroE , CadaldiniM . Daily versus alternate‐day deflazacort (DFZ) in Duchenne muscular dystrophy. Neurology1995;45(Suppl 4):A182. ">Angelini 1995</a>; <a href="./references#CD003725-bbs2-0018" title="Luz AvilesC , GutiérrezC , NovoaF , GilE , StuardoA . Steroid treatment of Duchenne's muscular dystrophy [Tratamiento esteroidal en distrofia muscular de Duchenne]. Revista Chilena de Pediatra1982;53(3):187‐91. ">Aviles 1982</a>; <a href="./references#CD003725-bbs2-0029" title="deGrootIJM . The effectiveness of prednisolone treatment (10 days on/10 days off) in the ambulatory phase of Duchenne muscular dystrophy: an open study. Neuromuscular Disorders2002;12(7‐8):737‐8. ">de Groot 2002</a>; <a href="./references#CD003725-bbs2-0033" title="DubrovskyAL , DeVitoE , SuarezA , MesaLE , PessolanoF , SobrinoR , et al. Deflazacort treatment and respiratory function in Duchenne muscular dystrophy. Neurology1999;52 Suppl(2):A544. ">Dubrovsky 1999</a>; <a href="./references#CD003725-bbs2-0050" title="PandyaS , MyersG , MoxleyRT . Effect of daily prednisone on independent ambulation in patients with Duchenne dystrophy treated for up to 15 years. Neuromuscular Disorders2001;11(6‐7):630. ">Pandya 2001</a>; <a href="./references#CD003725-bbs2-0054" title="ResendeMBD , ReedUC , EspindolaAA , FerreiraLG , CarvalhoMS , DiamentA , et al. Deflazacort in Duchenne muscular dystrophy: preliminary results in a Brazilian series. Neuromuscular Disorders2001;11:630. ">Resende 2001</a>; <a href="./references#CD003725-bbs2-0064" title="TuncaO , KabakusO , HergunerA , KaradumanA , TopalogluH . Alternate day prednisone therapy in Duchenne muscular dystrophy. Neuromuscular Disorders2001;11:630. ">Tunca 2001</a>). One paper was a discussion of corticosteroid use (<a href="./references#CD003725-bbs2-0038" title="GriggsRC , HerrBE , RehaA , ElfringG , AtkinsonL , CwikV , et al. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle &amp; Nerve2013; Vol. 48, issue 1:27‐31. ">Griggs 2013</a>). We identified and excluded six review articles reporting the various studies (<a href="./references#CD003725-bbs2-0016" title="AngeliniC . The role of corticosteroids in muscular dystrophy: a critical appraisal. Muscle &amp; Nerve2007;36(4):424‐35. ">Angelini 2007</a>; <a href="./references#CD003725-bbs2-0017" title="AngeliniC , PeterleE . Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myologica2012; Vol. 31, issue 1:9‐15. ">Angelini 2012</a>; <a href="./references#CD003725-bbs2-0026" title="CampbellC , JacobP . Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurology2003; Vol. 3, issue 1:7. ">Campbell 2003</a>; <a href="./references#CD003725-bbs2-0036" title="FlaniganKM . The muscular dystrophies. Seminars in Neurology2012;32(3):255‐63. ">Flanigan 2012</a>; <a href="./references#CD003725-bbs2-0047" title="McAdamLC , MayoAL , AlmanBA , BiggarWD . The Canadian experience with long‐term deflazacort treatment in Duchenne muscular dystrophy. Acta Myologica2012; Vol. 31, issue 1:16‐20. ">McAdam 2012</a>; <a href="./references#CD003725-bbs2-0066" title="WongBL , ChristopherC . Corticosteroids in Duchenne muscular dystrophy: a reappraisal. Journal of Child Neurology2002;17(3):183‐9. ">Wong 2002</a>). </p> </section> <section id="CD003725-sec-0062"> <h5 class="title">Ongoing studies</h5> <p>See <a href="./references#CD003725-sec-0227" title="">Characteristics of ongoing studies</a>. </p> <p><a href="./references#CD003725-bbs2-0072" title="GuglieriM , VanRuitenHJA , SpeedC , HartK , WatsonG , McCollE , et al. FOR‐DMD: Double‐blind randomised trial to optimise corticosteroid regime in Duchenne muscular dystrophy (DMD). Developmental Medicine and Child Neurology2015; Vol. 57, issue Suppl s1:25‐6. NCT01603407 . Finding the optimum regimen for Duchenne muscular dystrophy (FOR‐DMD). www.clinicaltrials.gov/ct2/show/NCT01603407 (accessed 14 December 2015). ">Guglieri 2015</a> is a large ongoing randomised double‐blind study taking place at 40 centres throughout the US, UK, Canada, Germany, Italy, and Spain. This study is comparing three corticosteroid regimens for efficacy and adverse events: prednisone 0.75 mg/kg/day, prednisone 0.75 mg/kg/day switching between 10 days on and 10 days off treatment, and deflazacort 0.9 mg/kg/day daily. The planned follow‐up period is three to five years. No outcome data are yet available. </p> </section> </section> </section> <section id="CD003725-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD003725-fig-0002">Figure 2</a> illustrates the review authors' 'Risk of bias' assessments of included studies. </p> <div class="figure" id="CD003725-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003725-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003725-sec-0064"> <h4 class="title">Allocation</h4> <p>Although all the studies were described as randomised, most reports did not provide enough detail to assess whether the method of randomisation was adequate. We were able to determine that three studies were at low risk of bias (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a>), and one was at high risk of bias (<a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>). For allocation concealment, we assessed three trials at low risk of bias on the basis of information provided by the trial authors (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>), eight studies at unclear risk of bias, as the reports provided no information, and one study at high risk of bias (<a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>) (see <a href="./references#CD003725-sec-0224" title="">Characteristics of included studies</a>). </p> </section> <section id="CD003725-sec-0065"> <h4 class="title">Blinding</h4> <p>Trial authors described eight of the 12 studies as double blind, but we considered only six of them at low risk of both performance and detection bias (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>; <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>; <a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> blinded participants but it is unclear whether blinding of outcome assessors or investigators was attempted. Three studies provided too little information to form a judgement (<a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>; <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0012" title="TodorovicSM . High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Muscle &amp; Nerve. 1998; Vol. 7 Suppl:72. ">Todorovic 1998</a>). We judged both <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>, which used a vitamin control intervention, and <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>, a single‐blind study, at high risk of bias. </p> </section> <section id="CD003725-sec-0066"> <h4 class="title">Incomplete outcome data</h4> <p>Six of the 12 studies described withdrawals and dropouts and we judged these studies at low risk of bias (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). Trialists described dropouts from <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> in a subsequent sequential study (<a href="./references#CD003725-bbs2-0037" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology1993;43(3 Pt 1):520‐7. ">Griggs 1993</a>). <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> reported one dropout and described it in response to the Cochrane authors' request. </p> <p>The risk of attrition bias was unclear in four studies (<a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>; <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>; <a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a>; <a href="./references#CD003725-bbs2-0012" title="TodorovicSM . High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Muscle &amp; Nerve. 1998; Vol. 7 Suppl:72. ">Todorovic 1998</a>). . <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> was at high risk of attrition bias, as dropouts were those with worse outcomes. Most two‐year analyses in <a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> included fewer than 50% of the randomised participants and we judged it at high risk of attrition bias. </p> </section> <section id="CD003725-sec-0067"> <h4 class="title">Selective reporting</h4> <p>Reporting bias was difficult to assess as trial registration records and protocols are not available for earlier trials, and outcomes were rarely fully defined in methods. Our assessment of bias was 'high' for six trials and 'unclear' for two. Only <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>, <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>, and <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> had a 'low risk' assessment. </p> </section> <section id="CD003725-sec-0068"> <h4 class="title">Other potential sources of bias</h4> <p><a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> and <a href="./references#CD003725-bbs2-0012" title="TodorovicSM . High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Muscle &amp; Nerve. 1998; Vol. 7 Suppl:72. ">Todorovic 1998</a> were reported in abstracts and provided no information to assess the presence of other bias. Our assessment was 'unclear' for these trials and low risk for others. </p> </section> </section> <section id="CD003725-sec-0069"> <h3 class="title" id="CD003725-sec-0069">Effects of interventions</h3> <p>See: <a href="./full#CD003725-tbl-0001"><b>Summary of findings for the main comparison</b> Corticosteroids versus placebo for Duchenne muscular dystrophy</a>; <a href="./full#CD003725-tbl-0002"><b>Summary of findings 2</b> Weekend‐only versus daily prednisone for Duchenne muscular dystrophy</a>; <a href="./full#CD003725-tbl-0003"><b>Summary of findings 3</b> Deflazacort versus prednisone for Duchenne muscular dystrophy</a> </p> <section id="CD003725-sec-0070"> <h4 class="title">Corticosteroids versus placebo</h4> <p>Six studies provided data for this comparison (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>, a cross‐over trial, reported efficacy as the numbers improving (improved or unchanged across two‐thirds or more of the tested measures) and numbers deteriorating. Although these data were not adequate for inclusion in the comparison of outcome measures, the trial did provide adverse event data. The two studies reported in abstract form provided only limited information: <a href="./references#CD003725-bbs2-0012" title="TodorovicSM . High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Muscle &amp; Nerve. 1998; Vol. 7 Suppl:72. ">Todorovic 1998</a> reported no usable results and <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided some numerical data, but with insufficient detail for analysis. </p> <p>See <a href="./full#CD003725-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD003725-sec-0071"> <h5 class="title">Primary outcome measure: prolongation of time to loss of ambulation</h5> <p>Only <a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> (n = 28), a two‐year study, used prolongation of time to loss of ambulation as an outcome measure. The other studies were of short duration (six months or one year), and not designed to demonstrate prolongation of walking. </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> reported that deflazacort (2 mg/kg on alternate days) prolonged ambulation by 13 months, but the statistical technique used to infer this result was not appropriate. Four of the 17 participants in the deflazacort group became wheelchair dependent, at a mean interval of 33.2 months after randomisation, versus six of 11 placebo participants, at a mean interval of 20.5 months. The trial authors reported the difference of 13 months between these two sets of participants who lost walking ability as "mean prolongation of walking", ignoring the 13 participants in the deflazacort group and five in the placebo group who were still walking at the end of the study. The trialists did not report the age of boys who remained ambulant at the end of the study and this information was not available on contacting the lead investigator. We therefore were not able to construct Kaplan‐Meier survival curves for evaluating prolongation of walking as an outcome measure. </p> </section> <section id="CD003725-sec-0072"> <h5 class="title">Secondary outcome measures</h5> <section id="CD003725-sec-0073"> <h6 class="title">(1) Muscle strength</h6> <section id="CD003725-sec-0074"> <p><b>(a) Average muscle score</b></p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> and <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> reported muscle strength as an average muscle score (as described in <a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a> and <a href="./references#CD003725-bbs2-0083" title="BrookeMH , FenichelGM , GriggsRC , MendellJR , MoxleyR , ProvinceMA . Clinical investigation in Duchenne dystrophy. 2. Determination of the 'power' of therapeutic trials based on natural history. Muscle &amp; Nerve1983;6(2):91‐103. ">Brooke 1983</a>). The two large studies had one placebo arm and two treatment arms (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> studied two prednisone dose regimens (0.75 mg/kg/day and 1.5 mg/kg/day), comparing them with a placebo group. <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> compared 0.3 mg/kg/day and 0.75 mg/kg/day prednisone regimens with placebo. <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> studied a 0.75 mg/kg daily prednisone regimen, reporting scores for lower limb muscle strength (right hip flexion and right knee extension) according to the MRC scale expanded to a 10‐point scale, at six and 12 months. These data were not suitable for meta‐analysis with <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> and <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>. <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a> evaluated muscle strength in three ways: (a) average muscle strength from 26 muscle groups on the MRC zero to five grading system and the performance scores were added and divided by the number of muscle groups to get the average muscle strength; (b) isometric muscle strength, measured in 24 muscle groups with a Penny and Giles myometer; and (c) hand‐grip strength measured bilaterally with a strain gauge. The publication did not report data, nor could the review authors obtain data from the surviving study author. <a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> measured muscle strength in two ways: (a) MRC index calculated by assessing four limb muscle groups using the MRC scale; and (b) myometry (but the number of muscle groups tested and the myometer used were not described). <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> assessed changes in muscle force in nine muscle groups with hand‐held dynamometry (<a href="./references#CD003725-bbs2-0078" title="BeenakkerEAC , van derHoevenJH , FockJM , MauritsNM . Reference values of maximum isometric muscle force obtained in 270 children aged 4 ‐16 years by hand‐held dynamometry. Neuromuscular Disorders2001;11(5):441‐6. ">Beenakker 2001</a>; <a href="./references#CD003725-bbs2-0079" title="BeenakkerEAC , MauritsNM , FockJM , BrouwerOF , van derHoevenJH . Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. European Journal of Paediatric Neurology2005;9(6):387–93. ">Beenakker 2005b</a>). <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> was a four‐way comparison of two doses of deflazacort (0.9 mg/kg and 1.2 mg/kg), prednisone (0.75 mg/kg), and placebo, which reported average change in muscle strength at three months ("based on a standardised method used in several previous trials"). </p> <p>Analysis of pooled data from three trials (n = 147) demonstrated a statistically significant improvement in average muscle score in the prednisone 0.75 mg/kg/day group versus placebo, with a mean difference (MD) of 0.52 (95% confidence interval (CI) 0.33 to 0.71) after six months of treatment; moderate quality evidence (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>) (see <a href="./references#CD003725-fig-0008" title="">Analysis 1.2</a>; <a href="#CD003725-fig-0003">Figure 3</a>; <a href="./full#CD003725-tbl-0001">summary of findings Table for the main comparison</a>). Removal of <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>, the trial at high risk of bias, had no substantial effect on the result (MD 0.47, 95% CI 0.32 to 0.63). </p> <div class="figure" id="CD003725-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.1 MRC ‐ Average muscle score after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.1 MRC ‐ Average muscle score after 6 months of treatment ‐ prednisone. </p> </div> </div> </div> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> (n = 61) also compared prednisone 0.3 mg/kg/day with placebo and after six months of treatment there was statistically significant improvement in average muscle score in favour of the prednisone group, with a MD of 0.34 (95% CI 0.17 to 0.51) (see <a href="./references#CD003725-fig-0008" title="">Analysis 1.2</a>). </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> (n = 65) also compared prednisone 1.5 mg/kg/day with placebo and after six months of treatment there was a statistically significant improvement in average muscle score in the prednisone group, with a MD of 0.45 (95% CI 0.23 to 0.67) (see <a href="./references#CD003725-fig-0008" title="">Analysis 1.2</a>). </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> (n = 16), a cross‐over study, compared an intermittent regimen of prednisone (0.75 mg/kg/day given for the first 10 days of every month for six months) with placebo. There was a statistically significant difference in the muscle force during the prednisone phase compared to the placebo phase. Using the standard errors (SEs) inferred from the quoted P values, the RevMan GIV facility gave a difference in favour of prednisone of 99.2 N (95% CI 15.63 to 182.81) (see <a href="./references#CD003725-fig-0026" title="">Analysis 1.20</a>). </p> <p><a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> (n = 196) reported an average change in muscle strength ("based on a standardised method used in several previous trials") after three months. Reported changes were ‐0.1 with placebo, +0.27 with prednisone 0.75 mg/kg, +0.8 with deflazacort 0.9 mg/kg, and +0.26 with deflazacort 1.2 mg/kg. For all comparisons versus placebo, P &lt; 0.0001. The abstract provided no participant numbers for intervention groups, or standard deviation (SD). </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> reported that lower limb muscle strength grade "remained stable" in the prednisone group, whereas it declined in the placebo group. The MD between groups favoured prednisone over placebo for both hip flexion and knee extension at six months (MD 0.64, 95% CI 0.20 to 1.08 and MD 0.71, 95% CI 0.27 to 1.15, respectively; n = 63) and at 12 months (MD 1.27, 95% CI 0.74 to 1.80 and MD 1.23, 95% CI 0.71 to 1.75, respectively; n = 58) (<a href="./references#CD003725-fig-0010" title="">Analysis 1.4</a>; <a href="./references#CD003725-fig-0011" title="">Analysis 1.5</a>). </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> was a 24‐month trial comparing deflazacort (2 mg/kg administered on alternate days) with placebo. Treatment continued until the participants became wheelchair dependent. After six months, the MD for change in MRC index (%) was similar in the deflazacort and placebo groups (MD 1.97, 95% CI ‐1.79 to 5.73, n = 26); after 24 months the difference favoured deflazacort (MD 6.60, 95% CI ‐3.79 to 16.99, n = 13) (<a href="./references#CD003725-fig-0009" title="">Analysis 1.3</a>). </p> </section> <section id="CD003725-sec-0075"> <p><b>(b) Ability to lift weights</b></p> <p>Ability to lift standardised weights (as described in <a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a>) was assessed and reported in two studies (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). Analysis of pooled data from these studies demonstrated a statistically significant improvement in lifting weights in the prednisone 0.75 mg/kg/day group after six months of treatment as compared to placebo, with a MD of 0.75 (95% CI 0.50 to 0.99, n = 94) (see <a href="./references#CD003725-fig-0021" title="">Analysis 1.15</a>). </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.3 mg/kg/day with placebo, and after six months of treatment there was a statistically significant improvement in lifting weights in the prednisone group, with a MD of 0.38 (95% CI 0.13 to 0.63, n = 39) (see <a href="./references#CD003725-fig-0021" title="">Analysis 1.15</a>). </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> compared prednisone 1.5 mg/kg/day with placebo and after six months of treatment there was a statistically significant improvement in lifting weights in the prednisone group, with a MD of 0.96 (95% CI 0.52 to 1.40, n = 57) (see <a href="./references#CD003725-fig-0021" title="">Analysis 1.15</a>). </p> </section> </section> <section id="CD003725-sec-0076"> <h6 class="title">(2) Functional outcome measures</h6> <section id="CD003725-sec-0077"> <p><b>(a) Time taken to rise from the floor (Gowers' time)</b></p> <p>Five studies provided six‐month data on time taken to rise to the standing position (as described in <a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a>) (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). A decrease in Gowers' time indicates better ability to rise from the floor, representing improvement. </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>, a cross‐over study in which 16 participants were analysed (17 randomised), compared an intermittent regimen of prednisone (0.75 mg/kg/day given for the first 10 days of every month, for six months) with placebo. There was a statistically significant difference in the time taken to rise from the floor during the prednisone phase compared to the rising time in the placebo phase. Using the SEs inferred from the quoted P values, the RevMan GIV facility gave a difference in favour of prednisone of ‐1.08 seconds (95% CI ‐2.51 to 0.35) (see <a href="./references#CD003725-fig-0012" title="">Analysis 1.6</a>). </p> <p>Analysis of pooled data from <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>, <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>, and <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> demonstrated statistically significant improvement in the prednisone 0.75 mg/kg/day group compared with placebo after six months of treatment. Using the SEs inferred from the quoted P values for the older studies, or derived using the RevMan calculator function from the <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> group means, SD and N, the RevMan GIV facility gave a difference in favour of prednisone of ‐2.28 seconds (95% CI ‐3.12 to ‐1.44) (see <a href="./references#CD003725-fig-0012" title="">Analysis 1.6</a>). Removal of <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> had no substantial effect on the result (MD ‐2.22, 95% CI ‐3.17 to ‐1.26), </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.3 mg/kg/day with placebo. The GIV analysis showed that after six months of treatment, there was a difference in favour of prednisone of ‐1.59 seconds (95% CI ‐3.75 to 0.57) (see <a href="./references#CD003725-fig-0012" title="">Analysis 1.6</a>). </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> also compared prednisone 1.5 mg/kg/day with placebo. The GIV analysis showed that after six months of treatment, there was a difference in favour of prednisone of ‐2.74 seconds (95% CI ‐3.98 to ‐1.50) (see <a href="./references#CD003725-fig-0012" title="">Analysis 1.6</a>). </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> compared the effects of daily 12‐month treatment with 0.75 mg/kg/day prednisone to placebo (n = 60). The results indicated a MD in Gowers' time post treatment in favour of prednisone of ‐2.21 seconds (95% CI ‐3.88 to ‐0.54) (see <a href="./references#CD003725-fig-0012" title="">Analysis 1.6</a>). </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> reported change in Gowers' time (units assumed to be seconds) with no significant difference between deflazacort (2 mg/kg alternate days) and placebo at 6 months (MD ‐2.06, 95% CI ‐6.70 to 2.58, n = 19) or 24 months (MD ‐4.86, 95% CI ‐11.01 to 1.29, n = 10) (<a href="./references#CD003725-fig-0013" title="">Analysis 1.7</a>; <a href="./references#CD003725-fig-0015" title="">Analysis 1.9</a>). </p> </section> <section id="CD003725-sec-0078"> <p><b>(b) Timed walk</b></p> <p>The time taken to walk nine metres (as described in <a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a>) was reported in four studies (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). A decrease in walking time indicates ability to walk faster, representing improvement. </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> compared an intermittent regimen of prednisone (0.75 mg/kg/day given for the first 10 days of every month, for six months) with placebo, in a cross‐over design study. There was a statistically significant difference in nine metres running time during the prednisone phase compared to the running time in the placebo phase. Using the SEs inferred from the quoted P values, the RevMan GIV facility gave a difference in favour of prednisone of ‐0.68 seconds (95% CI ‐1.15 to ‐0.21, n = 16) (see <a href="./references#CD003725-fig-0016" title="">Analysis 1.10</a>). </p> <p>Analysis of pooled data from <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>, and <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> demonstrated a statistically significant improvement in nine‐metre walking time in the prednisone 0.75 mg/kg/day group after six months of treatment. Using the SEs inferred from the quoted P values, the RevMan GIV facility gave a difference in favour of prednisone of ‐2.73 seconds (95% CI ‐3.97 to ‐1.50, n = 111; moderate quality evidence) (see <a href="./references#CD003725-fig-0016" title="">Analysis 1.10</a>; <a href="#CD003725-fig-0004">Figure 4</a>; <a href="./full#CD003725-tbl-0001">summary of findings Table for the main comparison</a>). Removal of <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> had no substantial effect on the result (MD ‐2.39 seconds, 95% CI ‐3.50 to ‐1.27). </p> <div class="figure" id="CD003725-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.7 Nine‐metre walking/running time after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.7 Nine‐metre walking/running time after 6 months of treatment ‐ prednisone. </p> </div> </div> </div> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.3 mg/kg/day with placebo. The GIV analysis showed that after six months of treatment, there was a difference in favour of prednisone of ‐1.18 (95% CI ‐2.65 to 0.29, n = 40) (see <a href="./references#CD003725-fig-0016" title="">Analysis 1.10</a>). </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> also compared prednisone 1.5 mg/kg/day with placebo. The GIV analysis showed that after six months of treatment, there was a difference in favour of prednisone of ‐2.64 seconds (95% CI ‐4.45 to ‐0.83, n = 57) (see <a href="./references#CD003725-fig-0016" title="">Analysis 1.10</a>). </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> reported time to walk 10 metres, which prevented inclusion of data in the meta‐analysis. The trial reported a post treatment MD (seconds) in favour of daily prednisone 0.75 mg/kg/day over placebo; at six months, the MD was ‐0.94 (95% CI ‐1.73 to ‐0.15, n = 63), and at one year ‐1.71 seconds (95% CI ‐2.74 to ‐0.68, n = 58) (see <a href="./references#CD003725-fig-0018" title="">Analysis 1.12</a>; <a href="./references#CD003725-fig-0019" title="">Analysis 1.13</a>. </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> reported change in timed walk (we assume in seconds); the MD favoured deflazacort (2 mg/kg alternate days) at six months (MD ‐3.01, 95% CI ‐4.76 to ‐1.26, n = 23), but no clear difference was present at 24 months (MD ‐0.67, 95% CI ‐2.37 to 1.03, n = 12) (see <a href="./references#CD003725-fig-0017" title="">Analysis 1.11</a>; <a href="./references#CD003725-fig-0020" title="">Analysis 1.14</a>). </p> </section> <section id="CD003725-sec-0079"> <p><b>(c) Four‐stair climbing time</b></p> <p>Five studies reported the time taken to climb four standardised stairs (as described in <a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a>) at six months (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). A decrease in four‐stair climbing time indicates ability to ascend stairs faster, representing improvement. </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> compared an intermittent regimen of prednisone (0.75 mg/kg/day given for the first 10 days of every month for six months) with placebo, in a cross‐over design study. There was a statistically significant difference in four‐stair climbing time during the prednisone phase compared to the placebo phase. Using the SEs inferred from the quoted P values the RevMan GIV facility gave a difference in favour of prednisone of ‐1.93 seconds (95% CI ‐3.56 to ‐0.30, n = 16) at 6 months (see <a href="./references#CD003725-fig-0022" title="">Analysis 1.16</a>). </p> <p>Analysis of pooled data from <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>, <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>, and <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> demonstrated a statistically significant benefit over placebo in four‐stair climbing time in the prednisone 0.75 mg/kg/day group after six months of treatment. Using the SEs inferred from the quoted P values for the older studies, and using the RevMan calculator tool to derive SE from the <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> (final values) data, the RevMan GIV facility gave a difference in favour of prednisone of ‐3.09 seconds (95% CI ‐4.33 to ‐1.85, n = 135; moderate quality evidence) (see <a href="./references#CD003725-fig-0022" title="">Analysis 1.16</a>; <a href="./full#CD003725-tbl-0001">summary of findings Table for the main comparison</a>). Removal of <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> had no substantial effect on the result (MD ‐2.98, 95% CI ‐4.43 to ‐1.53), and increased heterogeneity (I<sup>2</sup> = 66%). </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.3 mg/kg/day with placebo. The GIV analysis showed that after six months of treatment, there was a difference in favour of prednisone of ‐2.68 seconds (95% CI ‐4.06 to ‐1.30, n = 32) (see <a href="./references#CD003725-fig-0022" title="">Analysis 1.16</a>; <a href="#CD003725-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD003725-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.11 Four‐stair climbing time after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.11 Four‐stair climbing time after 6 months of treatment ‐ prednisone. </p> </div> </div> </div> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> compared prednisone 1.5 mg/kg/day with placebo. The GIV analysis showed that after six months of treatment, there was a difference in favour of prednisone of ‐3.05 seconds (95% CI ‐ 4.41 to ‐1.69, n = 42) (see <a href="./references#CD003725-fig-0022" title="">Analysis 1.16</a>). </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> compared daily prednisone 0.75 mg/kg/day with placebo. After a year of treatment, the mean difference in four‐stair climb time favoured prednisone, at ‐1.63 seconds (95% CI ‐3.07 to ‐0.19, n = 52) (see <a href="./references#CD003725-fig-0024" title="">Analysis 1.18</a>). </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> reported change in "time, stairs" (not further specified), comparing deflazacort (2 mg/kg alternate days) and placebo. The results (we assume in seconds) were imprecise, allowing for the possibility of effects in either direction, MD ‐2.96, 95% CI ‐7.02 to 1.10, n = 23 at six months, and MD 0.63, 95% CI ‐4.29 to 5.55, n = 11 at 24 months (see <a href="./references#CD003725-fig-0023" title="">Analysis 1.17</a>; <a href="./references#CD003725-fig-0025" title="">Analysis 1.19</a>). </p> </section> <section id="CD003725-sec-0080"> <p><b>(d) Leg function grade</b></p> <p>Leg function grade (as described in <a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a> and <a href="./references#CD003725-bbs2-0083" title="BrookeMH , FenichelGM , GriggsRC , MendellJR , MoxleyR , ProvinceMA . Clinical investigation in Duchenne dystrophy. 2. Determination of the 'power' of therapeutic trials based on natural history. Muscle &amp; Nerve1983;6(2):91‐103. ">Brooke 1983</a>) was assessed in two studies (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). The leg function grade is assessed on a 10‐point scale: grade 1 representing ability to walk and climb stairs without assistance; and grade 10 representing confinement to bed. Analysis of pooled data from these studies demonstrated a statistically significant improvement in the prednisone 0.75 mg/kg/day group versus placebo after six months of treatment, with a MD of ‐0.41 points (95% CI ‐0.73 to ‐0.09, n = 129) (see <a href="./references#CD003725-fig-0027" title="">Analysis 1.21</a>). </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.3 mg/kg/day with placebo. After six months of treatment the mean improvement in leg function grade was 0.39 points (95% CI 0.01 to 0.79, n = 58) less than in the placebo group (see <a href="./references#CD003725-fig-0027" title="">Analysis 1.21</a>). </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> also compared prednisone 1.5 mg/kg/day with placebo and after six months of treatment the mean improvement in the prednisone group was 0.49 points (95% CI 0.05 to 0.93, n = 68) less than in the placebo group (see <a href="./references#CD003725-fig-0027" title="">Analysis 1.21</a>). </p> </section> </section> <section id="CD003725-sec-0081"> <h6 class="title">(3) Pulmonary function ‐ forced vital capacity (FVC)</h6> <p>FVC (as described in <a href="./references#CD003725-bbs2-0082" title="BrookeMH , GriggsRC , MendellJR , FenichelGM , ShumateJB , PellegrinoRJ . Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle &amp; Nerve1981;4(3):186‐97. ">Brooke 1981</a>) was measured in two studies (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). Analysis of pooled data from these studies demonstrated a mean improvement in FVC in the prednisone 0.75 mg/kg/day group, after six months of treatment of 0.17 L more than in the placebo group (95% CI 0.10 to 0.24, n = 127) (see <a href="./references#CD003725-fig-0028" title="">Analysis 1.22</a>). </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.3 mg/kg/day with placebo. After six months of treatment the improvement in FVC in the prednisone group was 0.16 L (95% CI 0.05 to 0.27, n = 59) more than in the placebo group (see <a href="./references#CD003725-fig-0028" title="">Analysis 1.22</a>). </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> also compared prednisone 1.5 mg/kg/day with placebo. After six months of treatment the mean improvement in FVC in the prednisone group was 0.14 L (95% CI 0.05 to 0.23, n = 62) more than in the placebo group (see <a href="./references#CD003725-fig-0028" title="">Analysis 1.22</a>). </p> </section> <section id="CD003725-sec-0082"> <h6 class="title">(4) Quality of life (QoL)</h6> <p>Measured in <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> and <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>. </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> measured QoL with the DUX‐25 at the start and end of both six‐month trial periods. This questionnaire covers four domains: physical, emotional, social, and home functioning. The items are scored using a five‐point scale. The raw data or statistical analysis of QoL were not available. The QoL did not change significantly during the prednisone period. With every new measurement, however, participants reported a slightly higher QoL, irrespective of the medication given, resulting in a significant improvement in the last measurement on two scales (emotional functioning and the total scale); Beenakker et al considered this to be possibly related to the attention of being involved in a trial. </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> assessed child self reported and parent proxy reported quality of life using the Chinese version of PedsQTLM 3.0 NMM (total score). Items are rated on a five‐point scale, and transformed linearly to a zero to 100 scale. "Scores were computed as the sum of items divided by the number of items answered." Higher scores indicated better quality of life. </p> <p>Twenty‐nine boys were too young to complete the questionnaire at baseline, being under seven years old. Clear differences in favour of prednisone 0.75 mg/kg/day were present at six and 12 months in self reported and proxy reported quality of life. At six months, the MD for the self reported questionnaire was 10.87, 95% CI 0.64 to 21.10, n = 38 and 9.97, 95% CI 1.96 to 17.98, n = 63, for the proxy reported measure. At 12 months, corresponding values were MD 16.05, 6.46 to 25.64, n = 41 and MD 14.42, 95% CI 5.85 to 22.99, n = 58 (<a href="./references#CD003725-fig-0029" title="">Analysis 1.23</a>; <a href="./references#CD003725-fig-0030" title="">Analysis 1.24</a>). </p> </section> <section id="CD003725-sec-0083"> <h6 class="title">(5) Adverse events</h6> <p>Adverse events were evaluated by the different investigators as follows.</p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> examined the participants for adverse effects in an area separate from that of clinical evaluation at baseline and at one, two, three, and six months after the start of prednisone treatment. Trialists reported data for both treatment and placebo groups. </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> examined the participants and interviewed the parents for adverse effects at baseline and at one, two, three, and six months of treatment. Trialists reported data for both treatment and placebo groups. </p> <p><a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> did not report adverse effect data. </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> measured and reported body weight, height, body mass index (BMI) and diastolic blood pressure in prednisone (0.75 mg/kg/day) and control groups at six and 12 months. The report did not provide data on the incidence of other adverse effects for the placebo group; adverse effects occurred in 16 of the 31 children receiving prednisone who completed the 12‐month study. </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> monitored the participants every two months of the study for adverse effects. Trialists reported weight gain data for treatment (deflazacort) and placebo groups, but incidence of the other adverse effects only for the deflazacort group. </p> <p><a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a> asked the parents of participants at the end of the study to report any signs or symptoms that could possibly be related to the treatment. </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> evaluated the adverse effects at each visit by using a standard list that described the corticosteroid‐related adverse effects. This included patient and parent interview for symptoms and examination for physical signs relating to adverse effects. </p> <section id="CD003725-sec-0084"> <p><b>(a) Weight gain</b></p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> and <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> reported this adverse event as per cent weight gain at last visit above baseline (first visit), on the presumption of six months of treatment. As per cent weight gain was only available as the number of participants in each of a set of intervals on the per cent weight gain scale, we derived the mean and SD for each group assuming each individual had the mid‐value of the interval in which they fell. The review authors did not use Sheppard's correction for bias in variances obtained using grouped data because the interval widths were variable and the magnitude of the correction for bias in the SDs was found to be less than 2%. Analysis of pooled data from <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> and <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> demonstrated a statistically significant weight gain in the prednisone 0.75 mg/kg/day group after six months of treatment as compared to placebo, with a MD of 9.27% (95% CI 6.87% to 11.68%, n = 126; moderate quality evidence) (see <a href="./references#CD003725-fig-0031" title="">Analysis 1.25</a>; <a href="./full#CD003725-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> reported that one participant in the prednisone (0.75 mg/kg/day) group showed obvious weight gain at 12 months (placebo group not reported). However, no clear difference in weight was present between the prednisone and placebo groups at six and 12 months, with wide CIs (<a href="./references#CD003725-fig-0034" title="">Analysis 1.28</a>; <a href="./references#CD003725-fig-0035" title="">Analysis 1.29</a>). Similarly, BMI (kg/m<sup>2</sup>) showed no clear difference at six or 12 months, with wide CIs (<a href="./references#CD003725-fig-0036" title="">Analysis 1.30</a>; <a href="./references#CD003725-fig-0037" title="">Analysis 1.31</a>). </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> compared an intermittent regimen of prednisone (0.75 mg/kg/day given for the first 10 days of every month, for six months) with placebo, in a cross‐over design study. They reported the difference and P value in weight as daily rate of change, obtained from a regression using data from a six‐month follow‐up period. We scaled up the response to 24 weeks (six months) equivalent, and deduced the standard error (SE) from the P values. The mean weight gain during the prednisone phase (2.37 kg) was greater than in the placebo phase (1.47 kg), but the analysis using the SEs inferred from the quoted P values and the RevMan GIV facility showed that the difference, 0.84 kg (95% CI ‐0.04 to 1.72), did not quite reach statistical significance (see <a href="./references#CD003725-fig-0032" title="">Analysis 1.26</a>). </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> compared deflazacort with placebo and presented weight gain data for 11 deflazacort and five placebo patients as per cent weight change. As per cent weight change was only reported as the number of participants in each of a set of intervals on the per cent weight gain scale, the mean and SD for each group were derived as described above for <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> and <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>. After two years of treatment, the degree of weight gain in the deflazacort group was slightly greater than that in the placebo group, but as CIs include the possibility of large effects in either direction (MD 1.09%, 95% CI ‐13.92 to 16.10, n = 16) (see <a href="./references#CD003725-fig-0033" title="">Analysis 1.27</a>), we can draw no conclusions. </p> </section> <section id="CD003725-sec-0085"> <p><b>(b) Behavioural changes</b></p> <p>Three studies reported the number of patients with behavioural changes in treatment and placebo groups (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). </p> <p>Analysis of pooled data from these studies demonstrated a statistically non‐significant risk of behavioural changes in the prednisone 0.75 mg/kg/day group after six months of treatment as compared to placebo, with a RR of 1.39 (95% CI 0.94 to 2.06; moderate quality evidence) (see <a href="./references#CD003725-fig-0039" title="">Analysis 1.33</a>; <a href="./full#CD003725-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.3 mg/kg/day with placebo. After six months of treatment there was no statistically significant difference in behavioural changes in the prednisone and placebo groups, with a RR of 1.02 (95% CI 0.67 to 1.56) (see <a href="./references#CD003725-fig-0039" title="">Analysis 1.33</a>). </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> compared prednisone 1.5 mg/kg/day with placebo. After six months of treatment there was a trend to increased risk of behavioural changes in the prednisone group but this was not statistically significant, with a RR of 1.43 (95% CI 0.92 to 2.24) (see <a href="./references#CD003725-fig-0039" title="">Analysis 1.33</a>). </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> compared an intermittent regimen of prednisone (0.75 mg/kg/day given for the first 10 days of every month, for six months) with placebo, in a cross‐over design study. The study reported the number of patients with behavioural side effects (hyperactivity, irritability, euphoria) in prednisone‐treated and placebo‐ treated participants, but data on occurrence of these adverse effects during all four phases of the cross‐over trial were not presented or available, and because of this, the review authors could not undertake appropriate statistical analysis. </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> reported behavioural changes in six of 11 participants in the deflazacort group at six months but did not report the data for the placebo group. </p> </section> <section id="CD003725-sec-0086"> <p><b>(c) Cushingoid appearance</b></p> <p>Three studies reported the number of participants with cushingoid appearance in treatment and placebo groups (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> compared an intermittent regimen of prednisone (0.75 mg/kg/day given for the first 10 days of every month, for six months) with placebo, in a cross‐over design study. Four participants were noted to have cushingoid appearance during the prednisone treatment period as compared to one in the placebo period. Data on occurrence of this adverse effect during all four phases of the cross‐over trial were not presented or available, and because of this, we could not undertake appropriate statistical analysis. </p> <p>Analysis of pooled data from <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> and <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> demonstrated a significant risk of cushingoid appearance in the prednisone 0.75 mg/kg/day group after six months of treatment as compared to placebo, with a RR of 2.37 (95% CI 1.53 to 3.67) (see <a href="./references#CD003725-fig-0040" title="">Analysis 1.34</a>). </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.3 mg/kg/day with placebo. After six months of treatment there was no significant difference in cushingoid appearance in the prednisone and placebo groups, with a RR of 1.15 (95% CI 0.60 to 2.17) (see <a href="./references#CD003725-fig-0040" title="">Analysis 1.34</a>). </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> also compared prednisone 1.5 mg/kg/day with placebo, and after six months of treatment there was a significant risk of cushingoid appearance in the prednisone group, with a RR of 4.36 (95% CI 2.04 to 9.33) (see <a href="./references#CD003725-fig-0040" title="">Analysis 1.34</a>). </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> reported a cushingoid appearance in two of 11 participants in the deflazacort group at six months but did not report data for the placebo group. </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> reported a cushingoid appearance in three of 31 participants in the prednisone (0.75 mg/kg/day) group at 12 months but did not report data for the placebo group. </p> </section> <section id="CD003725-sec-0087"> <p><b>(d) Excessive hair growth (hirsutism)</b></p> <p>Two studies reported the number of participants with excessive hair growth in treatment and placebo groups (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). Analysis of pooled data from these studies demonstrated a statistically significant risk of excessive hair growth in the prednisone 0.75 mg/kg/day group after six months of treatment as compared to the placebo group, with a RR of 2.60 (95% CI 1.47 to 4.60) (see <a href="./references#CD003725-fig-0038" title="">Analysis 1.32</a>). </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.3 mg/kg/day with placebo. After six months of treatment there was no significant difference in excessive hair growth in the prednisone and placebo groups, with a RR of 0.73 (95% CI 0.18 to 3.0) (see <a href="./references#CD003725-fig-0038" title="">Analysis 1.32</a>). </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> also compared prednisone 1.5 mg/kg/day with placebo, and after six months of treatment there was a significant increase in the number of boys with excessive hair growth in the prednisone group, with a RR of 2.32 (95% CI 1.16 to 4.64) (see <a href="./references#CD003725-fig-0038" title="">Analysis 1.32</a>). </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> reported excessive hair growth in none of the 11 participants at six months and in three out of eight patients at two years in the deflazacort group, but did not report data for the placebo group. </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> reported hair growth in two of 31 participants in the prednisone group at 12 months, but did not report data for the placebo group. </p> </section> <section id="CD003725-sec-0088"> <p><b>(e) Acne</b></p> <p>Two studies reported the number of participants with acne in treatment and placebo groups (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). Analysis of pooled data from these studies demonstrated a trend to develop acne in the prednisone 0.75 mg/kg/day group after six months of treatment as compared to placebo but this was not statistically significant, with a RR of 1.78 (95% CI 0.96 to 3.32) (see <a href="./references#CD003725-fig-0041" title="">Analysis 1.35</a>). </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.3 mg/kg/day with placebo and after six months of treatment there was no significant difference in acne in the prednisone and placebo groups, with a RR of 0.73 (95% CI 0.18 to 3.0) (see <a href="./references#CD003725-fig-0041" title="">Analysis 1.35</a>). </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> compared prednisone 1.5 mg/kg/day with placebo and after six months of treatment there was a trend to develop acne in the prednisone group, but this was not statistically significant, with a RR of 1.77 (95% CI 0.84 to 3.73) (see <a href="./references#CD003725-fig-0041" title="">Analysis 1.35</a>). </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> reported acne in two of 31 participants in the prednisone group at 12 months, but did not report data for the placebo group. </p> </section> <section id="CD003725-sec-0089"> <p><b>(f) Osteoporosis, fractures</b></p> <p>None of the included studies performed bone densitometry studies. Two studies instructed the participants in the study to take 0.3 g calcium carbonate with each meal (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). Two of the included studies commented upon fractures (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>). <a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> reported pathological fracture of the tibia in one participant in the deflazacort‐treated group. There was no description of the timing of the fracture in relation to duration of deflazacort treatment, circumstances leading to the fracture, or results of any bone density studies. One participant, randomised to the placebo group in the first phase of <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>, developed a traumatic fracture of the femur 10 days into the study and dropped out. One participant in the placebo treatment group in <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> dropped out of the study because of an arm fracture; <a href="./references#CD003725-bbs2-0037" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology1993;43(3 Pt 1):520‐7. ">Griggs 1993</a> subsequently reported this incident. </p> </section> <section id="CD003725-sec-0090"> <p><b>(g) Hyperglycemia/glycosuria</b></p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> and <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a> checked blood glucose, and another two studies checked urine dipstix (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> reported glycosuria in one participant, who was on prednisone 0.75 mg/kg/day. The report did not state the severity of glycosuria and its impact. </p> </section> <section id="CD003725-sec-0091"> <p><b>(h) Hypokalemia</b></p> <p>Only <a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> and <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a> performed blood tests for electrolyte surveillance. <a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> reported "mild hypokalemia" in three of 11 deflazacort‐treated participants but this was "easily correctable" with oral potassium supplements. </p> </section> <section id="CD003725-sec-0092"> <p><b>(i) Hypertension</b></p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> reported hypertension with a blood pressure of 130/110 in one participant taking prednisone 0.75 mg/kg/day. </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> did not report any hypertension. Monitoring of diastolic blood pressure revealed no statistically significant differences at six or 12 months between the group treated with prednisone 0.75 mg/kg/day and the group receiving placebo. </p> </section> <section id="CD003725-sec-0093"> <p><b>(j) Gastrointestinal side effects</b></p> <p>Gastrointestinal side effects were defined differently and inconsistently in the included studies. </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> grouped increased appetite, nausea and stomach discomfort under the umbrella of gastrointestinal symptoms; these, as a whole, were not significantly different between the placebo and prednisone treatment groups. <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> reported increased appetite as a separate side effect and this was significantly more frequent in the prednisone 0.75 mg/kg/day group as compared to the placebo group (P = 0.02). <a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> reported that in their two‐year study, none of the participants developed gastrointestinal disturbances on deflazacort 2 mg/kg on alternate days; they had, however, treated all the children with antacids (drug name not specified). Parents of the participants in <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>, the study of prednisolone 0.35 mg/kg/day, did not report gastrointestinal side effects. </p> </section> <section id="CD003725-sec-0094"> <p><b>(k) Increased appetite</b></p> <p>Two studies reported the number of participants with increased appetite in treatment and placebo groups or phases (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>). </p> <p><a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> compared an intermittent regimen of prednisone (0.75 mg/kg/day given for the first 10 days of every month, for six months) with placebo, in a cross‐over design study. Four of the 16 participants were noted to have increased appetite during the prednisone treatment period as compared to one out of 16 in the placebo period. Data on occurrence of this adverse effect during all four phases of the cross‐over trial were not presented or available, and because of this, review authors could not undertake appropriate statistical analysis. </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> compared prednisone 0.3 mg/kg/day with placebo. After six months of treatment, there was no significant difference in the prednisone and placebo groups with a RR of 1.54 (95% CI 0.90 to 2.62) (see <a href="./references#CD003725-fig-0042" title="">Analysis 1.36</a>). </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> also compared prednisone 0.75 mg/kg/day with placebo. After six months of treatment, there was no significant difference in the prednisone and placebo groups, with a RR of 1.80 (95% CI 1.09 to 2.99) (see <a href="./references#CD003725-fig-0042" title="">Analysis 1.36</a>). </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> reported increased appetite in six of 31 participants in the prednisone (0.75 mg/kg/day) group at 12 months, but did not report data for the placebo group. </p> </section> <section id="CD003725-sec-0095"> <p><b>(l) Cataracts</b></p> <p>The participants were evaluated for cataracts in four of the six included studies (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>), but the studies did not describe the precise examination (slit lamp or red reflex) performed for detection of cataracts. No cataracts were reported. </p> </section> <section id="CD003725-sec-0096"> <p><b>(m) Death</b></p> <p><a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a> reported two deaths during the study. A 16‐year‐old boy died of pneumonia and a four‐year‐old died during an appendectomy. The authors did not report whether the deaths occurred during the prednisolone or the placebo phases. </p> </section> <section id="CD003725-sec-0097"> <p><b>(n) Life‐threatening infections</b></p> <p>Two studies described specific monitoring to document episodes of intercurrent infection (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). None of the studies described the treatment strategy for exposure to chicken pox (varicella zoster). Apart from the 16‐year‐old boy who died of pneumonia described above (<a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>), the trials reported no other episodes of infection. </p> <p><i>(o) Height restriction</i> </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> and <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> stated that they measured height, but presented no data. <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>, <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005,</a> and <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> did not describe height measurement. </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> measured height (cm) at 6 and 12 months, reporting no clear difference in height between prednisone‐treated and placebo‐treated boys, although the results were imprecise, and allowed for effects in either direction (MD ‐0.88, 95 CI ‐6.89 to 5.13, n = 63 at 6 months and MD ‐2.62, 95% CI ‐8.66 to 3.42; n = 58, at 12 months) (see <a href="./references#CD003725-fig-0043" title="">Analysis 1.37</a>; <a href="./references#CD003725-fig-0044" title="">Analysis 1.38</a>). </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> monitored height every 2 months. By two years, growth was 11.4 ± 2.7 cm in the treated group and 11.2 ± 2.2 cm in the placebo group; however, the report does not state the numbers of boys measured at this time point. </p> </section> </section> </section> <section id="CD003725-sec-0098"> <h5 class="title">Observations on prednisone dose‐response relationship and adverse events</h5> <p>A full investigation of the prednisone dose‐response relationship to identify the optimum dose would need individual patient data within‐study analyses, and the included studies reported no such analyses. We consider this further in the <a href="#CD003725-sec-0156">Discussion</a>. </p> <p>Two studies made direct comparisons of prednisone doses (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). </p> <p><a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> compared 0.3 mg/kg/day prednisone to 0.75 mg/kg/day prednisone, finding statistically significant differences in favour of the higher dose in average muscle strength scores (5.82 versus 6.00, P = 0.026, n = 65), time (seconds) to climb stairs (5.76 versus 4.23, P = 0.0014, n = 37), time (seconds) to stand (6.64 versus 4.56, P = 0.004, n = 33), and lifting weights (kg) (1.64 versus 2.04, P = 0.0006, n = 43), but no statistically significant differences in leg function grade (4.07 versus 4.19, P = 0.53, n = 63), time (seconds) to travel nine metres (7.33 versus 6.37, P = 0.127, n = 44), or measures of pulmonary function. </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> compared 0.75 mg/kg/day prednisone with 1.5 mg/kg/day prednisone, finding no statistically significant differences in strength or functional outcomes between the two doses: muscle strength score (6.23 versus 6.5, P = 0.84, n = 60), leg function grade (3.25 versus 3.36, P = 0.67, n = 64), time (seconds) to climb stairs (3.87 versus 4.00, P = 0.74, n = 47), time (seconds) to travel nine metres (6.81 versus 7.04, P = 0.77, n = 55), time (seconds) to stand (4.15 versus 3.43, P = 0.055, n = 34), lifting weights (1.88 versus 2.13, P = 0.06, n = 55), or in measures of pulmonary function. </p> <p>From the forest plots showing studies grouped by dosage of prednisone on several outcome variables, the confidence in effect estimates for the efficacy of prednisone doses of 0.75 mg/kg/day or above appears fairly secure. There was no evidence from <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> of further benefit at 1.5 mg/kg/day. </p> <p>Comparing adverse event rates at the 0.3 mg/kg/day (n = 33) and 0.75 mg/kg/day (n = 34) prednisone doses, the only statistically significant differences between groups were in numbers reporting hair growth (9% versus 41%, P = 0.006) and cushingoid features (41% versus 71%, P = 0.02) (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>). The between‐group difference in number of participants with over 20% weight gain (11% versus 31%) was not statistically significant (P = 0.18), and this was also the case for differences in ankle oedema (3% versus 6%, P = 0.60), acne (9% versus 26%, P = 0.08), insomnia (9% versus 18%, P = 0.33), anorexia (3% versus 3%, P = 0.97), hyperactivity (16% versus 26%, P = 0.42), irritability (34% versus 50%, P = 0.20), increased appetite (59% versus 68%, P = 0.49), and glycosuria (0% versus 3%, P = 0.71). No cataracts occurred. </p> <p><a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> reported no statistically significant differences in rates of individual adverse events between a 0.75 mg/kg/day daily prednisone dose (n = 33) and a 1.5 mg/kg/day daily dose (n = 33). Adverse events reported were: behavioural change (48% versus 64%, P = 0.22), cushingoid appearance (55% versus 73%, P = 0.13), gastrointestinal symptoms (55% versus 61%, P = 0.62), excessive hair growth (52% versus 52%, P = 1.0), acne (36% versus 39%, P = 0.80), and easy bruising (3% versus 6%, P = 0.56). No participants had glycosuria or cataracts. </p> </section> </section> <section id="CD003725-sec-0099"> <h4 class="title">Weekend‐only versus daily prednisone</h4> <p>Studied in <a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a>. See <a href="./full#CD003725-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD003725-sec-0100"> <h5 class="title">Primary outcome measure: prolongation of time to loss of ambulation</h5> <p>Not reported.</p> </section> <section id="CD003725-sec-0101"> <h5 class="title">Secondary outcome measures</h5> <section id="CD003725-sec-0102"> <h6 class="title">(1) Muscle strength</h6> <p><a href="./references#CD003725-fig-0045" title="">Analysis 2.1</a>. </p> <section id="CD003725-sec-0103"> <p><b>(a) Average muscle score</b></p> <p><a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a> measured upper and lower extremity muscle strength using QMT scores ("the summation of maximal isometric voluntary contraction force of flexors and extensors of elbow and knee") as primary outcomes. The trialists also conducted manual muscle testing (MMT) using the modified MRC scale. </p> <p>The mean change from baseline to month 12 in the MMT score (SD) in 54 participants was 4 (24.3) in the weekend‐only dosing group and ‐0.6 (23.2) in the daily dose group, with a MD of 4.60 (95% CI ‐8.07 to 17.27); low quality evidence. The trial authors defined an 'equivalence limit' for MMT as one point on the 10‐point scale for each of the 34 muscles tested, which was ± 17 points; by this test, the upper CI just allows for the possibility of a difference between weekend‐only and daily dosing. </p> <p>Results for QMT scores all included data from 57 participants. For the QMT arm score and QMT leg score, the trial authors reported an equivalent improvement in the two groups (with equivalence defined as approximately 1 SD of the baseline distribution, which was ± 2 lb for all muscle strength tests). The mean change in QMT arm score from baseline (SD) was 0.70 lb (1.7) in the weekend‐only dosing group and 1.3 lb (2.4) in the daily dose group. This was a MD of ‐0.60 lb (95% CI ‐1.67 to 0.47); moderate quality evidence (<a href="./full#CD003725-tbl-0002">summary of findings Table 2</a>). The change in QMT leg score was 2.2 lb (3.7) in the weekend‐only dosing group and 2.10 lb (3.4) in the daily dosing group, with a MD of 0.10 (95% CI ‐1.75 to 1.95; moderate quality evidence; <a href="./full#CD003725-tbl-0002">summary of findings Table 2</a>). </p> <p>QMT scores for elbow flexors (MD ‐0.4, 95% CI ‐1.60 to 0.80) and elbow extensors (MD ‐0.9, 95% CI ‐2.00 to 0.20) also met the test for equivalence. However, knee flexors (MD 1.40, 95% CI ‐0.50 to 3.30), knee extensors (MD ‐1.20, 95% CI ‐3.52 to 1.12), and grip score (MD ‐1.70, 95% CI ‐3.22 to ‐0.18) did not, with the CIs allowing for the possibility of a difference between groups. </p> </section> <section id="CD003725-sec-0104"> <p><b>(b) Ability to lift weights</b></p> <p>Not reported.</p> </section> </section> <section id="CD003725-sec-0105"> <h6 class="title">(2) Functional outcome measures</h6> <p><a href="./references#CD003725-fig-0046" title="">Analysis 2.2</a>. </p> <p>In <a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a>, the trial authors defined an 'equivalence limit' for timed functional tests of ± 0.4 seconds. </p> <section id="CD003725-sec-0106"> <p><b>(a) Time taken to rise from the floor (Gowers' time)</b></p> <p>Using the trial authors' definition of equivalence, we found no evidence of difference between weekend‐only and daily prednisone in change in mean Gowers' time (seconds) at 12 months (MD 0.15, 95% CI ‐0.02 to 0.32, n = 46). </p> </section> <section id="CD003725-sec-0107"> <p><b>(b) Timed walk</b></p> <p>Using the trial authors' definition of equivalence, we found no evidence of a difference between weekend‐only and daily prednisone on change in the 10‐metre walking time (seconds) between weekend‐only and daily prednisone groups (MD 0.00, 95% CI ‐0.21 to 0.21, n = 56; moderate quality evidence; <a href="./full#CD003725-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD003725-sec-0108"> <p><b>(c) Four‐stair climbing time</b></p> <p>Using the trial authors' definition of equivalence, we found no evidence of a difference between weekend‐only and daily prednisone on change in mean four‐stair climbing time (seconds) (MD 0.0, 95% CI ‐0.22 to 0.22, n = 55; moderate quality evidence; <a href="./full#CD003725-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD003725-sec-0109"> <p><b>(d) Leg function grade</b></p> <p><a href="./references#CD003725-fig-0047" title="">Analysis 2.3</a>. </p> <p>We found no difference between weekend‐only and daily prednisone in change on the Vignos scale (MD 0.04, 95% CI ‐0.7 to 0.8, n = 58). This is a 10‐point lower extremity mobility function scale, grade 1 representing ability to walk and climb stairs without assistance and grade 10 representing confinement to bed. The trial authors defined equivalence as ± 0.6, so the results are too imprecise to rule out difference on this measure. </p> </section> <section id="CD003725-sec-0110"> <p><b>(e) Arm function grade</b></p> <p><a href="./references#CD003725-fig-0048" title="">Analysis 2.4</a>. </p> <p>We found no significant difference in arm function grade measured using the Brooke scale, a six‐point scale in which grade 1 represents full straight arm abduction (to touch above the head) and grade 6 represents no useful function of the hands (MD 0.10, 95% CI ‐0.62 to 0.82). The trial authors defined equivalence as ± 0.3, so the results are too imprecise to rule out a difference on this measure. </p> </section> </section> <section id="CD003725-sec-0111"> <h6 class="title">(3) Pulmonary function ‐ forced vital capacity (FVC), forced expiratory volume in one second (FEV<sub>1</sub>) </h6> <p><a href="./references#CD003725-fig-0049" title="">Analysis 2.5</a>; <a href="./references#CD003725-fig-0050" title="">Analysis 2.6</a>; <a href="./references#CD003725-fig-0051" title="">Analysis 2.7</a>; <a href="./references#CD003725-fig-0052" title="">Analysis 2.8</a>. </p> <p>In 31 participants, the FVC% and the FEV<sub>1</sub>% (n = 31) predicted showed no clear difference between the two treatments (MD 4.4%, 95% CI ‐9.79 to 18.59, and MD 6.0%, 95% CI ‐9.15 to 21.15, respectively). For pulmonary function tests the authors defined equivalence as ± 10% of the per cent predicted. The CIs therefore do not rule out the possibility of a difference between the groups. </p> <p>Maximal voluntary ventilation (MVV) was measured in 27 participants. There was not a clear difference between weekend‐only and daily prednisone (MD 4.00, 95% CI ‐1.68 to 9.68). </p> <p>Maximal inspiratory pressure (MIP) was measured in 42 people. We did not find evidence of a difference between the two treatments in this comparison (MD 0.00, 95% CI ‐7.63 to 7.63). </p> </section> <section id="CD003725-sec-0112"> <h6 class="title">(4) Quality of life (QoL)</h6> <p>Not assessed.</p> </section> <section id="CD003725-sec-0113"> <h6 class="title">(5) Adverse events</h6> <section id="CD003725-sec-0114"> <p><b>(a) Weight gain</b></p> <p><a href="./references#CD003725-fig-0053" title="">Analysis 2.9</a>; <a href="./references#CD003725-fig-0054" title="">Analysis 2.10</a>. </p> <p>We found no clear evidence of a difference in mean body mass index (BMI) (mg/m<sup>2</sup>) with weekend‐only versus daily dosing at 12 months (MD ‐1.8 kg/m<sup>2</sup>, 95% CI ‐3.74 to 0.14, n = 58). Weight in kg after 12 months of treatment showed no clear difference between the groups (MD ‐2.5 kg, 95% CI ‐7.54 to 2.54, n = 58; low quality evidence; <a href="./full#CD003725-tbl-0002">summary of findings Table 2</a>). </p> <p>Dosage reductions because of BMI increases were necessary in three participants in the daily group and one participant in the weekend‐only group. </p> </section> <section id="CD003725-sec-0115"> <p><b>(b) Behavioural changes</b></p> <p><a href="./references#CD003725-fig-0055" title="">Analysis 2.11</a>; <a href="./references#CD003725-fig-0056" title="">Analysis 2.12</a>; <a href="./references#CD003725-fig-0057" title="">Analysis 2.13</a>; <a href="./references#CD003725-fig-0058" title="">Analysis 2.14</a>; <a href="./references#CD003725-fig-0059" title="">Analysis 2.15</a>; <a href="./references#CD003725-fig-0060" title="">Analysis 2.16</a>; <a href="./references#CD003725-fig-0061" title="">Analysis 2.17</a>; <a href="./references#CD003725-fig-0062" title="">Analysis 2.18</a>. </p> <p><a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a> measured behavioural changes using the Child Behavior Checklist, a rating scale on which higher scores indicate more severe behavioural changes. There was no clear difference between weekend‐only and daily prednisone on any of the scales: total problems (MD 1.00, 95% CI ‐4.34 to 6.34, n = 54; low quality evidence; <a href="./full#CD003725-tbl-0002">summary of findings Table 2</a>), internalising (MD 4.0, 95% CI ‐0.8 to 8.8, n = 54), externalising (MD ‐1.0, 95% CI ‐6.62 to 4.62, n = 54), anxious/depressed (MD ‐1.0, 95% CI ‐4.99 to 2.99, n = 55), somatic complaints (MD 2.0, 95% CI ‐2.24 to 6.24, n = 55), withdrawn/depressed (MD 4.0, 95% CI ‐0.3 to 8.3, n = 55), attention problems (MD 2.0, 95% CI ‐2.4 to 6.4, n = 56), or aggressive behaviour (MD 1.0, 95% CI ‐3.52 to 5.52, n = 55). </p> <p>One participant in the daily group had a dosage reduction because of behaviour problems, but there were no withdrawals. </p> </section> <section id="CD003725-sec-0116"> <p><b>(c) Cushingoid appearance</b></p> <p>One participant on weekend‐only dosing had dosage reduction for the development of cushingoid features. </p> </section> <section id="CD003725-sec-0117"> <p><b>(d) Excessive hair growth (hirsutism)</b></p> <p>Not reported.</p> </section> <section id="CD003725-sec-0118"> <p><b>(e) Acne</b></p> <p>Not reported.</p> </section> <section id="CD003725-sec-0119"> <p><b>(f) Osteoporosis, fractures</b></p> <p><a href="./references#CD003725-fig-0063" title="">Analysis 2.19</a>. </p> <p>In 53 participants, there was no significant difference between groups in lumbar spine Z scores (SD) at 12 months: weekend‐only dose ‐0.88 (0.85); daily dose ‐1.33 (0.91), P = 0.06. However, the change in Z score from baseline to 12 months favoured weekend‐only dosing, with a small increase in the weekend‐only dosing group (change of +0.26), compared with a small decline with daily prednisone (change of ‐0.30), P = 0.001. </p> </section> <section id="CD003725-sec-0120"> <p><b>(g) Hyperglycemia/glycosuria</b></p> <p>Not reported.</p> </section> <section id="CD003725-sec-0121"> <p><b>(h) Hypokalemia</b></p> <p>Not reported.</p> </section> <section id="CD003725-sec-0122"> <p><b>(i) Hypertension</b></p> <p>Not reported.</p> </section> <section id="CD003725-sec-0123"> <p><b>(j) Gastrointestinal side effects</b></p> <p>One participant in the weekend‐only group withdrew from the study because of severe vomiting. </p> </section> <section id="CD003725-sec-0124"> <p><b>(k) Increased appetite</b></p> <p>Not reported.</p> </section> <section id="CD003725-sec-0125"> <p><b>(l) Cataracts</b></p> <p>Not reported.</p> </section> <section id="CD003725-sec-0126"> <p><b>(m) Death</b></p> <p>Not reported.</p> </section> <section id="CD003725-sec-0127"> <p><b>(n) Life‐threatening infections</b></p> <p>One participant in the weekend‐only group had a severe case of flu and fever and one participant in the daily group had acute appendicitis necessitating discontinuation (events graded by the trialists as 3 or 4 on the National Cancer Institute (NCI) Common Toxicity Criteria). </p> </section> <section id="CD003725-sec-0128"> <p><b>(o) <i>Height restriction</i> </b></p> <p><a href="./references#CD003725-fig-0064" title="">Analysis 2.20</a>; <a href="./references#CD003725-fig-0065" title="">Analysis 2.21</a>. </p> <p>At 12 months, height was measured in 58 participants in <a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a> and was not significantly different in the weekend‐only dosing group than the daily dosing group (MD 1.00 cm, 95% CI ‐4.67 to 6.67). The trial authors report a "significant increase in linear growth in the weekend‐only compared to the daily dosing group (mean change 6.6 cm versus 4.1 cm, P = 0.002). We calculated SD (assuming they were the same in each group) of 2.93, producing a MD of 2.5 cm (95% CI 0.99 to 4.01), favouring weekend‐only dosing. </p> </section> </section> </section> </section> <section id="CD003725-sec-0129"> <h4 class="title">Deflazacort versus prednisone</h4> <p>Studied in <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>, <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> and <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>. See <a href="./full#CD003725-tbl-0003">summary of findings Table 3</a>. </p> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> was a one‐year study of 18 randomised participants with DMD. </p> <p>Although <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> was an 18‐month study that initially randomised 34 participants to deflazacort or prednisone, we discarded the 18‐month data as invalid; at one year the investigators excluded four prednisone participants from the study because of uncontrollable weight gain, and these participants also had a reduction in motor function. </p> <p><a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> was a larger trial involving 196 participants, reported only in an abstract. The only reported efficacy outcome was average change in strength at three months. </p> <section id="CD003725-sec-0130"> <h5 class="title">Primary outcome: prolongation of time to loss of ambulation</h5> <p>Not measured.</p> </section> <section id="CD003725-sec-0131"> <h5 class="title">Secondary outcome measures</h5> <section id="CD003725-sec-0132"> <h6 class="title">(1) Muscle strength</h6> <section id="CD003725-sec-0133"> <p><b>(a) Average muscle score</b></p> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> measured muscle strength using the MRC scale in four muscles: right deltoid, triceps, iliopsoas, and quadriceps femoris. The authors compared the differences in summed MRC scores at 3, 6, 9, and 12 months compared to baseline. The results were presented graphically without measures of variability and are not suitable for analysis. The authors reported that there were no between‐group differences in MRC score at one year, and measures at 3, 6, and 9 months were "similar" between groups. </p> <p><a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> did not measure muscle strength. </p> <p><a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> reported an average change in muscle strength ("based on a standardised method used in several previous trials") after three months of +0.8 with deflazacort 0.9 mg/kg, +0.26 with deflazacort 1.2 mg/kg, and +0.27 with prednisone, but the abstract provided no participant numbers, SD or P values for comparisons. </p> </section> <section id="CD003725-sec-0134"> <p><b>(b) Ability to lift weights</b></p> <p>Not measured in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> or <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>. <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided no information. </p> </section> </section> <section id="CD003725-sec-0135"> <h6 class="title">(2) Functional outcome measures</h6> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> reported a composite score that was a sum of the grades in functional scores (10‐metre walk, rising from a chair and from the floor, and four‐stair climb) and also measured the time taken to perform each test. The report did not provide data from each individual test. We contacted the trial authors for details, but received no response. </p> <p><a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> measured movement function every three months using the same three modalities as in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>, grading each modality in three levels (performed without assistance, performed with assistance, or not able to perform the task) at 3, 6, 9, 12, and 18 months. We were unable to reliably interpret the data because of inconsistencies between text and tables in the trial report. </p> <p><a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided no information. </p> <section id="CD003725-sec-0136"> <p><b>(a) Leg function grade</b></p> <p>Not measured in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> or <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>. <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided no information. </p> </section> </section> <section id="CD003725-sec-0137"> <h6 class="title">(3) Pulmonary function ‐ forced vital capacity (FVC)</h6> <p>Not measured in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>. <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> reported that none of the groups had an abnormal vital respiratory capacity (less than 80% normal based on age and gender) during the study, and that there were no between‐group differences, without providing numerical data. </p> <p><a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided no information on pulmonary function. </p> </section> <section id="CD003725-sec-0138"> <h6 class="title">(4) Quality of life (QoL)</h6> <p>Not measured in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>, <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>, or <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>. </p> </section> <section id="CD003725-sec-0139"> <h6 class="title">(5) Adverse events</h6> <section id="CD003725-sec-0140"> <p><b>(a) Weight gain</b></p> <p>Data for 3‐, 6‐ and 9‐month time points were not provided by <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>, and were presented graphically in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>, without any measures of variability. For <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>, we read the data from the graph using the ruler method, and figures are therefore very approximate. The percentage body weight increase in the deflazacort and prednisone groups respectively were 2.5% and 6% at three months, 3% and 10% at six months, and 5.8% and 18% at nine months. The reported P value for the difference between groups was &lt; 0.05 at six months and "the difference remained statistically significant at 9 and 12 months". </p> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> reported the mean increase from initial weight at 12 months to be 9% (2.17 kg) in the deflazacort group (n = 9) and 21.3% (5.08 kg) in the prednisone group (n = 8) without providing SD. This was reported as a significant difference at an assumed significance threshold of P &lt; 0.05 (the stated significance threshold for the difference at 6 months). Using the most conservative value of P = 0.05 for the between‐group difference at one year, and assuming that the SD of outcome measurements were the same in each group, the estimated SD was 11.88. This gave a MD of ‐12.30% (95% CI ‐23.61 to ‐0.99) (<a href="./references#CD003725-fig-0066" title="">Analysis 3.1</a>). </p> <p><a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> did not clearly report the numbers in which weight gain was measured at 12 months. However, authors state that the study was continued after early dropouts with 14 patients taking deflazacort, and 12 using prednisone. The MD between groups assuming these sample sizes was ‐8.70% (95% CI ‐14.84 to ‐2.56) (<a href="./references#CD003725-fig-0066" title="">Analysis 3.1</a>). </p> <p>This trial reported a mean change of weight of 12.95% (SD 9.23, 95% CI 7.6 to 18.3) in the deflazacort group (n = 14) and 21.65% (SD 6.68, 95% CI 16.1 to 27.2) in the prednisone group (n = 12). </p> <p>Combining the one‐year weight gain data from <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> and <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> (n = 43), the MD was ‐9.52% (95% CI ‐14.91 to ‐4.12; very low quality evidence) in favour of deflazacort (see <a href="#CD003725-fig-0006">Figure 6</a>; <a href="./references#CD003725-fig-0066" title="">Analysis 3.1</a>; <a href="./full#CD003725-tbl-0003">summary of findings Table 3</a>). These data must be interpreted with caution. </p> <div class="figure" id="CD003725-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Deflazacort versus prednisone, outcome: 3.1 Weight gain (%)." data-id="CD003725-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Deflazacort versus prednisone, outcome: 3.1 Weight gain (%). </p> </div> </div> </div> <p>The <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> abstract reported weight gain as a percentage of baseline weight at 12 months as follows: deflazacort 0.9 mg/kg = 16.8%, deflazacort 1.2 mg/kg = 18.3%, and prednisone = 26.7%; P &lt; 0.1 for comparisons of deflazacort versus prednisone. The abstract did not give the number of participants in each group or SD. <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> also reported the percentage of participants with moderate or severe obesity: 24% in the deflazacort 0.9 mg/kg group, 11% in the deflazacort 1.2 mg/kg group, and 41% in the prednisone group; without sufficient detail for analysis. </p> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> reported the number of participants with an increase in body weight of over 20% at one year. This was 1/9 (11%) in the deflazacort group and 4/8 (50%) in the prednisone group. </p> </section> <section id="CD003725-sec-0141"> <p><b>(b) Behavioural changes</b></p> <p>The number of children with behavioural changes in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> was four participants (44%) in the deflazacort group and four participants (50%) in the prednisone group at six months (RR 0.89, 95% CI 0.32 to 2.43; <a href="./references#CD003725-fig-0067" title="">Analysis 3.2</a>), and six participants (66%) in the deflazacort group and five participants (62%) in the prednisone group at one year (RR 1.07, 95% CI 0.53 to 2.17; very low quality evidence; <a href="./references#CD003725-fig-0068" title="">Analysis 3.3</a>; <a href="./full#CD003725-tbl-0003">summary of findings Table 3</a>). The changes were reportedly "slight".<a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> and <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided no information on behavioural changes. </p> </section> <section id="CD003725-sec-0142"> <p><b>(c) Cushingoid appearance</b></p> <p>The number of children with Cushingoid appearance in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> was two (22%) in the deflazacort group and five (55%) in the prednisone group at six months (RR 0.59; 95% CI 0.13 to 2.70; <a href="./references#CD003725-fig-0067" title="">Analysis 3.2</a>) and five (55%) in the deflazacort group and four (50%) in the prednisone group at one year (RR 1.11; 95% CI 0.45 to 2.75; <a href="./references#CD003725-fig-0068" title="">Analysis 3.3</a>). These changes were also reported as "slight". Cushingoid appearance was not evaluated in <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>. </p> <p><a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> reported the percentage of participants with moderate or severe moon face: 36% in the deflazacort 0.9 mg/kg group, 32% in the deflazacort 1.2 mg/kg group, and 43% in the prednisone group. The report did not give SD or the numbers of participants in each group. </p> </section> <section id="CD003725-sec-0143"> <p><b>(d) Excessive hair growth (hirsutism)</b></p> <p>In <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>, hirsutism occurred in five participants (55%) in the deflazacort group and four participants (50%) in the prednisone group at six months (RR 1.11, 95% CI 0.45 to 2.75; <a href="./references#CD003725-fig-0067" title="">Analysis 3.2</a>), and five participants (55%) in the deflazacort group and three participants (37%) in the prednisone group at one year (RR 1.48, 95% CI 0.51 to 4.31; <a href="./references#CD003725-fig-0068" title="">Analysis 3.3</a>). <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> did not report on the presence of hirsutism. <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided no information. </p> </section> <section id="CD003725-sec-0144"> <p><b>(e) Acne</b></p> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> reported that no case of acne occurred. <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> did not report on the presence of acne. <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided no information. </p> </section> <section id="CD003725-sec-0145"> <p><b>(f) Osteoporosis, fractures</b></p> <p>Participants in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> underwent an x‐ray of the hand at baseline and after one year of corticosteroid treatment. The authors do not report the results other than that during the year of treatment, bone age was similar in the two groups. One boy in the deflazacort group had a traumatic bone fracture after four months of treatment. </p> <p><a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> and <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> did not report the occurrence of fractures or osteoporosis. </p> </section> <section id="CD003725-sec-0146"> <p><b>(g) Hyperglycemia/glycosuria</b></p> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> measured glucose. The trial authors reported no significant change in laboratory parameters, without providing further details. <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> reported that no glucosuria was detected in either treatment group "in the 3‐month evaluation" ‐ we thought this likely to mean at the three‐monthly evaluations. <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided no information on this adverse event. </p> </section> <section id="CD003725-sec-0147"> <p><b>(h) Hypokalaemia</b></p> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> measured electrolytes. The trial authors reported no significant change in laboratory parameters, without providing further details. <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> and <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> did not report on the presence of hypokalaemia. </p> </section> <section id="CD003725-sec-0148"> <p><b>(i) Hypertension</b></p> <p>No study reported blood pressure data in detail. In <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> blood pressure was measured every three months, with no increase in either group according to the age‐specific standard curve. <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> reported that no case of hypertension occurred. <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided no information on this adverse event. </p> </section> <section id="CD003725-sec-0149"> <p><b>(j) Gastrointestinal side effects</b></p> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> reported 'Gastric symptoms' in one participant (11%) in the deflazacort group and two participants (25%) in the prednisone group at six months (RR 0.44, 95% CI 0.05 to 4.02; <a href="./references#CD003725-fig-0067" title="">Analysis 3.2</a>), and one participant (11%) in the deflazacort group and one participant (12%) in the prednisone group at one year (RR 0.89, 95% CI 0.07 to 12.00; <a href="./references#CD003725-fig-0068" title="">Analysis 3.3</a>). Antacid treatment produced complete resolution of pain. <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> and <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> did not report on gastrointestinal effects. </p> </section> <section id="CD003725-sec-0150"> <p><b>(k) Increased appetite</b></p> <p>In <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>, appetite increase occurred in two participants (22%) in the deflazacort group and six participants (75%) in the prednisone group at six months (RR 0.30, 95% CI 0.08 to 1.07; <a href="./references#CD003725-fig-0067" title="">Analysis 3.2</a>) and three participants (33%) in the deflazacort group and six participants (75%) in the prednisone group at one year (RR 0.44, 95% CI 0.16 to 1.22; <a href="./references#CD003725-fig-0068" title="">Analysis 3.3</a>). The trial authors reported the change in appetite as "slight". <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> and <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> did not report on appetite change. </p> </section> <section id="CD003725-sec-0151"> <p><b>(l) Cataracts</b></p> <p>Participants in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> underwent a slit lamp examination of the eye at baseline and after one year of corticosteroid treatment; a "slight cataract" was found in two boys in the deflazacort group and one in the prednisone group. <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> reported no cataracts at the one‐year evaluation. <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> provided no information. </p> </section> <section id="CD003725-sec-0152"> <p><b>(m) Death</b></p> <p>None reported in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>, <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> or <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>. </p> </section> <section id="CD003725-sec-0153"> <p><b>(n) Life‐threatening infections</b></p> <p>The occurrence of sepsis was not reported in <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>, <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>, or <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>. </p> </section> <section id="CD003725-sec-0154"> <p><b>(o) <i>Height restriction</i> </b></p> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> monitored height but did not provide any information on it in the results. <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> reported height and growth "at the end of the study" (18 months), but we discarded these data for reasons given above. <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> did not report height data. </p> </section> <section id="CD003725-sec-0155"> <p><b>(p) Others</b></p> <p><a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> reported that adverse event monitoring identified no ankle oedema, insomnia, or anorexia. </p> <p><a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> reported no cardiomyopathy (measured by decrease in ejection fraction at one year). One participant had scoliosis at the start of the study and was treated with a brace, and had no increase in scoliosis at one‐year follow‐up. No scoliosis was otherwise detected. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003725-sec-0156" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003725-sec-0156">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003725-sec-0258">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003725-sec-0156"></div> <section id="CD003725-sec-0157"> <h3 class="title" id="CD003725-sec-0157">Summary of main results</h3> <p>We identified 50 studies of corticosteroids in Duchenne muscular dystrophy (DMD) conducted over the last four decades. From these, 12 randomised controlled trials (RCTs), with a total of 667 participants, were eligible for inclusion in this review based on our predefined criteria. </p> <p>Among these studies, six (n = 332) were RCTs comparing corticosteroids against placebo; five studied prednisolone or prednisone and one studied deflazacort. With regard to ambulatory status, 282 participants were walking, either independently or with the help of long leg braces. Two large studies contributed the majority of the patients (202 of 332) to the corticosteroid versus placebo comparison (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). The treatment groups within this comparison included prednisone (n = 217), prednisolone (n = 10) and deflazacort (n = 17). Unfortunately, two large studies of deflazacort in DMD comprising 206 participants in total have not been published beyond abstract form and their final data are not available (<a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>; <a href="./references#CD003725-bbs2-0053" title="ReitterB . Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain &amp; Development1995;17 Suppl:39‐43. ">Reitter 1995</a>). </p> <p>We identified one RCT of daily prednisone versus weekend‐only prednisone in 64 ambulant boys and two RCTs (n = 52) of prednisone versus deflazacort. A further large multicentre international RCT comparing daily prednisolone (0.75 mg/kg/day), daily deflazacort (0.9 mg/kg.day), and intermittent prednisolone (0.75 mg/kg/day 10 days on, 10 days off) is of major interest, but still in progress at the time of this review (<a href="./references#CD003725-bbs2-0072" title="GuglieriM , VanRuitenHJA , SpeedC , HartK , WatsonG , McCollE , et al. FOR‐DMD: Double‐blind randomised trial to optimise corticosteroid regime in Duchenne muscular dystrophy (DMD). Developmental Medicine and Child Neurology2015; Vol. 57, issue Suppl s1:25‐6. NCT01603407 . Finding the optimum regimen for Duchenne muscular dystrophy (FOR‐DMD). www.clinicaltrials.gov/ct2/show/NCT01603407 (accessed 14 December 2015). ">Guglieri 2015</a>). A further potentially eligible RCT is in progress in India, comparing daily prednisolone 0.75 mg/kg/day given for 10 consecutive days per month versus daily dosing (<a href="./references#CD003725-bbs2-0071" title="CTRI/2009/091/000738 . A clinical trial to compare the two ways of giving steroids (daily versus intermittent) in ambulatory patients with Duchenne muscular dystrophy. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000605 accessed 28 April 2016. ">CTRI/2009/091/000738</a>). </p> <section id="CD003725-sec-0158"> <h4 class="title">Corticosteroids versus placebo</h4> <section id="CD003725-sec-0159"> <h5 class="title">Primary outcome measure: prolongation of time to loss of ambulation</h5> <p>Loss of ambulation is the key milestone in the natural history of DMD, and is of maximal functional significance. Prevention or postponement of this event is the key aim of therapeutic interventions in the first decade of life, and a desired outcome measure. Prolongation of time to loss of ambulation was not the stated primary outcome measure of most RCTs, probably because to achieve sufficient power to demonstrate this effect, studies would require a large sample size and long duration (<a href="./references#CD003725-bbs2-0129" title="MuntoniF , FisherI , MorganJE , AbrahamD . Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research. Neuromuscular Disorders2002;12(Suppl 1):S162‐5. ">Muntoni 2002</a>). As progressive muscle weakness is the major contributor to loss of walking, trialists have used measurements of muscle strength as a surrogate marker, enabling clinical trials to be completed in as little as six months. These short‐term studies do not demonstrate prolongation of time to loss of ambulation or allow evaluation of adverse effects that develop after long‐term use of corticosteroids (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). </p> <p>Although <a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> assessed our primary outcome measure, the data available did not allow us to create survival curves for prolongation of walking. Some disparities that cannot be readily explained further highlight the need for appropriate statistical analysis. Deflazacort and placebo groups were evenly matched at randomisation, and among participants who lost ambulation during the study, the mean age at which boys became wheelchair‐dependent was very similar in the two groups (deflazacort group, 108 months; and placebo group, 104 months). Comparing these groups, the significance of the difference of 13 months in duration of walking between randomisation and becoming wheelchair‐dependent cannot be ascertained without knowing the ages of the ambulant children at the end of the study. </p> </section> <section id="CD003725-sec-0160"> <h5 class="title">Secondary outcome measures</h5> <section id="CD003725-sec-0161"> <h6 class="title">Strength</h6> <p>Strength parameters in the corticosteroid treatment groups demonstrated statistically significant improvement compared with placebo. All seven of the included studies measured muscle strength using MRC‐based scores (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>; <a href="./references#CD003725-bbs2-0012" title="TodorovicSM . High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Muscle &amp; Nerve. 1998; Vol. 7 Suppl:72. ">Todorovic 1998</a>). </p> <p>Pooled data from <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>, and <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> demonstrated a statistically significant improvement in muscle strength over six months (reported as muscle strength score) with prednisone/prednisolone treatment versus placebo. <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a> reported data on muscle strength as muscle force assessed by hand‐held dynamometry, which could not be pooled with data from the above three studies; nevertheless, this trial demonstrated improvement in muscle force during the six‐month prednisolone treatment phase over the placebo phase. The improvement in muscle strength or force occurred with all four treatment regimens (0.75 mg/kg/day for the first ten days of every month, 0.3 mg/kg daily, 0.75 mg/kg daily and 1.5 mg/kg daily). Data from the other trials were lacking or not suitable for analysis. </p> <p><a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> was a 12‐month study and demonstrated improvements in lower limb muscle strength at both six and 12 months. We could not include the data in meta‐analysis because although investigators used MRC‐based scores, they tested two muscles and did not combine results into a single score. </p> <p>The two‐year study of deflazacort (2 mg/kg on alternate days) versus placebo measured change in MRC index (%) over the initial score, demonstrating a difference in favour of deflazacort at 24 months, but not at 6 months (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>). </p> </section> <section id="CD003725-sec-0162"> <h6 class="title">Function</h6> <p>Functional parameters showed statistically significant improvement over the short term (up to a year) in corticosteroid‐treated groups. The functional parameters showing improvement included time taken to rise from the floor, time taken to walk nine metres, time taken to climb four stairs, and the leg functional grade. It is, however, important to note that none of the included studies reported any non‐ambulant (wheelchair‐dependent) participants regaining the ability to walk on treatment with prednisone. </p> <p>Data from <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>, <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>, <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>, and <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> demonstrated a statistically significant improvement in time taken to rise from the floor in the prednisone/prednisolone treatment groups on all dose regimens (0.3 mg/kg/day, 0.75 mg/kg/day, and 1.5 mg/kg/day in daily dose regimens or 0.75 mg/kg/day on the first 10 days of every month, in an intermittent regimen). The muscle weakness in DMD leads to increasing difficulty in rising from the floor at around five years of age, with loss of this ability towards the end of the first decade of life. </p> <p>Time taken to walk nine (or ten) metres showed a statistically significant improvement in all prednisone/prednisolone treatment groups versus placebo in five trials (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). Leg function grades also showed a statistically significant improvement in all prednisone/prednisolone treatment groups versus placebo in three trials (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>; <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>). </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>, a comparison of alternate day deflazacort (2 mg/kg) versus placebo, demonstrated a difference in favour of deflazacort in timed gait at six months. but no significance difference on our analyses in other functional parameters at the six‐month or two‐year time points. The study measured outcomes until participants became wheelchair dependent and had a high dropout rate at two years. </p> </section> <section id="CD003725-sec-0163"> <h6 class="title">Pulmonary function</h6> <p>One of the desired effects of any successful treatment in DMD is the preservation of respiratory muscle strength, thereby preserving pulmonary function and postponing or removing the risk of nocturnal hyperventilation and respiratory failure. A good marker of respiratory reserve is forced vital capacity (FVC) and two of the large included studies measured this outcome (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). A statistically significant improvement in the FVC in all prednisone treatment groups versus placebo was present after six months of treatment. Parallel results are available from non‐randomised cohort studies (<a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a>; <a href="./references#CD003725-bbs2-0021" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. ">Biggar 2004</a>; <a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a>; <a href="./references#CD003725-bbs2-0061" title="SilversidesCK , WebbGD , HarrisVA , BiggarDW . Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. American Journal of Cardiology2003;91(6):769‐72. ">Silversides 2003</a>), which showed strength improvement and stabilisation of FVC over the long term in deflazacort‐treated patients (see below). </p> </section> <section id="CD003725-sec-0164"> <h6 class="title">Quality of life</h6> <p>Two trials measured quality of life (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015)</a>, with only <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> providing numerical data. Self reported and proxy reported quality of life measures were better with prednisone 0.75 mg/kg/day than with placebo. </p> </section> <section id="CD003725-sec-0165"> <h6 class="title">Adverse events</h6> <p>Caution is required in extrapolating the adverse effects of corticosteroid therapy reported in these included studies to circumstances of long‐term clinical use. Five of the seven included studies used daily doses of prednisone/prednisolone over a six‐month period; one used a daily dose for a year. The longest included study, of two years' duration, used deflazacort 2 mg/kg on alternate days (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>). We would expect the side effects observed during these studies to be much less than those likely to occur during five years or longer use, as may be anticipated in clinical practice. These short‐term studies would be unlikely to detect long‐term adverse effects, especially loss of bone mineral density, increased bone fracture incidence, cataracts, and growth failure with short stature. </p> <p>The propensity for excessive weight gain on corticosteroid treatment was clear. This did not appear to adversely affect strength or function in these short‐term studies, except for one participant (in the prednisone 0.3 mg/kg/day group), who at the end of the six months of the <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> study refused to continue to another subsequent study of prednisone versus azathioprine (<a href="./references#CD003725-bbs2-0037" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology1993;43(3 Pt 1):520‐7. ">Griggs 1993</a>). Behavioural changes and cushingoid side effects were statistically significant in the corticosteroid treatment groups, but were not considered important enough for treatment to be discontinued in these short‐term studies. </p> <p>Participants treated with prednisone 0.75 mg/kg/day over the six‐month period were at significant risk of excessive hair growth. Participants and their families appear to have tolerated this side effect, which caused no participants to drop out of the study. </p> <p>Combined data from <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> and <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> demonstrated more acne in the prednisone 0.75 mg/kg/day group during the six months of treatment compared to six months of placebo, but this difference was not statistically significant. </p> <p>As the intermittent corticosteroid regimens are postulated to have a better adverse effect profile, we wanted to compare the daily dose regimen (studied in <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>, <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, and <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a>) with the intermittent regimen (studied in <a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>). We were not able to make a comparison, as adverse effects data from the only RCT of intermittent prednisone were not available in a format that would allow statistical analysis (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>). In this six‐month randomised, controlled, cross‐over trial of intermittent prednisone (0.75 mg/kg/day for the first 10 days each month), increased appetite and behavioural side effects occurred more frequently during the prednisone period than during the placebo period, but these effects appear to have been mild, as they required no dose adjustment or drug discontinuation. </p> <p>Only one included study reported a pathological fracture (of the tibia) while on corticosteroid (deflazacort 2 mg/per kg on alternate days) (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>). The report did not describe the duration of treatment prior to the occurrence of fracture or the circumstances of the fracture. One participant in the placebo treatment group in <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a> dropped out of the study because of an arm fracture (reported in <a href="./references#CD003725-bbs2-0037" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology1993;43(3 Pt 1):520‐7. ">Griggs 1993</a>). </p> <p>None of the studies assessed bone mineral density by dual energy x‐ray absorptiometry (DEXA) scans. This relates to the age of most of the studies and their short‐term nature. However, in view of the benefit of corticosteroid therapy in DMD, the treatment regimen is routinely continued in these patients over a decade or longer. In these circumstances, the development of osteoporosis is a major risk, and future studies should consider bone health assessment and systematic DEXA scanning in their protocol for adverse event monitoring (<a href="./references#CD003725-bbs2-0080" title="BiggarWD , BachrachLK , HendersonRC , KalkwarfH , PlotkinH , WongBL . Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscular Disorders2005;15(1):80‐5. ">Biggar 2005</a>; <a href="./references#CD003725-bbs2-0140" title="QuinlivanR , RoperH , DavieM , ShawNJ , McDonaghJ , BushbyK . Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. Neuromuscular Disorders2005;15(1):72‐9. ">Quinlivan 2005</a>). </p> </section> </section> <section id="CD003725-sec-0166"> <h5 class="title">Corticosteroid dose‐response relationship</h5> <p>Clinically, it is important to use the minimum effective dose of corticosteroid. To answer the question of what this may be, we reviewed the forest plots showing studies grouped according to dosage of prednisone/prednisolone. On the basis of the evidence available for analysis, our confidence in the effect estimate for prednisone/prednisolone at doses of 0.75 mg/kg/day is fairly secure. There is little evidence of an increase in benefit when the dose is further increased from 0.75 to 1.5 mg/kg daily (<a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). This suggests that the daily dose regimen of 0.75 mg/kg/day is adequate to achieve what benefit prednisone can provide. </p> <p>Differences in the proportion of boys experiencing hair growth and cushingoid features was significantly greater on a daily prednisone dose of 0.75 mg/kg/day than on 0.3 mg/kg/day, but the higher dose did not significantly increase rates of other common adverse events (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>). <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> found no statistically significant increases in frequency of any adverse event when comparing 1.5 mg/kg/day with 0.75 mg/kg/day prednisone. </p> <p>A proper investigation of the prednisone dose‐response relationship to identify the optimum dose would need individual patient data within study analyses. We recommend that future studies make arrangements for provision of individual patient data for these analyses. </p> </section> <section id="CD003725-sec-0167"> <h5 class="title">Co‐interventions</h5> <p>The co‐interventions identified included daily calcium carbonate (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>), antacids given routinely to all participants (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>), and dietetic advice to avoid weight gain (<a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a>; <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). In <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>, concomitant interventions included a calcium‐rich diet, medications (vitamin D, calcium, ranitidine, over‐the‐counter antacid), a high protein, low carbohydrate, low fat diet, and respiratory, cardiac, and rehabilitative interventions (<a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>). These co‐interventions, however, are clinically extremely unlikely to be responsible for the benefits observed. None of the studies assessed physical activity levels as a potentially confounding factor. </p> </section> </section> <section id="CD003725-sec-0168"> <h4 class="title">Weekend‐only versus daily prednisone</h4> <p><a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a> was the only published RCT of weekend‐only versus daily prednisone. No appreciable difference was present in the primary outcomes of upper and lower limb strength or the safety outcome of body mass index (BMI) between the two groups at 12 months. We did find a difference with faster times to rise from the floor in the daily group, but no clear differences were seen for any other functional outcomes measured. The trial identified no clear difference in weight gain, as the result had wide confidence intervals that include the possibility of no benefit from weekend‐only over daily treatment. The weekend‐only treatment group had a larger increase in linear height. </p> </section> <section id="CD003725-sec-0169"> <h4 class="title">Deflazacort versus prednisone</h4> <p>Of the three RCTs of deflazacort versus prednisone, only <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> and <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> have been published in detail, while <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> (n = 106) has been published only as an abstract. <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> was a study with only 18 participants, comparing the adverse effects of prednisone with those of deflazacort, both given in a daily dose regimen over one year. The trialists did not present power calculations. The two corticosteroids demonstrated similar benefit on strength and functional tests, but the difference in weight gain was statistically significant, being more marked in the prednisone treatment group. One of the nine participants in the deflazacort group, in comparison to four of the nine in the prednisone group, experienced a weight gain of more than 20% over baseline. <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> randomised 34 participants to either daily prednisone 0.75 mg/kg/day or daily deflazacort 0.9 mg/kg/day. After early dropouts the trial continued for 12 months with 26 participants. At 12 months there was no appreciable difference in motor function scores between the two drug regimens. There was a clear difference in weight gain combining data from the two trials, with the greatest gain seen in the prednisone group, although this evidence is very low quality. </p> <p><a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a> and <a href="./references#CD003725-bbs2-0053" title="ReitterB . Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain &amp; Development1995;17 Suppl:39‐43. ">Reitter 1995</a> (which is not stated to be randomised) are of major clinical interest because they involved a large number of participants. These trials compared prednisone with deflazacort and, in addition, compared prednisone and deflazacort with a contemporaneous placebo control group. The review authors contacted the authors of these studies for an earlier version of this review, but data were not available. <a href="./references#CD003725-bbs2-0026" title="CampbellC , JacobP . Deflazacort for the treatment of Duchenne Dystrophy: a systematic review. BMC Neurology2003; Vol. 3, issue 1:7. ">Campbell 2003</a> reported similar difficulties in obtaining these data for their systematic review of deflazacort in DMD. </p> </section> <section id="CD003725-sec-0170"> <h4 class="title">Evidence from excluded randomised studies</h4> <p><a href="./references#CD003725-bbs2-0052" title="PradhanS , GhoshD , SrivastavaNK , KumarA , MittalB , PandeyCM , et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. Journal of Neurology2006;253(10):1309‐16. [DOI 10.1007/s00415‐006‐0212‐1] ">Pradhan 2006</a> explored the possibility that daily prednisolone initiated in the late ambulant phase of DMD would delay loss of ambulation, while also aiming to shorten the period of corticosteroid exposure and thereby diminish adverse effects. The investigators calculated the power of this study to detect a significant difference between the control and treatment groups, not on the basis of time to loss of ambulation, but on muscle power. This open, controlled trial assessed the effect of prednisolone 0.75 mg/kg daily, started at a stage when the participants had started falling several times in a day. The investigators randomly allocated 67 serially seen boys into a prednisolone treatment group (44 participants, mean age 8.83 ± 1.25 years) or control group (23 participants, mean age 8.18 ± 0.64 years). Both groups also received vitamin E. The trialists followed up participants for two years, and thereafter until the boys reached a "chair bound stage". Of the 44 participants in the prednisolone treatment group, 24 dropped out because of adverse effects and treatment was stopped in a further five because of no improvement in power. Fifteen of the remaining 19 in the treatment group could be followed up regularly for two years, and then up to "chair bound stage"; only data from these 15 participants were used for comparison with the control group. <a href="./references#CD003725-bbs2-0052" title="PradhanS , GhoshD , SrivastavaNK , KumarA , MittalB , PandeyCM , et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. Journal of Neurology2006;253(10):1309‐16. [DOI 10.1007/s00415‐006‐0212‐1] ">Pradhan 2006</a> reported that in this subgroup of 15, the mean age of becoming wheelchair‐dependent was 169 ± 9 months compared to 132 ± 8 months in the control group. As the statistical analysis was based only on the 15 participants who responded without significant adverse effects, and does not take into account dropouts or non‐responders in the prednisolone treatment group, we did not include <a href="./references#CD003725-bbs2-0052" title="PradhanS , GhoshD , SrivastavaNK , KumarA , MittalB , PandeyCM , et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. Journal of Neurology2006;253(10):1309‐16. [DOI 10.1007/s00415‐006‐0212‐1] ">Pradhan 2006</a> in the review. </p> <p>Though the trialists did not analyse the data in this study on an intention‐to‐treat basis, the results may be of clinical significance, as there appears to be a subgroup of boys with DMD who achieved prolongation of time to loss of ambulation by three years, without significant adverse effects. Caution is required in interpretation of these results as they cannot be generalised to the whole population of boys affected by DMD. </p> <p>The variability in response to corticosteroid treatment amongst individuals affected by DMD in this and other studies, remains unexplained and is likely to be multifactorial. <a href="./references#CD003725-bbs2-0023" title="BonifatiDM , WitchelSF , ErmaniM , HoffmanEP , AngeliniC , PegoraroE . The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(10):1177‐9. ">Bonifati 2006</a> suggested glucocorticoid receptor polymorphisms to be one of the possible factors modulating the long‐term response to corticosteroids. </p> </section> <section id="CD003725-sec-0171"> <h4 class="title">Evidence from non‐randomised studies</h4> <p>Though non‐randomised, these studies listed in <a href="#CD003725-tbl-0004">Table 1</a> still constitute an important body of evidence. </p> <div class="table" id="CD003725-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Excluded non‐randomised studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Regimen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0031" title="DrachmanDB , ToykaKV , MyerE . Prednisone in Duchenne muscular dystrophy. Lancet1974;2(7894):1409‐12. ">Drachman 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 2 mg/kg/day for 3 months, then two‐thirds dose on alternate days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks to 28 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events in 4 patients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0059" title="SiegelIM , MillerJE , RayRD . Failure of corticosteroid in the treatment of Duchenne (pseudo‐hypertrophic) muscular dystrophy. Report of a clinically matched three year double‐blind study. Illinois Medical Journal1974;145(1):32‐3. ">Siegel 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 5 mg/kg on alternate days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No benefit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0025" title="BrookeMH , FenichelGM , GriggsRC , MendellJR , MoxleyRT3rd , MillerJP , et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Archives of Neurology1987;44(8):812‐7. ">Brooke 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 dropouts</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0030" title="DeSilvaS , DrachmanDB , MellitsD , KunclR . Prednisone treatment in Duchenne muscular dystrophy. Long‐term benefit. Archives of Neurology1987;44(8):818‐22. ">DeSilva 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 to 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 2 mg/kg/day for 3 months, then two‐thirds dose on alternate days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 11 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Walking prolonged by 2 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excessive weight gain in 12 patients; cataracts in 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0035" title="FenichelGM , FlorenceJM , PestronkA , MendellJR , MoxleyRT3rd , GriggsRC , et al. Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology1991;41(12):1874‐7. ">Fenichel 1991b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stabilisation for 2 yrs Prednisone 0.56 mg/kg/day least effect dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataracts in 10 patients;<br/> glycosuria in 10 patients;<br/> significant weight gain </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0049" title="MesaLE , DubrovskyAL , CorderiJ , MarcoP , FloresD . Steroids in Duchenne muscular dystrophy ‐ deflazacort trial. Neuromuscular Disorders1991;1(4):261‐6. ">Mesa 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ 1 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improved up to 6 months, then stable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35% cushingoid; no significant weight gain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0056" title="SansomeA , RoystonP , DubowitzV . Steroids in Duchenne muscular dystrophy; pilot study of a new low‐dosage schedule. Neuromuscular Disorders1993;3(5‐6):567‐9. ">Sansome 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day for 10 days/months (given 10 days on, 20 days off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 6 to 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Strength improved at 6 months; slow decline at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fewer adverse events, but<br/> 26% of boys had more than 20% weight gain </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ 0.9 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8 (+/‐ SD 1.5) yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ambulation prolonged<br/> FVC preserved: mean % predicted FVC 72% in DFZ group; 35% in non‐treated group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataracts in 30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0032" title="DubowitzV , KinaliM , MainM , MercuriE , MuntoniF . Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low‐dosage prednisolone therapy. European Journal of Paediatric Neurology2002;6(3):153‐9. ">Dubowitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 yrs 10 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day (given 10 days on, 10 days off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stabilisation of motor function for up to 5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability in 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0027" title="ConnollyAM , SchierbeckerJ , RennaR , FlorenceJ . High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscular Disorders2002;12(10):917‐25. ">Connolly 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open, historical controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 treated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 5 mg/kg twice weekly<br/> (every Friday and Saturday). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (+/‐ 1.5) months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improved strength over 6 to 12 months in majority</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability in 6. 2 stopped, 4 reduced prednisone dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0048" title="MerliniL , CicognaniA , MalaspinaE , GennariM , GnudiS , TalimB , et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle &amp; Nerve2003;27(2):222‐7. ">Merlini 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open, parallel‐group, double consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 treated, 3 control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone<br/> 0.75 mg/kg for 2 weeks, then 1.25 mg/kg on alternate days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 to 63 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ability to rise from floor prolonged; stairs and 10‐metre walking time similar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Growth rate decline; irritability requiring niaprazine in 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0041" title="KinaliM , MercuriE , MainM , MuntoniF , DubowitzV . An effective, low‐dosage, intermittent schedule of prednisolone in the long‐term treatment of early cases of Duchenne dystrophy. Neuromuscular Disorders2002;12(Suppl 1):S169‐74. ">Kinali 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (including 2 patients from <a href="./references#CD003725-bbs2-0032" title="DubowitzV , KinaliM , MainM , MercuriE , MuntoniF . Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low‐dosage prednisolone therapy. European Journal of Paediatric Neurology2002;6(3):153‐9. ">Dubowitz 2002</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 yrs 10 months to 4.5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day (given 10 days on, 10 days off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 yrs to over 5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stabilisation of motor function for up to 5 yrs; loss of ambulation in 1 boy at age 9 yrs, after 5 yrs of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density on DEXA scans at 1 to 6 yrs of treatment was normal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0061" title="SilversidesCK , WebbGD , HarrisVA , BiggarDW . Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. American Journal of Cardiology2003;91(6):769‐72. ">Silversides 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study; patients refusing treatment formed control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (21 treated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 (+/‐2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ<br/> Start: 0.9 mg/kg/day<br/> (gradual decrease in dose with age) </p> <p>At 18 yrs: 0.59 +/‐0.15 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1 (+/‐ 2.4) yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Walking prolonged, 48% ambulant at 14 +/‐ 2 yrs of age</p> <p>Mean % predicted FVC:<br/> 83% in treated, 41% control group </p> <p>Cardiomyopathy:<br/> 5% of DFZ vs 58% of controls </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marked retardation of height gain; weight gain similar to controls; cataracts in 50% (asymptomatic) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0018" title="Luz AvilesC , GutiérrezC , NovoaF , GilE , StuardoA . Steroid treatment of Duchenne's muscular dystrophy [Tratamiento esteroidal en distrofia muscular de Duchenne]. Revista Chilena de Pediatra1982;53(3):187‐91. ">Aviles 1982</a> <br/> (Published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone<br/> 3 mg/kg on alternate days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0033" title="DubrovskyAL , DeVitoE , SuarezA , MesaLE , PessolanoF , SobrinoR , et al. Deflazacort treatment and respiratory function in Duchenne muscular dystrophy. Neurology1999;52 Suppl(2):A544. ">Dubrovsky 1999</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (compared to 59 age‐matched controls)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 to 21 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ<br/> 0.5 to 1 mg/kg/day. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 yrs to 9 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FVC significantly preserved in DFZ‐treated group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0064" title="TuncaO , KabakusO , HergunerA , KaradumanA , TopalogluH . Alternate day prednisone therapy in Duchenne muscular dystrophy. Neuromuscular Disorders2001;11:630. ">Tunca 2001</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (compared with 22 historical controls)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 to 11 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg on alternate days; Vit D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 to 5 <br/> (mean 2.75) yrs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age at loss of ambulation ‐ prednisolone 10 yrs, controls 7.69 yrs); no scoliosis at a mean age of 11 .7 yrs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0050" title="PandyaS , MyersG , MoxleyRT . Effect of daily prednisone on independent ambulation in patients with Duchenne dystrophy treated for up to 15 years. Neuromuscular Disorders2001;11(6‐7):630. ">Pandya 2001</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 independently ambulant patients from clinical Investigation group of Duchenne Dystrophy (CIDD) studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone<br/> 0.75 mg/kg/day,<br/> gradually decreased over time </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age of loss of ambulation prolonged to 14.5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0054" title="ResendeMBD , ReedUC , EspindolaAA , FerreiraLG , CarvalhoMS , DiamentA , et al. Deflazacort in Duchenne muscular dystrophy: preliminary results in a Brazilian series. Neuromuscular Disorders2001;11:630. ">Resende 2001</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ 1 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 treated for 12 to 43 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 of the 15 boys ambulant beyond 10 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GI disturbances and depression needing discontinuation of treatment in 1 patient; cataracts in 2 patients </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0029" title="deGrootIJM . The effectiveness of prednisolone treatment (10 days on/10 days off) in the ambulatory phase of Duchenne muscular dystrophy: an open study. Neuromuscular Disorders2002;12(7‐8):737‐8. ">de Groot 2002</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 to 9 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day (given 10 days on,10 days off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Functional ability improved"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Osteoporosois 2 ‐3 SD at the start, but did not change under treatment"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0013" title="AhlanderAC , KroksmarkAK , TuliniusM . Low‐dosage prednisolone in the long‐term treatment of Duchenne muscular dystrophy. Neuromuscular Disorders2003;13(7‐8):630. ">Ahlander 2003</a> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (15 not treated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.35 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 7.5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Authors perceived a prolongation of walking by 0.9 yrs, but the patient groups compared are from different eras and there may be confounding factors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavioural problems; weight gain; dyspepsia; growth retardation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open cohort study; patients declining treatment formed comparison (control) group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 treated, 34 not treated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 to 18 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ 0.9 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean of 5.5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ‐treated boys were able to rise from supine to standing walk 10 metres without aids, 3 to 5 yrs longer than boys not treated </p> <p>At 18 yrs, only 4/40 treated boys had scoliosis greater than 20 degrees, compared to 30/34 untreated boys </p> <p>At 18 yrs, 4/40 boys treated with DFZ had cardiac left ventricular ejection fraction of &lt; 45%, compared with 20/34 untreated boys </p> <p>Two of the 40 DFZ‐treated boys died by 18 yrs of age, compared with 12/34 boys in the untreated group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ‐treated boys were significantly shorter, but did not have excessive weight gain</p> <p>22/40 treated boys had asymptomatic cataracts</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0021" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. ">Biggar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description and comparison of 2 cohorts in open study of 2 DFZ protocols, in 2 different centres:<br/> 1. Naples protocol (retrospective); 2. Toronto protocol (<a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a> cohort) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 boys started on DFZ</p> <p>30 boys on DFZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 8 yrs</p> <p>6 to 8 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ 0.6 mg/kg/day for 1st 20 days every month, Vit D 880 iu &amp; Ca 1000 mg daily<br/> <br/> <br/> DFZ 0.9 mg/kg/day, Vit D 1000 iu &amp; Ca 750 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 yrs +</p> <p>4 yrs +</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 15 yrs of age 25% able to walk 10 metres<br/> <br/> <br/> <br/> At 15 yrs of age 77% able to walk 10 metres </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cataracts<br/> <br/> <br/> <br/> Cataracts in 30%. Shorter in height than the Naples study cohort </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0067" title="YilmazO , KaradumanA , ArasO , BasogluB , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Neuromuscular Disorders2004; Vol. 14:581. YilmazO , KaradumanA , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. European Journal of Neurology2004;11(8):541‐4. ">Yilmaz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort study with historical controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 treated</p> <p>22 controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8 ± 2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg given on alternate days,<br/> Vit D 600 to 1200 iu daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.75 ± 1.1 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No scoliosis &gt; 24° in prednisolone‐treated group at end of study (mean age 10.8±1.2 yrs) </p> <p>7/22 in the historical controls had scoliosis &gt; 45° aged 11.7± 0.8 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of follow‐up limited with young mean age at end of study</p> <p>Scoliosis appears postponed as compared to historical controls, but potential for worsening in pubertal growth spurt in early teens remains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0014" title="AlmanBA , RazaNS , BiggarWD . Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. Journal of Bone and Joint Surgery. American Volume2004;86‐A(3):519‐24. ">Alman 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort study (same cohort as <a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (30 treated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 to 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ Start: 0.9 mg/kg/day<br/> (gradual decrease in dose with age) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 (5 to 8) yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scoliosis &gt; 20° developed in 5/30 DFZ group versus 16/24 in non‐treated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic stress fractures in 3/30 in DFZ group<br/> <br/> Cataracts in 33% of DFZ group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0019" title="BalabanB , MatthewsDJ , ClaytonGH , CarryT . Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long‐term effect. American Journal of Physical Medicine and Rehabilitation2005;84(11):843‐50. ">Balaban 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 49<br/> <br/> 18 prednisone‐treated </p> <p>12 DFZ‐treated<br/> <br/> 19 no drug treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone starting dose: 0.75 mg/kg/day<br/> <br/> DFZ starting dose:<br/> 0.9 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroid therapy for &gt; 2 yrs before loss of ambulation<br/> <br/> Mean duration of treatment was 5.49 yrs and 5.85 yrs in prednisone and DFZ‐treated groups, respectively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Similar benefit for walking in both prednisone and DFZ‐ treated groups, with approximate prolongation of walking of 2 yrs as compared to non‐treated control group<br/> <br/> Markedly decreased need for scoliosis surgery in DFZ and prednisone groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose decrease required in prednisone group because of excessive weight gain<br/> <br/> <br/> DFZ dose decreased in 3 boys because of hypertension, behavioural changes and vertebral fracture </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0057" title="ScharaU , MortierJ , MortierW . Long‐term steroid therapy in Duchenne muscular dystrophy‐positive results versus side effects. Journal of Clinical Neuromuscular Disease2001;2(4):179‐83. ">Schara 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 DFZ‐treated boys</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 to 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ starting dose 0.9 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More than 2 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All DFZ‐treated boys were able to walk independently during the study period to a mean age of 13 yrs (range 9.4 to 18.11 yrs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fourteen of the 19 DFZ‐treated boys developed cataracts; one patient's progressive cataracts lead to implantation of lenses after 56 months into the treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0043" title="KingWM , RuttencutterR , NagarajaHN , MatkovicV , LandollJ , HoyleC . Orthopedic outcomes of long‐term daily dose corticosteroid treatment in Duchenne muscular dystrophy. Neurology2007;68(19):1607‐13. ">King 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 143<br/> <br/> 75 prednisone or DFZ‐treated boys<br/> <br/> 68 non‐treated (or briefly treated, and therefore considered appropriate as controls) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean 16.9<br/> (6 to 30 yrs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily dose prednisone or DFZ</p> <p>Average "steroid" dose at last clinic review 0.55 mg/kg/day (range 0.1 ‐ 0.78)</p> <p>Corticosteroid‐treated boys were given Ca carbonate 350 mg 3 times daily, or a calcium tablet with vit D (750 to 1200 mg) daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 8 yrs (+/‐5.2 yrs, range 0.5 to 18 yrs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treated boys walked 3.3 yrs longer than the untreated group</p> <p>Lower prevalence (31% versus 91%) and severity (Cobb angle 11˚ versus 33˚) in the corticosteroid‐treated as opposed to the non‐treated boys </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertebral compression fractures reported in 32% of the treated group (none in the steroid‐naïve group) </p> <p>Long‐bone fractures were 2.6 times greater in corticosteroid‐treated patients</p> <p>Eight of the 75 treated boys discontinued corticosteroid treatment because of adverse effects. Another 2 boys stopped treatment as it was thought that the maximum benefit had been achieved </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0028" title="DaftaryAS , CrisantiM , KalraM , WongB , AminR . Effect of long‐term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics2007;119(2):e320‐4. ">Daftary 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective,<br/> case‐control study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 35<br/> <br/> 10 prednisone or DFZ‐ treated<br/> <br/> 25 non‐treated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 to 21 yrs in the treated group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.75 mg/kg/day and DFZ at 0.9 mg/kg/day, were the starting doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 yrs<br/> (range 1 yr to 14 yrs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS model suggested that the corticosteroid‐treated group had higher peak cough flow values (27 L/min higher than the non‐treated group (95% CI 2 to 52 L/min; P = 0.0328) </p> <p>Longitudinal effect on peak cough flow could not be assessed because of the study design </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0042" title="KinaliM , MainM , EliahooJ , MessinaS , KnightRK , LehovskyJ . Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. European Journal of Paediatric Neurology2007;11(3):160‐6. ">Kinali 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective study analysing predictive factors for scoliosis in DMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 123<br/> <br/> 37 prednisolone‐treated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All boys 17 yrs or older at time of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day, 10 consecutive days/month<br/> <br/> (Prednisolone started at mean age of 9.5 yrs (range 7.7 to 12.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 1 yr (range 2 months to 9 yrs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a positive relationship between age at scoliosis onset (later) and duration (longer) of prednisolone treatment (r = 0.44, P = 0.01, n = 36)<br/> <br/> There was no relationship between severity of scoliosis at 17 yrs and duration of prednisolone treatment (P = 0.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0051" title="ParreiraSL , ResendeMB , Della Corte PedutoM , MarieSK , CarvalhoMS , ReedUC . Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arquivos de Neuro‐Psiquiatria2007;65(2A):245‐50. ">Parreira 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective single (treated) cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age at start of treatment: 5 yrs 8 months to 8 yrs 8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day in an intermittent course of 10 days on, 10 days off<br/> or<br/> DFZ 1 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Focus of the study was to select an assessment protocol which could be applied in outpatient settings<br/> <br/> 8 boys stopped walking during the study period<br/> <br/> Muscle strength MRC score decreased over time, but there was some functional improvement in lifting weights, 9‐metre walking time </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 withdrew from treatment and 2 took it irregularly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0044" title="MarkhamLW , SpicerRL , KhouryPR , WongBL , MathewsKD , CripeLH . Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatric Cardiology2005;26(6):768‐71. [10.1007/s00246‐005‐0909‐4] ">Markham 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 111<br/> <br/> Prednisone‐treated n = 29<br/> <br/> DFZ‐treated n = 19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 to 11 yrs<br/> <br/> Treated 11 ± 4 yr<br/> <br/> Non‐treated 12 ± 5 yr </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean length of treatment was 3 ± 2.5 yr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Article focuses on cardiac outcome and presents cross‐sectional echocardiographic data<br/> <br/> The shortening fraction was lower in the non‐treated group than in the corticosteroid‐treated group (30% ± 7% vs 36% ± 5%; P &lt; 0.001)<br/> <br/> In comparison with the corticosteroid‐treated boys, the non‐treated boys older than 10 yrs were 15 times more likely to have a shortening fraction less than 28% (P &lt; 0.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0040" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. ">Houde 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study (patients declining to take corticosteroid or used for less than 6 months formed the control group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 treated</p> <p>42 untreated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 13.1 +/‐3.2 yrs treated group</p> <p>Mean 9.5 +/‐2.9 yrs untreated group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ started at 0.9 mg/kg</p> <p>Adjusted according to evolution or side effects (max 1 mg/kg)</p> <p>Mean dose at most recent visit 0.69 +/‐ 0.22 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean treatment 66 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Walking prolonged:</p> <p>mean age loss of ambulation 11.5 years treated versus 9.6 yrs control</p> <p>Muscle strength improved:</p> <p>63% of normal in DFZ group versus 32% of normal in control group</p> <p>FVC improved:</p> <p>66% DFZ versus 48% control</p> <p>Cardiomyopathy reduced:</p> <p>present in 32% DFZ versus 58% control</p> <p>Scoliosis reduced:</p> <p>present in 27% DFZ versus 67% control (43% of whom required surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All fractures:</p> <p>43% DFZ versus 26% control</p> <p>At least 1 limb fracture:</p> <p>24% DFZ versus 26% control</p> <p>Vertebral fractures:</p> <p>20% DFZ versus 0% control</p> <p>Decline in bone density:</p> <p>Z‐score ‐1.8 after 1 yr DFZ and ‐4.5 after 7 yrs</p> <p>Weight excess:</p> <p>62% DFZ versus 55% control</p> <p>Mean height gain:</p> <p>3 times as much in controls versus DFZ group</p> <p>Cataracts:</p> <p>developed in 49% of DFZ group (1 required surgery)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0039" title="HenricsonEK , AbreschRT , CnaanA , HuF , DuongT , ArrietaA , et al. CINRG Investigators. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle &amp; Nerve2013;48(1):55–67. ">Henricson 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort study over 12 months of 3 groups:</p> <p>GC‐naïve (treated &lt; 1 month total or never),</p> <p>current GC users,</p> <p>past GC users (treated in past for &gt; 1 month but not currently receiving GC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340 total</p> <p>82 GC‐naïve</p> <p>210 current GC</p> <p>48 past GC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age range 2 to 28 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessments performed over a 12‐month period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Better upper and lower extremity function in current GC group versus GC‐naïve P &lt; 0.001 </p> <p>Better functional milestones in GC users versus GC‐naïve P = 0.0022</p> <p>No significant differences in MMT scores although rate of decline slower than compared with historical GC‐naïve controls </p> <p>Requirement for surgical spinal stabilisation reduced in GC group versus GC‐naïve between ages 13 to 15 yrs P = 0.013 </p> <p>Better FVC in GC‐treated versus GC‐ naïve in ages 10 to 15 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractures:</p> <p>no significant differences between groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0063" title="TakeuchiF , YonemotoN , NakamuraH , ShimizuR , KomakiH , Mori‐YoshimuraM , et al. Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. Journal of Neurology2013;260(12):3023‐9. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study of prednisolone‐treated (current and past) versus steroid‐naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553 total</p> <p>242 prednisolone‐treated, 311 steroid‐naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age range &gt; 5 to &lt; 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone (no data on dose, regimen or duration)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review of registry data compiled from July 2009 to June 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased age at loss of ambulation:</p> <p>steroid‐naïve median 10.1 yrs</p> <p>prednisolone‐treated 11.0 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not examined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0055" title="RicottiV , RidoutDA , ScottE , QuinlivanR , RobbSA , ManzurAY , et al. NorthStar Clinical Network. Long‐term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery &amp; Psychiatry2013;84(6):698‐705. ">Ricotti 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective longitudinal observational study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age range</p> <p>3 to 15 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily versus intermittent GC regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean duration of treatment 4 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased age at loss of ambulation for daily regimen:</p> <p>median 12 yrs intermittent versus 14.5 yrs daily</p> <p>Slower decline in NSAA score after age 7 for daily versus intermittent regimen</p> <p>No difference in respiratory or cardiac outcomes between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cushingoid features: 33% daily versus 15% intermittent</p> <p>Hyperactivity: 23% daily versus 15% intermittent</p> <p>GI symptoms: 14% daily versus 6% intermittent</p> <p>Hypertension: 22% daily versus 5% intermittent</p> <p>Excessive weight gain in both groups but greatest increase in overall BMI and shorter heights seen in daily regimen </p> <p>Low bone mineral density z scores &lt; 2.5 in 8% daily versus 5% intermittent</p> <p>Vertebral fractures: 8% daily versus 4% intermittent</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BMI: body mass index; Ca: calcium; CI: confidence interval; DEXA: dual energy x‐ray absorptiometry; DFZ: deflazacort; FVC: forced vital capacity; GC: glucocorticosteroid; GI: gastrointestinal; IRLS: iteratively reweighted least squares; MMT: manual muscle testing; MRC: Medical Research Council; NSAA: North Star Ambulatory Assessment; SD: standard deviation; vit D: vitamin D; yr: year; </p> </div> </div> <section id="CD003725-sec-0172"> <h5 class="title">The initial studies</h5> <p>Early, open studies aiming to document some benefit of corticosteroid therapy in DMD used prednisone in high doses ranging from 1.5 mg/kg/day to 5 mg/kg on alternate days (<a href="./references#CD003725-bbs2-0025" title="BrookeMH , FenichelGM , GriggsRC , MendellJR , MoxleyRT3rd , MillerJP , et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Archives of Neurology1987;44(8):812‐7. ">Brooke 1987</a>; <a href="./references#CD003725-bbs2-0030" title="DeSilvaS , DrachmanDB , MellitsD , KunclR . Prednisone treatment in Duchenne muscular dystrophy. Long‐term benefit. Archives of Neurology1987;44(8):818‐22. ">DeSilva 1987</a>; <a href="./references#CD003725-bbs2-0031" title="DrachmanDB , ToykaKV , MyerE . Prednisone in Duchenne muscular dystrophy. Lancet1974;2(7894):1409‐12. ">Drachman 1974</a>; <a href="./references#CD003725-bbs2-0059" title="SiegelIM , MillerJE , RayRD . Failure of corticosteroid in the treatment of Duchenne (pseudo‐hypertrophic) muscular dystrophy. Report of a clinically matched three year double‐blind study. Illinois Medical Journal1974;145(1):32‐3. ">Siegel 1974</a>). <a href="./references#CD003725-bbs2-0030" title="DeSilvaS , DrachmanDB , MellitsD , KunclR . Prednisone treatment in Duchenne muscular dystrophy. Long‐term benefit. Archives of Neurology1987;44(8):818‐22. ">DeSilva 1987</a>, an open study, used loss of ambulation as its primary endpoint and reported prolongation of walking by approximately two years. The adverse effects of corticosteroid treatment in this study were significant and included excessive weight gain, which occurred in the majority of the participants, and hyperactivity, cataracts, hypertension, and stress fractures. These initial studies led to RCTs and further open cohort studies to assess efficacy, and to find optimal dose regimens to minimise adverse effects (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>). </p> </section> <section id="CD003725-sec-0173"> <h5 class="title">Alternate day prednisone therapy</h5> <p><a href="./references#CD003725-bbs2-0034" title="FenichelGM , MendellJR , MoxleyRT , GriggsRC , BrookeMH , MillerJP . A comparison of daily and alternate‐day prednisone therapy in the treatment of Duchenne muscular dystrophy. Archives of Neurology1991;48(6):575‐9. ">Fenichel 1991a</a> compared alternate‐day dosing regimens of prednisone 1.25 mg/kg or 2.5 mg/kg over a six‐month period. The study recruited the same 103 patients who had just completed the <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> randomised study. The placebo group from <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> received prednisone 1.25 mg/kg on alternate days; they improved in strength at three months of treatment, but showed a decline in strength over the subsequent three months. The participants in <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> who were treated with prednisone 0.75 mg/kg/day or 1.5 mg/kg/day were changed to 2.5 mg/kg on alternate days for six months in <a href="./references#CD003725-bbs2-0034" title="FenichelGM , MendellJR , MoxleyRT , GriggsRC , BrookeMH , MillerJP . A comparison of daily and alternate‐day prednisone therapy in the treatment of Duchenne muscular dystrophy. Archives of Neurology1991;48(6):575‐9. ">Fenichel 1991a</a>; they showed a decline in muscle strength. Comparing the 1.25 mg/kg alternate day group of <a href="./references#CD003725-bbs2-0034" title="FenichelGM , MendellJR , MoxleyRT , GriggsRC , BrookeMH , MillerJP . A comparison of daily and alternate‐day prednisone therapy in the treatment of Duchenne muscular dystrophy. Archives of Neurology1991;48(6):575‐9. ">Fenichel 1991a</a> with the contemporaneous 2.5 mg/kg alternate day group, and also with the placebo control group of the previous <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> study, the trial authors concluded that daily dose prednisone was more effective than the alternate‐day regimen. </p> <p><a href="./references#CD003725-bbs2-0067" title="YilmazO , KaradumanA , ArasO , BasogluB , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Neuromuscular Disorders2004; Vol. 14:581. YilmazO , KaradumanA , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. European Journal of Neurology2004;11(8):541‐4. ">Yilmaz 2004</a> treated 66 boys with prednisolone 0.75 mg/kg on alternate days (plus vitamin D 600 to 1200 units/day) and compared this group with a control group of 22 boys who had been followed up in the same centre in the past ("pre‐steroid era"). The controls were reportedly chosen at random, but no details were given regarding this process. Duration of follow‐up was 2.75 ± 0.1 years. Age at loss of walking ability was 10.0 ± 1.5 (range 7 to 14) years in the prednisolone group, compared to 8.6 ± 2.6 (range 6 to 11) years in the control group. Amongst the prednisolone‐treated boys, 14 walked independently beyond the age of 12 years and three beyond 13 years, but all lost the ability to walk by the end of 14 years of age. At the end of the study, none of the prednisolone treatment group developed scoliosis during the follow‐up period (by a mean age 10.8 ± 1.2 years), whereas seven boys in the control group had scoliosis by a mean age of 11.7 ± 2 years. </p> </section> <section id="CD003725-sec-0174"> <h5 class="title">Daily prednisone therapy</h5> <p>At the end of <a href="./references#CD003725-bbs2-0034" title="FenichelGM , MendellJR , MoxleyRT , GriggsRC , BrookeMH , MillerJP . A comparison of daily and alternate‐day prednisone therapy in the treatment of Duchenne muscular dystrophy. Archives of Neurology1991;48(6):575‐9. ">Fenichel 1991a</a>, 93 of the 103 participants entered an open study in which they were given prednisone 0.75 mg/kg/day for two years, the results of which were published in <a href="./references#CD003725-bbs2-0035" title="FenichelGM , FlorenceJM , PestronkA , MendellJR , MoxleyRT3rd , GriggsRC , et al. Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology1991;41(12):1874‐7. ">Fenichel 1991b</a>. Muscle strength, described as average muscle score (previously described as muscle strength score) stabilised over a two‐year period. Over the two‐year period, the prednisone dose had to be decreased because of adverse effects, to as low as 0.15 mg/kg/day. Prednisone 0.65 mg/kg/day was considered to be the minimum effective dose, but only half of the participants could tolerate this dose by the end of the study. </p> </section> <section id="CD003725-sec-0175"> <h5 class="title">Long‐term daily prednisone therapy</h5> <p><a href="./references#CD003725-bbs2-0050" title="PandyaS , MyersG , MoxleyRT . Effect of daily prednisone on independent ambulation in patients with Duchenne dystrophy treated for up to 15 years. Neuromuscular Disorders2001;11(6‐7):630. ">Pandya 2001</a> reported the long‐term outcome of 30 participants who had received prednisone for a mean period of 10 years. This cohort comprised a subgroup of participants treated with prednisone 0.75 mg/kg/day in <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>, who were followed up at the University of Rochester. At the initiation of prednisone, 18 of the 30 participants were ambulant: 13 independently and five walking with long leg braces. At the time of the final visit, one participant was still walking independently at age 18 years, one participant was lost to follow‐up, and three participants had discontinued prednisone because of weight gain. The average age of loss of independent ambulation was 14.5 years. This represents significant improvement in comparison to previous natural history studies, which reported loss of walking in untreated boys with DMD at mean ages of 8.8 years (<a href="./references#CD003725-bbs2-0091" title="DubowitzV . Muscle Disorders in Childhood. 2nd Edition. Philadelphia: Saunders, 1978. ">Dubowitz 1978</a>), 9.5 years (<a href="./references#CD003725-bbs2-0107" title="Gardner‐MedwinD . Clinical features and classification of the muscular dystrophies. British Medical Bulletin1980;36(2):109‐15. ">Gardner‐Medwin 1980</a>), and 10.5 years (<a href="./references#CD003725-bbs2-0073" title="AllsopKG , ZiterFA . Loss of strength and functional decline in Duchenne dystrophy. Archives of Neurology1981;38(7):406‐11. ">Allsop 1981</a>). The prednisone dose had to be decreased because of systemic side effects; in this cohort of 30 participants the mean prednisone dose tolerated was 0.35 mg/kg/day. </p> </section> <section id="CD003725-sec-0176"> <h5 class="title">Studies comparing prednisone with corticosteroid‐naïve patients (but drug regimen not specified) </h5> <p><a href="./references#CD003725-bbs2-0063" title="TakeuchiF , YonemotoN , NakamuraH , ShimizuR , KomakiH , Mori‐YoshimuraM , et al. Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. Journal of Neurology2013;260(12):3023‐9. ">Takeuchi 2013</a> utilised the national registry of Japanese DMD/Becker muscular dystrophy (BMD) patients set up in 2009 to report the age at loss of ambulation only between those treated with prednisone and those who were corticosteroid‐naïve. The registry includes prednisone use status as current, past, or never, but does not record details of dose regimen, age at commencement, duration, or side effects. The study authors considered 245 patients in the prednisone‐treated group (171 current, 74 past), and 315 who had never been treated. Ultimately, loss of ambulation data were available on 242 treated and 311 untreated boys, with loss of ambulation reported in 123 and 190, respectively. The median age at loss of ambulation in the untreated group was 10.1 years (interquartile range (IQR) 10 years to 10.5 years) compared to 11 years (IQR 10.5 years to 11.5 years) in the treated group. </p> <p><a href="./references#CD003725-bbs2-0039" title="HenricsonEK , AbreschRT , CnaanA , HuF , DuongT , ArrietaA , et al. CINRG Investigators. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle &amp; Nerve2013;48(1):55–67. ">Henricson 2013</a> was a multicentre, international, prospective cohort study assessing 340 patients with DMD, ranging in age from 2 to 28 years, at three‐monthly (ambulant) or six‐monthly (non‐ambulant) intervals. Participants were divided into three groups: 82 corticosteroid‐naïve patients (never treated or treated for less than one month total), 210 current corticosteroid users, and 48 past corticosteroid users (treated for more than one month previously, but not currently receiving corticosteroids). The study authors did not specify the preparation of corticosteroid, the regimen (daily versus intermittent), and whether these were the same for all patients studied. They additionally considered and tabulated outcomes by age group. Main outcomes focused on ambulation and functional milestones: each visit attempted to assess timed tests for standing from supine, climbing four standard stairs, walking or running 10 metres, upper limb function (Brooke scale), and lower limb function (Vignos). Over the age of six years, current corticosteroid users consistently demonstrated greater functional abilities than past users or naïve patients. Past users had less ability than current users, but performed better than the naïve group. None of the naïve boys walked beyond age 12, compared to the 8% of past users and 45% of current users still able to walk independently between 13 and 15 years of age. In 16‐ to 18‐year‐olds, only in the group currently taking corticosteroids were any members ambulant (12%). In the upper limbs, 37% of current corticosteroid users, aged 18 years or above, could still lift hand to mouth to feed independently, compared to none of the past user or corticosteroid‐naïve groups. MRC manual muscle testing (MMT) scores did not significantly differ between the corticosteroid‐treated group and the cohort as a whole. Pulmonary function as measured by FVC and FEV<sub>1</sub> (forced expiratory volume in one second) was comparatively better in the corticosteroid‐treated group between the ages of 10 to 15 years. In terms of bone health, the trial authors reported a similar incidence of fractures between corticosteroid‐users and the other groups among those more than 13 years old, although the need for surgical spinal stabilisation was reduced in the corticosteroid group between the ages of 13 and 15 years. </p> </section> <section id="CD003725-sec-0177"> <h5 class="title">Daily dose deflazacort studies</h5> <p><a href="./references#CD003725-bbs2-0057" title="ScharaU , MortierJ , MortierW . Long‐term steroid therapy in Duchenne muscular dystrophy‐positive results versus side effects. Journal of Clinical Neuromuscular Disease2001;2(4):179‐83. ">Schara 2001</a>, a retrospective study, reported 19 ambulant boys with DMD who were treated with deflazacort 0.9 mg/kg/day for more than two years (mean 65 months, range 49 to 79 months). Fourteen of the 19 boys aged 9.4 to 13.8 years were able to rise from a supine position. Five boys lost this function at a mean age of 13.5 years (range 10 to 16 years, which is a marked improvement as compared to natural history controls (mean 8.2 ± 1.9 years). All deflazacort‐treated boys were able to walk independently during the study period to a mean age of 13 years (range 9.4 to 18.11 years). The key side effects reported were short stature and cataracts. Fourteen of the 19 deflazacort‐treated boys developed cataracts; one patient's progressive cataracts led to implantation of lenses 56 months into the treatment. </p> <p>Among the non‐randomised studies, the most impressive functional results of corticosteroid therapy in DMD have been reported from Bloorview MacMillan Children's Centre in Toronto, Canada in a series of five publications: <a href="./references#CD003725-bbs2-0014" title="AlmanBA , RazaNS , BiggarWD . Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. Journal of Bone and Joint Surgery. American Volume2004;86‐A(3):519‐24. ">Alman 2004</a>, <a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a>, <a href="./references#CD003725-bbs2-0021" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. ">Biggar 2004</a>, <a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a>, and <a href="./references#CD003725-bbs2-0061" title="SilversidesCK , WebbGD , HarrisVA , BiggarDW . Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. American Journal of Cardiology2003;91(6):769‐72. ">Silversides 2003</a>. All five studies describe the use of daily dose deflazacort in clinical practice at the Bloorview MacMillan Children's Centre from January 1990 onwards, and they report an overlapping cohort of patients. </p> <p><a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a> used a starting dose of deflazacort 0.9 mg/kg daily in 30 boys with DMD (age 7 to 15 years) over 3.8 years (SD 1.5) and compared this group with 24 boys who were followed up at the same clinic contemporaneously, who did not take up the option of deflazacort treatment because of parental choice (most commonly, fear of side effects). Seven of the 30 boys in the deflazacort group stopped walking at a mean of 12.3 (SD 2.7) years, and this contrasted with the non‐treated participants, all 24 of whom stopped walking at a mean of 9.8 (SD 1.8) years. The FVC in the deflazacort‐treated group was significantly greater at 15 years (P &lt; 0.001), but the trial authors did not report the number of participants at 15 years. Ten of the 30 boys in the deflazacort treatment group developed asymptomatic cataracts. The two groups were significantly different in height; mean height in the deflazacort‐treated group continued along the 3rd centile, compared to mean height between the 25th and 50th centiles for the non‐treated group. </p> <p>The primary outcome of interest in <a href="./references#CD003725-bbs2-0061" title="SilversidesCK , WebbGD , HarrisVA , BiggarDW . Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. American Journal of Cardiology2003;91(6):769‐72. ">Silversides 2003</a> was cardiac function. The trialists reported a cohort of 33 Duchenne patients who underwent echocardiographic evaluation. Twenty‐one participants had been on deflazacort, for a mean duration of 5.1 years ± 2.4, and trialists compared this group with the other 12 who had not accepted the option of deflazacort treatment. The mean age at final follow‐up was 14 (± 2) years for the deflazacort‐treated group and 16 (± 2) years for the non‐treated group. This age difference in the two groups was not statistically significant (P = 0.08), but the biological significance cannot be discounted. Cardiomyopathy, as indicated by left ventricular ejection fraction less than 45%, was demonstrated in only one of the 21 deflazacort‐treated participants, compared to seven out of 12 non‐treated participants (P = 0.001). The mean ejection fraction reduction was 33% (± 7) in the deflazacort group and 21% (± 8) in the non‐treated group (P = 0.002). </p> <p><a href="./references#CD003725-bbs2-0014" title="AlmanBA , RazaNS , BiggarWD . Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. Journal of Bone and Joint Surgery. American Volume2004;86‐A(3):519‐24. ">Alman 2004</a> focused on the development of scoliosis in the cohort of 54 boys followed up at the Bloorview Macmillan Centre and initially reported in <a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a>. The mean age at follow‐up was 16 years. Only five of the 30 deflazacort‐treated boys developed scoliosis of more than 20°. In comparison, 16 of the 24 untreated boys developed scoliosis of more than 20°. Deflazacort treatment was associated not only with a reduced incidence of scoliosis, but also delayed the onset and/or development of scoliosis; of the boys who developed scoliosis of &gt; 20°, the five deflazacort‐treated boys required spinal surgery at a later age of 15.1 ± 2.0 years, compared with the 16 non‐treated boys who underwent spinal surgery at 12.9 ± 2.4 years. </p> <p><a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a> reported the updated and cumulative results of the overlapping cohorts from <a href="./references#CD003725-bbs2-0014" title="AlmanBA , RazaNS , BiggarWD . Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. Journal of Bone and Joint Surgery. American Volume2004;86‐A(3):519‐24. ">Alman 2004</a>, <a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a>, <a href="./references#CD003725-bbs2-0021" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. ">Biggar 2004</a>. and <a href="./references#CD003725-bbs2-0061" title="SilversidesCK , WebbGD , HarrisVA , BiggarDW . Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. American Journal of Cardiology2003;91(6):769‐72. ">Silversides 2003</a>. The included participants were 74 boys with DMD between 10 and 18 years old who could co‐operate for reproducible muscle and pulmonary function testing and were followed up in Neuromuscular Clinics, Toronto, Canada between January 1990 and December 2004. (Investigators excluded four boys who stopped taking deflazacort within two to three years, before they were 10 years old; they are not included in these 74 patients). Boys were offered deflazacort treatment while they were still ambulant but had clinical evidence of worsening muscle function, as evidenced by frequent falls and difficulty in rising from the floor or climbing stairs. Of the 74 boys, 40 were treated with deflazacort; the remaining 34 who did not accept deflazacort (mainly due to fear of side effects, or family cultural or religious reasons) were used as the comparison group. Boys treated with deflazacort (and most boys not treated with deflazacort) received oral daily supplements of vitamin D (1000 units) and calcium (750 mg). Mean age at starting deflazacort was 7.7 ± 1.2 years. The deflazacort starting dose was 0.9 mg/kg daily, which gradually declined over the years as boys grew and gained weight, or was reduced because of side effects. By 10 years of age, the mean dose was 0.8 ± 0.18 mg/kg/day, by 15 years it was 0.55 ± 0.09 mg/kg/day, and by 18 years 0.5 ± 0.2 mg/kg/day. Mean age at the end of the study period was 15.2 ± 2.7 years in the deflazacort‐treated group and 15.2 ± 2.5 years in the non‐treated group. Mean time on deflazacort was 5.5 years. The key results are listed as follows.<br/> <br/> <i>Walking (10 metres)</i>: In the deflazacort‐treated group, 25 of 31 (81%) could walk at 12 years, 13 of 17 (76%) at 15 years, and two of six boys walked independently at 18 years. By contrast, all 34 boys not treated stopped walking by 12 years of age (mean age 9.8 ± 1.8 years). </p> <p><i>Scoliosis</i>: Scoliosis is a frequent complication of DMD in the second decade of life, occurring in up to 90% of affected boys, and in the huge majority, is clinically evident in the 13 to 15 year age group. In the <a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a> cohort, by 18 years of age (mean 13.8 ±1.6 years), 30 of 34 (90%) boys who were not treated developed a spinal curve of more than 20°. In contrast, only four of 40 (10%) deflazacort‐treated boys developed scoliosis of more than 20° during the study period. The possible explanations for this could be deflazacort‐related prolongation of the ambulatory phase, improvement in paraspinal and truncal muscle strength, or both. </p> <p><i>Cardiac function</i>: Moderate or severe left ventricular systolic dysfunction (ejection fraction below 45%) was noted in only four out of 40 boys in the deflazacort‐treated group as compared with 20 of 34 boys in the not treated group. </p> <p><i>Pulmonary function</i>: FVC, reported as per cent predicted (for age and height) (FVC‐PP), was remarkably preserved in the deflazacort treated group. Both groups of boys, treated and untreated, were reported to have similar FVC‐PP before 10 years of age, but the report did not present the data. As anticipated, in line with the natural history of DMD, in the no treatment group, FVC‐PP showed a gradual decline with age (65 ± 13% at 10 years, 47 ± 19% at 15 years, and 34 ± 10% at 18 years). In contrast, in the deflazacort‐treated group, the FVC‐PP was 95 ± 17% at 10 years, 88 ± 12% at 15 years, and 81 ± 13% at 18 years. The clinically‐important implication was that by 18 years of age, 46% of the boys not treated required nocturnal ventilatory support, compared to none in the deflazacort‐treated group. </p> <p><i>Survival</i>: To our knowledge, <a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a> was the first study reporting the impact of corticosteroid therapy on survival in DMD. Twelve of the 34 (35%) boys not treated died at mean age 17.6 ± 1.7 years, of cardiorespiratory complications (details not reported). Only two of the 40 deflazacort‐treated boys died; cause of death was left ventricular failure, and age at death was 13 years and 18 years. </p> <p><i>Adverse events</i>: The growth suppression effect of long‐term glucocorticoid treatment was evident in short stature in the deflazacort‐treated group; at age 15 years, the height of deflazacort‐treated boys was 143 ± 9 cm, compared to 164 ± 8 cm for boys not treated. Twenty‐two of the 40 deflazacort‐treated boys developed bilateral cataracts, though they were asymptomatic for the duration of the study. </p> <p><a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a> gave dietary recommendations to all boys on each hospital visit, and referred boys to a nutritionist if weight exceeded expected weight by 5% to 10%, or if weight loss exceeded 10%. With this approach, excessive weight gain, which is a common side effect of corticosteroid therapy, was not noted to be a significant clinical problem amongst these 40 deflazacort‐treated boys, over a mean treatment period of five years. Trialists reported only one boy from the Bloorview Macmillan Centre to have discontinued deflazacort because of excessive weight gain, and this boy was not included in the 74 participants reported in <a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a>. Three boys in the deflazacort‐treated group developed fragility vertebral fractures compared with none in the non‐treated group. Long‐bone fractures were documented in 25% of boys in both groups, with no difference between groups. </p> <p><a href="./references#CD003725-bbs2-0040" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. ">Houde 2008</a> retrospectively analysed the medical charts of 105 boys with DMD over an eight‐year period. The boys were divided into those receiving deflazacort for more than one year (treated) and those not receiving the drug or who had received it for less than six months (untreated). The trialists excluded five boys in the treated group; four because they had stopped taking the drug after two years, and one because he had received prednisone for six years before switching to deflazacort. Among the untreated group, they excluded 21 because of missing data or because boys were too young to participate in all regular assessments. Overall, 37 boys received deflazacort, and 42 were untreated. The starting dose was 0.9 mg/kg/day, adjusted according to progression or side effects, with a maximum of 1 mg/kg. The mean length of treatment was 66 months, with 70% taking deflazacort for more than five years, and 22% for more than eight years. The mean age on beginning treatment was 7.6 ± 1.7 years and the mean dose at the most recent clinic visit recorded was 0.69 ± 0.2 mg/kg. All boys, treated and untreated, were offered review every three months. The mean age of the treated group was 13.1 ± 3.2 years. Among the untreated patients, 24 were over 18 and no longer actively followed at the clinic. Of the 18 who were still under regular clinic review, the mean age was 9.5 ± 2.9 years. Key findings were as follows. </p> <p><i>Ambulation</i>: The trialists reported loss of ambulation as when a boy could no longer walk, even with help. For those who used long leg braces, it was recorded as the time when natural walking stopped or when the use of braces began. Twelve of 37 boys in the treated group had lost ambulation at a mean age of 11.5 ± 1.9 years, compared with 32/42, mean age of 9.6 ± 1.4 years (P &lt; 0.05) in the untreated group. Of boys aged 12 years or more, 13/23 (53%) of the treated group could still walk compared to none of the untreated group. </p> <p><i>Muscle strength</i>: MRC score of 34 muscles was recorded every six months. Scores were cumulated and converted to a percentage of normal (where 100% = normal). Muscle strength at age 16 was 63% ± 4 in the treated group compared to 31% ± 3 in the untreated group, P &lt; 0.003. </p> <p><i>FVC</i>: The treated group improved in FVC: 66% ± 14 treated versus 48% ± 22 untreated, P &lt; 0.007. </p> <p><i>Cardiac function</i>: The deflazacort group improved in cardiac function, with significantly better values for fractional shortening and ejection fraction, and a lower incidence of dilated cardiomyopathy. Of note, angiotensin converting enzyme inhibitors were used more frequently in the treated group but their effect could not be isolated from those of deflazacort. The older age of the untreated group may also have biased the incidence of cardiomyopathy. </p> <p><i>Scoliosis development</i>: Fewer boys developed scoliosis in the treated group 10/37 (27%) than in the untreated group 28/42 (67%). Scoliosis when it did occur also tended to be less severe; none of the treated boys required corrective surgery in the treated group, compared with 12/28 (43%) of the untreated group. </p> <p><i>Adverse events</i>: All adverse events were more common in the treated group. Fractures occurred in both groups, with a similar incidence of long‐bone fractures (24% treated group, 26% untreated group) but the incidence of vertebral fractures was greater in the treated group (20% versus 0%), although none contributed to any functional decline. Nineteen of the 37 participants in the treated group required bisphosphonates compared with none in the untreated group. Excess weight (BMI &gt; 85% percentile) was present in both groups; 13/21 (62%) of the treated group versus 6/11 (55%) of the untreated group. Evidence of growth suppression and short stature was also seen in the treated group, with mean height gain being three times as much in the untreated group at age 12 years. Height values were not available for all children and some were younger than 12 years old, but the available data showed that only 3/20 (15%) of the treated group grew 4 cm per year or more, compared to 19/19 of the untreated group at age 12. Cataracts developed in 18/37 (49%) of the treated group; in 17 of 18 (94%) this was after more than five years of treatment. One patient required surgery. </p> </section> <section id="CD003725-sec-0178"> <h5 class="title">Studies comparing deflazacort with prednisone daily dose regimens</h5> <p><a href="./references#CD003725-bbs2-0019" title="BalabanB , MatthewsDJ , ClaytonGH , CarryT . Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long‐term effect. American Journal of Physical Medicine and Rehabilitation2005;84(11):843‐50. ">Balaban 2005</a> reported a retrospective study of the long‐term effect of daily dose corticosteroids in a cohort of 49 boys with DMD between the ages of 12 and 15 years. Eighteen boys were treated with prednisone, 12 with deflazacort, and 19 had no treatment. Parents had been informed about treatment alternatives and were offered the option of corticosteroid medication, and the choice of deflazacort or prednisone. The study site was in Denver, Colorado, USA; the authors report that the cost of deflazacort was much greater than prednisone (USD 3 per day versus USD 0.50 per day), and some families chose on the basis of cost. </p> <p>The mean age of starting deflazacort was 7.45 ± 0.97 years, mean duration of treatment was 5.85 ± 1.5 years, and the starting dose was 0.9 mg/kg/day. The mean age of starting prednisone was 6.90 ± 1.0 years, mean duration of treatment 5.49 ± 1.98 years, and the starting dose 0.75 mg/kg/day. The benefits, including prolongation of the ability to walk 30 feet on level ground, were similar in groups treated with deflazacort or prednisone, as compared to the untreated boys. Excessive weight gain was more common in prednisone‐treated boys, leading to discontinuation of prednisone in three of the 18 boys in this group. Two of the 12 deflazacort‐treated boys developed asymptomatic cataracts. </p> </section> <section id="CD003725-sec-0179"> <h5 class="title">Intermittent corticosteroid regimens</h5> <section id="CD003725-sec-0180"> <h6 class="title">Dubowitz regimen ‐ prednisolone 10 days on, 10/20 days off</h6> <p>In order to lessen the adverse effects of long‐term corticosteroid treatment, Dubowitz recommended an intermittent regimen of prednisolone 0.75 mg/kg/day for the first 10 days of every calendar month (treatment cycles of 10 days on prednisolone, 20 days off; <a href="./references#CD003725-bbs2-0092" title="DubowitzV . Prednisone in Duchenne dystrophy. Neuromuscular Disorders1991;1(3):161‐3. ">Dubowitz 1991</a>). An open study of 32 patients demonstrated that this intermittent regimen had a positive influence on strength at six months, followed by a slow decline at 12 and 18 months (<a href="./references#CD003725-bbs2-0056" title="SansomeA , RoystonP , DubowitzV . Steroids in Duchenne muscular dystrophy; pilot study of a new low‐dosage schedule. Neuromuscular Disorders1993;3(5‐6):567‐9. ">Sansome 1993</a>); weight gain and other side effects were much less than would be expected with continuous therapy. Subsequently, to increase efficacy, the investigators modified the regimen to a 10 days on prednisolone 0.75 mg/kg/day and 10 days off treatment cycle. The same research group highlighted the long‐term tolerability of the intermittent (10 days on treatment, 10 days off) regimen of prednisolone (<a href="./references#CD003725-bbs2-0032" title="DubowitzV , KinaliM , MainM , MercuriE , MuntoniF . Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low‐dosage prednisolone therapy. European Journal of Paediatric Neurology2002;6(3):153‐9. ">Dubowitz 2002</a>; <a href="./references#CD003725-bbs2-0041" title="KinaliM , MercuriE , MainM , MuntoniF , DubowitzV . An effective, low‐dosage, intermittent schedule of prednisolone in the long‐term treatment of early cases of Duchenne dystrophy. Neuromuscular Disorders2002;12(Suppl 1):S169‐74. ">Kinali 2002</a>). The four boys reported in these studies were started on prednisolone between four and five years of age, and followed up over a period of between 3.75 and over five years. These boys showed "remarkable improvement" (described by authors as gaining the ability to rise from the floor without Gowers' manoeuvre, hop on one or both legs, and run without waddle) and the functional benefit was partly sustained without the evidence of abnormal weight gain, demineralisation of bone, or other signs of chronic prednisolone toxicity. These studies, though including small numbers, also suggested that the beneficial effects of corticosteroids appear to be greater when treatment is initiated at a younger age, in the early ambulant phase (<a href="./references#CD003725-bbs2-0032" title="DubowitzV , KinaliM , MainM , MercuriE , MuntoniF . Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low‐dosage prednisolone therapy. European Journal of Paediatric Neurology2002;6(3):153‐9. ">Dubowitz 2002</a>; <a href="./references#CD003725-bbs2-0041" title="KinaliM , MercuriE , MainM , MuntoniF , DubowitzV . An effective, low‐dosage, intermittent schedule of prednisolone in the long‐term treatment of early cases of Duchenne dystrophy. Neuromuscular Disorders2002;12(Suppl 1):S169‐74. ">Kinali 2002</a>). No long‐term data exist reporting prolongation of ambulation with this intermittent regimen. </p> <p><a href="./references#CD003725-bbs2-0042" title="KinaliM , MainM , EliahooJ , MessinaS , KnightRK , LehovskyJ . Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. European Journal of Paediatric Neurology2007;11(3):160‐6. ">Kinali 2007</a> retrospectively analysed predictive factors for development of scoliosis in DMD in 123 DMD boys, aged 17 years or older. Thirty‐seven of the 123 boys (30%) had received intermittent prednisolone (0.75 mg/kg/day, 10 consecutive days/month) for a median time of one year (two months to nine years), starting between 7.7 and 12.4 years (mean 9.5 years). The study authors used univariate analysis to relate age at onset of scoliosis and scoliosis severity at 17 years with glucocorticoid treatment and other factors. There was a positive relationship between age at scoliosis onset (later) and duration (longer) of prednisolone treatment (r = 0.44, P = 0.01, n = 36). Severity of scoliosis at 17 years and duration of prednisolone treatment showed no relationship (P = 0.64). The intermittent prednisolone regimen in <a href="./references#CD003725-bbs2-0042" title="KinaliM , MainM , EliahooJ , MessinaS , KnightRK , LehovskyJ . Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. European Journal of Paediatric Neurology2007;11(3):160‐6. ">Kinali 2007</a> appeared to be associated with a later onset of scoliosis; the trial author concluded that the observation of unchanged scoliosis severity at 17 years probably reflected the shorter overall glucocorticoid exposure in this cohort. </p> <p><a href="./references#CD003725-bbs2-0051" title="ParreiraSL , ResendeMB , Della Corte PedutoM , MarieSK , CarvalhoMS , ReedUC . Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arquivos de Neuro‐Psiquiatria2007;65(2A):245‐50. ">Parreira 2007</a> "sought to select a sequence of tests which can be applied in a practical and swift fashion in an outpatient setting to assess patients' response to steroid therapy" and reported its application to 32 boys with DMD who were treated with intermittent prednisolone (0.75 mg/kg/day in an intermittent course of 10 days on, 10 days off), or deflazacort (1 mg/kg/day). The trialists did not report the number of boys using prednisolone or deflazacort regimens. Age range at the start of treatment was 5 years 8 months to 8 years 8 months, and the boys were assessed on 10 visits, monthly for the first six months and then every two months until the 14‐month end point. Of the 26 boys who complied with the medication and assessment regimen, eight lost ambulation during the study period. The benefit appeared modest. Over the 14‐month period, muscle strength assessment showed worsening of MRC indices, but there was a statistically significant improvement in weight lifting test results (P &lt; 0.001), and improvement in time taken to walk nine metres. The data presented did not allow comparison of the effect of intermittent prednisolone with that of daily dose deflazacort. The study authors did not describe adverse effects. <a href="./references#CD003725-bbs2-0051" title="ParreiraSL , ResendeMB , Della Corte PedutoM , MarieSK , CarvalhoMS , ReedUC . Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arquivos de Neuro‐Psiquiatria2007;65(2A):245‐50. ">Parreira 2007</a> emphasised that muscle strength measurements alone are not sufficient for evaluating the results of corticosteroid treatment, and that tests analysing function and execution should also be performed. </p> </section> <section id="CD003725-sec-0181"> <h6 class="title">Connolly regimen ‐ twice weekly prednisolone (5 mg/kg/dose)</h6> <p>In a further attempt to decrease long‐term adverse effects, <a href="./references#CD003725-bbs2-0027" title="ConnollyAM , SchierbeckerJ , RennaR , FlorenceJ . High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscular Disorders2002;12(10):917‐25. ">Connolly 2002</a> devised a twice‐weekly regimen of prednisone given every Friday and Saturday (5 mg/kg/dose). Twenty treated boys (with an average age of eight years) were compared to historical controls. Strength, evaluated with hand‐held manometer and grip meter, improved over six to 12 months. At least six of the 20 boys developed irritability, which led to discontinuation of treatment in two, and a 25% to 30% dose reduction in four patients. Long‐term results for this treatment regimen have not been reported. </p> </section> <section id="CD003725-sec-0182"> <h6 class="title">Nigro regimen ‐ Deflazacort 0.6 mg/kg/day 20 days on, 10 days off</h6> <p>Professor Nigro's group in Naples, Italy, who studied 56 boys, utilised this intermittent regimen of deflazacort; <a href="./references#CD003725-bbs2-0021" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. ">Biggar 2004</a> reported the results, and compared them with the daily dose deflazacort regimen used in 32 of 60 boys in Toronto, Canada. (The Toronto patients were part of the overlapping patient cohorts described in <a href="./references#CD003725-bbs2-0014" title="AlmanBA , RazaNS , BiggarWD . Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. Journal of Bone and Joint Surgery. American Volume2004;86‐A(3):519‐24. ">Alman 2004</a>, <a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a>, <a href="./references#CD003725-bbs2-0023" title="BonifatiDM , WitchelSF , ErmaniM , HoffmanEP , AngeliniC , PegoraroE . The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy. Journal of Neurology, Neurosurgery, and Psychiatry2006;77(10):1177‐9. ">Bonifati 2006</a>, and <a href="./references#CD003725-bbs2-0061" title="SilversidesCK , WebbGD , HarrisVA , BiggarDW . Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. American Journal of Cardiology2003;91(6):769‐72. ">Silversides 2003</a>). </p> <p>In Professor Nigro's Naples group, 56 boys at mean age 6.0 ± 1.5 years, were started on the intermittent regimen of deflazacort 0.6 mg/kg given on the first 20 days of each month. Nineteen of the 56 stopped deflazacort within one month because of "economical and/or environmental reasons", and they served as a control group for comparison. The deflazacort‐treated boys were also given daily supplements of vitamin D (880 iu) and calcium (1000 mg). Duration of deflazacort treatment was more than four years in all boys. </p> <p>In the control group of 19 boys from Naples, Italy, only four (21%) were able to walk 10 metres at nine years and none at 12 years. Of the 37 boys treated with intermittent deflazacort (0.6 mg/kg/day for the first 20 days of each month), 97% (36/37) could walk 10 metres at nine years, 35% (9/26) at 12 years and 25% (3/12) at 15 years. This represents significant improvement in comparison to the previous natural history studies, which reported loss of walking in untreated boys with DMD at mean ages of 8.8 years (<a href="./references#CD003725-bbs2-0091" title="DubowitzV . Muscle Disorders in Childhood. 2nd Edition. Philadelphia: Saunders, 1978. ">Dubowitz 1978</a>), 9.5 years (<a href="./references#CD003725-bbs2-0107" title="Gardner‐MedwinD . Clinical features and classification of the muscular dystrophies. British Medical Bulletin1980;36(2):109‐15. ">Gardner‐Medwin 1980</a>), and 10.5 years (<a href="./references#CD003725-bbs2-0073" title="AllsopKG , ZiterFA . Loss of strength and functional decline in Duchenne dystrophy. Archives of Neurology1981;38(7):406‐11. ">Allsop 1981</a>). However, in comparison, the daily dose deflazacort 0.9 mg/kg/day regimen used to treat the 32 boys in Toronto, Canada, appears to have a bigger impact on walking; all 32 were able to walk 10 metres at 9 years, 83% (19/23) at 12 years, and 77% (10/33) at 15 years. The key difference in side effects was with regards to cataracts. No cataracts were noted in the 37 patients treated with the intermittent 20 days on, 10 days off Nigro regimen, compared with the 30% who developed asymptomatic cataracts among 32 patients treated with daily dose deflazacort. </p> </section> </section> <section id="CD003725-sec-0183"> <h5 class="title">Long‐term studies comparing daily prednisolone with intermittent prednisolone (10 days on, 10 days off) </h5> <p><a href="./references#CD003725-bbs2-0055" title="RicottiV , RidoutDA , ScottE , QuinlivanR , RobbSA , ManzurAY , et al. NorthStar Clinical Network. Long‐term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery &amp; Psychiatry2013;84(6):698‐705. ">Ricotti 2013</a> was an observational study utilising longitudinal clinical data entered into the UK North Star database from 17 participating paediatric neuromuscular centres. The investigators analysed data on 360 boys (age range 3 to 17 years) who had received prednisolone (191 on an intermittent regimen of 10 days on, 10 days off, and 169 on a daily dose regimen). The mean duration of treatment and follow‐up was 3.9 years. The median time to loss of ambulation was 12 years in the intermittent treatment group and 14.5 years in the daily treatment group; the hazard ratio (HR) for intermittent treatment was 1.57 (95% CI 0.87 to 2.82). Longitudinal analysis of the North Star Ambulatory Assessment (a validated composite scale to measure function in ambulant DMD boys) showed a faster rate of decline after age seven in those on the intermittent versus the daily regimen, with the difference between the two regimens increasing by 1.58 units per year (95% CI 1.04 to 2.11, P &lt; 0.001), although respiratory and cardiac outcomes did not differ between the two groups. Side effects were more common in the daily treatment group, including cushingoid features (33% versus 15%), hyperactivity (23% versus 15%), and hypertension (22% versus 5%). Both groups gained excessive weight. The daily group had a lower mean height, MD 1.09 (95% CI 0.78 to 1.40, P &lt; 0.001). Overall increase in BMI was greatest in the daily treatment group: MD 0.43 (95% CI 0.11 to 0.74, P &lt; 0.01). <a href="./references#CD003725-bbs2-0055" title="RicottiV , RidoutDA , ScottE , QuinlivanR , RobbSA , ManzurAY , et al. NorthStar Clinical Network. Long‐term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery &amp; Psychiatry2013;84(6):698‐705. ">Ricotti 2013</a> reported vertebral fractures (vertebral wedging on lateral spine radiography) in 4% of boys on the intermittent regimen and 8% of boys on the daily regimen. </p> </section> <section id="CD003725-sec-0184"> <h5 class="title">Studies selectively focusing on cardiac outcome</h5> <p><a href="./references#CD003725-bbs2-0044" title="MarkhamLW , SpicerRL , KhouryPR , WongBL , MathewsKD , CripeLH . Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatric Cardiology2005;26(6):768‐71. [10.1007/s00246‐005‐0909‐4] ">Markham 2005</a> reported cross‐sectional echocardiographic shortening fraction data in a retrospective review of 111 subjects with DMD who had been followed up in two centres. Forty‐eight subjects had been treated (29 with prednisolone, 19 with deflazacort) for six months or longer, and they were compared with the 63 untreated subjects. The dose regimen was not reported. Age range was three to 11 years (treated 11 ± 4, untreated 12 ± 5), and mean length of treatment was 3 ± 2.5 years. Of the 48 treated subjects, 10 had been treated with corticosteroids for 4.2 ± 1.6 years, but the treatment had been stopped because of adverse effects at the time of echocardiography. </p> <p>The shortening fraction was lower in the untreated group than in the corticosteroid‐treated group (30% ± 7% versus 36% ± 5%; P &lt; 0.001). The difference in shortening fraction between the two groups was most obvious in subjects over 10 years of age: in comparison with the corticosteroid‐treated subjects, the untreated subjects older than 10 years were 15 times more likely to have a shortening fraction less than 28% (P &lt; 0.01). Though the two groups were similar with regards to baseline age, body mass and left ventricular indices, the retrospective design of this study carries the implicit risk of biased treatment allocation. </p> <p>In this update we did not select any further studies selectively focusing on cardiac outcome, as a separate Cochrane review addressing this issue is in development (<a href="./references#CD003725-bbs2-0141" title="QuinlivanR , BourkeJP , BueserT . Prevention and treatment for cardiac complications in Duchenne and Becker muscular dystrophy and X‐linked dilated cardiomyopathy. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD009068.pub2] ">Quinlivan 2012</a>). </p> </section> <section id="CD003725-sec-0185"> <h5 class="title">Studies selectively focusing on cough efficiency and respiratory muscle strength</h5> <p><a href="./references#CD003725-bbs2-0028" title="DaftaryAS , CrisantiM , KalraM , WongB , AminR . Effect of long‐term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics2007;119(2):e320‐4. ">Daftary 2007</a> studied 10 corticosteroid‐treated and 25 non‐treated patients in a retrospective case‐control study. The age range of the treated group was seven to 21 years (median 10 years). Three patients were treated exclusively with prednisone, five exclusively with deflazacort, and two were started on intermittent prednisone but later switched to daily deflazacort. Prednisone was started at a dosage of 0.75 mg/kg/day and deflazacort at 0.9 mg/kg/day. The mean duration of corticosteroid therapy was 8.2 years (range 1 to 14 years). Peak cough flow (PCF) and maximum expiratory pressure were significantly higher in the corticosteroid‐treated group. Median PCF was 215.0 L/min in the treated group compared with 177.5 L/min in the non‐treated group (P ≤ 0.05). Median maximum expiratory pressure (MEP) was 62.5 cm H<sub>2</sub>O in the treated group as compared with 44.5 cm H<sub>2</sub>O in the non‐treated group (P ≤ 0.05). These results are suggestive that corticosteroid therapy is beneficial in preserving respiratory muscle strength and cough efficiency in DMD, and are in concordance with previous randomised (<a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>; <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a>) and non‐randomised studies (<a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a>), which reported preservation of FVC. Of note, <a href="./references#CD003725-bbs2-0028" title="DaftaryAS , CrisantiM , KalraM , WongB , AminR . Effect of long‐term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics2007;119(2):e320‐4. ">Daftary 2007</a> observed that patients with DMD were weak and therefore often unable to sustain exhalation for six seconds, as required by the American Thoracic Society to meet pulmonary function test acceptability criteria, and arbitrarily chose a three second (or more) exhalation criterion for acceptability. This indicates the need for consensus on customisation of the test protocols, taking into consideration the marked respiratory muscle weakness in DMD. </p> <p>In this update we did not select any further non‐randomised studies selectively focusing on cough efficiency and respiratory muscle strength as these outcomes are not the primary focus of this review. A Cochrane review of Mechanical insufflation‐exsufflation for people with neuromuscular disorders has been published (<a href="./references#CD003725-bbs2-0126" title="MorrowB , ZampoliM , vanAswegenH , ArgentA . Mechanical insufflation‐exsufflation for people with neuromuscular disorders. Cochrane Database of Systematic Reviews2013, Issue 12. [DOI: 10.1002/14651858.CD010044.pub2] ">Morrow 2013</a>). </p> </section> <section id="CD003725-sec-0186"> <h5 class="title">Vertebral fractures with daily dose corticosteroid regimens</h5> <p><a href="./references#CD003725-bbs2-0024" title="BothwellJE , GordonKE , DooleyJM , MacSweenJ , CummingsEA , SalisburyS . Vertebral fractures in boys with Duchenne muscular dystrophy. Clinical Pediatrics2003;42(4):353‐6. ">Bothwell 2003</a> highlighted the need for caution with the long‐term use of corticosteroids. Twenty‐five boys with DMD were treated with daily corticosteroids (one prednisolone, 13 deflazacort, and 11 prednisolone before switching to deflazacort) for a median duration of 4.5 years (inter‐quartile range (IQR) 3 to 10 years). The dosage used was 1 mg/kg/day. The trial authors do not describe whether the dose was reduced over time, for example in response to excessive weight gain. All boys were prescribed calcium supplements and 22 of the 25 boys were also on vitamin D. Ten of the 25 boys (40%) sustained vertebral fractures; eight were symptomatic with backache and two had fractures detected on spinal radiographs taken because of low bone mineral density results. The first fracture occurred 40 months into treatment. Extrapolating from the 10 boys who sustained a vertebral fracture, Kaplan‐Meier analysis predicted that 50% of treated boys would have a vertebral fracture by 53.5 months, and 75% by 100 months of treatment. </p> <p><a href="./references#CD003725-bbs2-0043" title="KingWM , RuttencutterR , NagarajaHN , MatkovicV , LandollJ , HoyleC . Orthopedic outcomes of long‐term daily dose corticosteroid treatment in Duchenne muscular dystrophy. Neurology2007;68(19):1607‐13. ">King 2007</a> reported vertebral and long‐bone fractures among 75 boys in the course of long‐term daily dose corticosteroid treatment, comparing them with 68 boys who had not been treated or had received brief submaximal doses. The mean age of treated boys was 16.9 ± 5.6 years (range 6.1 to 30.5 years) compared to 14.4 ± 8.1 years (range 1.1 to 39.6 years) in the non‐treated group. Thirty‐six boys were treated with prednisone, 25 with deflazacort, and 14 had been on both. The daily dose regimen starting dose was prednisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day. At the final clinic visit prior to data collation, the average corticosteroid dose of the treated group was 0.55 mg/kg (range 0.10 to 0.78 mg/kg). The mean duration of corticosteroid treatment was 8.04 years (± 5.2 years, range 0.5 to 18.5 years). The boys who began treatment were also prescribed calcium supplements, either as calcium carbonate 350 mg three times daily or a calcium tablet with vitamin D supplement (750 to 1200 mg daily), but the trialists did not report the degree of compliance with these supplements. Treated boys walked independently 3.3 years longer, had lower prevalence (31% versus 91%) and severity (Cobb angle 11˚ versus 33˚) of scoliosis as compared to the non‐treated boys, but 32% of these 75 corticosteroid‐treated boys developed a compression vertebral fracture. Eighty per cent of vertebral fractures were identified incidentally during routine scoliosis screening radiographs, and not because of patient complaint. Vertebral fractures were reported not to be a motivation for discontinuing corticosteroids. Vertebral compression fractures are not a feature in the natural history of DMD, and none were found in the 68 non‐treated boys in this study (<a href="./references#CD003725-bbs2-0043" title="KingWM , RuttencutterR , NagarajaHN , MatkovicV , LandollJ , HoyleC . Orthopedic outcomes of long‐term daily dose corticosteroid treatment in Duchenne muscular dystrophy. Neurology2007;68(19):1607‐13. ">King 2007</a>). A higher percentage of corticosteroid‐treated boys experienced long‐bone fractures, with a risk 2.6 times greater than boys on no treatment. Whether the long‐bone fractures were more frequent in the boys who suffered vertebral fractures was not reported, and how these complications might best be prevented or treated was not discussed. The percentage of vertebral fractures with a long‐term intermittent, versus a daily prednisolone regimen is discussed above. </p> </section> </section> <section id="CD003725-sec-0187"> <h4 class="title">Controversy in clinical role of corticosteroids in DMD</h4> <p>The 124th European Neuromuscular Centre (ENMC) International Workshop on treatment of DMD agreed "that the evidence for the use of daily steroids in DMD is now established and that trials of other treatments should be against this 'gold standard'" (<a href="./references#CD003725-bbs2-0085" title="BushbyK , MuntoniF , Urtizberea , HughesR , GriggsR . Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2‐4 April 2004, Naarden, The Netherlands. Neuromuscular Disorders2004;14(8‐9):526‐34. ">Bushby 2004</a>). The Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society recommended that boys with DMD should be offered prednisone (at a dose of 0.75 mg/kg/day) as treatment, and that "the offer of treatment with corticosteroids should include a balanced discussion of potential risks" (<a href="./references#CD003725-bbs2-0127" title="MoxleyRT3rd , AshwalS , PandyaS , ConnollyA , FlorenceJ , MathewsK , et al. Practice Parameter: corticosteroid treatment of Duchenne dystrophy, report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology2005;64(1):13‐20. ">Moxley 2005</a>) . <a href="./references#CD003725-bbs2-0095" title="DubowitzV . Prednisone for Duchenne muscular dystrophy. The Lancet Neurology2005;4(5):264. ">Dubowitz 2005</a> expressed concern regarding the adverse effects of long‐term daily dose corticosteroid treatment and concluded, "What is now urgently needed is a prospective, collaborative, multicentre, comparative study of the time‐honoured, and somewhat entrenched, daily regimen against some of the alternative schedules, in order to compare both efficacy and side‐effects". He further recommended that "in the meantime, paediatricians as well as parents should be offered the choice of either the continuous or the intermittent schedule. Hopefully we shall not be having the same debate in another 10 years time". </p> <p>For this review we were only able to identify one RCT comparing daily with intermittent prednisolone regimens over a 12‐month period (<a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a>). This study, performed in boys with a mean age of 7.3 years, found no difference in efficacy between the regimens or overall side effect profile, with the notable exception of greater weight gain and lower linear height in the daily treatment group. A non‐randomised longitudinal study over four years demonstrated consistent findings in terms of weight and height but also a divergence in efficacy for time to loss of ambulation and functional ability, favouring a daily regimen after the age of seven years. In this study, other side effects, including hypertension, were also more common on the daily regimen. Overall, the long‐term (more than 12 months) risk/benefit ratio of daily versus intermittent prednisolone regimens remains unclear. </p> <p>The FOR‐DMD Study is currently open and aims to find the optimum corticosteroid regimen for DMD (<a href="./references#CD003725-bbs2-0072" title="GuglieriM , VanRuitenHJA , SpeedC , HartK , WatsonG , McCollE , et al. FOR‐DMD: Double‐blind randomised trial to optimise corticosteroid regime in Duchenne muscular dystrophy (DMD). Developmental Medicine and Child Neurology2015; Vol. 57, issue Suppl s1:25‐6. NCT01603407 . Finding the optimum regimen for Duchenne muscular dystrophy (FOR‐DMD). www.clinicaltrials.gov/ct2/show/NCT01603407 (accessed 14 December 2015). ">Guglieri 2015</a>). It is an international trial enrolling patients at 40 sites in five countries, randomising them to one of three regimens: daily prednisolone, daily deflazacort or intermittent prednisolone (10 days on and 10 days off). It aims to follow participants for three to five years and may address remaining questions over the long‐term outcomes of intermittent regimens. </p> </section> <section id="CD003725-sec-0188"> <h4 class="title">Costs</h4> <p>The oral corticosteroids, including prednisone/prednisolone and deflazacort are not expensive. In the United Kingdom, the annual cost of prednisolone (soluble tablets) for a 30 kg boy is estimated at GBP 133 and the corresponding figure for deflazacort at the equivalent dosage of 0.9 mg/kg/day is GBP 480 (<a href="./references#CD003725-bbs2-0081" title="Joint Formulary Committee. British National Formulary (online). www.medicinescomplete.com (accessed 4 April 2016). ">BNF 2016</a>). The much bigger costs are those for drug administration and the surveillance required to monitor both benefits and adverse effects, and these have not been calculated. The issue of cost should not be underestimated, as in countries where the parent or patient has to buy medication, cost of the corticosteroid preparation may force the patient's choice in favour of the cheaper drug (<a href="./references#CD003725-bbs2-0019" title="BalabanB , MatthewsDJ , ClaytonGH , CarryT . Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long‐term effect. American Journal of Physical Medicine and Rehabilitation2005;84(11):843‐50. ">Balaban 2005</a>). </p> <p>The major aim of corticosteroids in the ambulant phase of DMD is to prolong the ability to walk. In the natural course of DMD, loss of walking ability at the mean age of 9.5 years (range 6 to 13) is followed by development of scoliosis, which is rapidly progressive during pubertal growth spurt years. This complication requires treatment with bracing, surgery, or both. Scoliosis and its treatment have implications for patients' quality of life and involve anaesthetic hazards and the surgical risks of extensive spine surgery. Data from non‐randomised studies suggest that prolongation of ambulation, either with rehabilitation in calipers (<a href="./references#CD003725-bbs2-0145" title="RodilloEB , Fernandez‐BermejoE , HeckmattJZ , DubowitzV . Prevention of rapidly progressive scoliosis in Duchenne muscular dystrophy by prolongation of walking with orthoses. Journal of Child Neurology1988;3(4):269‐74. ">Rodillo 1988</a>), or pharmacologically with prednisolone (<a href="./references#CD003725-bbs2-0064" title="TuncaO , KabakusO , HergunerA , KaradumanA , TopalogluH . Alternate day prednisone therapy in Duchenne muscular dystrophy. Neuromuscular Disorders2001;11:630. ">Tunca 2001</a>; <a href="./references#CD003725-bbs2-0067" title="YilmazO , KaradumanA , ArasO , BasogluB , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Neuromuscular Disorders2004; Vol. 14:581. YilmazO , KaradumanA , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. European Journal of Neurology2004;11(8):541‐4. ">Yilmaz 2004</a>), or deflazacort (<a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a>), reduces the risk of development and progression of scoliosis. The decrease in incidence and severity of scoliosis in corticosteroid‐treated individuals has been postulated in part to the possible increase in paraspinal/axial muscle strength (<a href="./references#CD003725-bbs2-0131" title="MuntoniF , BushbyK , ManzurAY . Muscular Dystrophy Campaign Funded Workshop on Management of Scoliosis in Duchenne Muscular Dystrophy 24 January 2005, London, UK. Neuromuscular Disorders2006;16(3):210–9. ">Muntoni 2006</a>). A decrease in incidence of scoliosis and avoidance of scoliosis surgery as a result of corticosteroid therapy would reduce the financial cost of managing these patients, but evidence for this from randomised studies is lacking. The same optimism and caution can be extended to respiratory and cardiac complications of DMD. </p> </section> </section> <section id="CD003725-sec-0189"> <h3 class="title" id="CD003725-sec-0189">Overall completeness and applicability of evidence</h3> <p>DMD has a uniform course with regards to evolution of motor and function disabilities. Most of the participants in the included studies were between eight and 15 years old. There were not enough data available to stratify the participants according to age and to observe the response to corticosteroids in relation to age. Future updates could consider subgroup analysis by genotype or phenotype, although trials may be too small for this to be possible. </p> <p>Data from the included studies and the non‐randomised and cohort studies converge in suggesting a similar improvement in response to corticosteroids in DMD. It is very likely that the results are applicable to all boys with DMD, especially in their ambulant phase. We would not anticipate that in non‐ambulant, wheelchair‐dependent patients with DMD who have been corticosteroid‐naïve in the past, corticosteroid treatment would restore the ability to walk. However, the benefit to upper limbs, cardiac and respiratory function remains a possibility, and this area needs further study. </p> <p>The option of treatment with corticosteroids should be discussed in detail with the carers of ambulant boys with DMD. It would be prudent to undertake this treatment only in centres with expertise and facilities for comprehensive multidisciplinary pre‐treatment assessment and regular long‐term monitoring of benefits and adverse effects. Protocols of management, with close monitoring for adverse effects and adjustment of corticosteroid dose would be an essential prerequisite for patient safety. </p> </section> <section id="CD003725-sec-0190"> <h3 class="title" id="CD003725-sec-0190">Quality of the evidence</h3> <section id="CD003725-sec-0191"> <h4 class="title">Corticosteroids versus placebo</h4> <p>Trials included in the meta‐analyses for this comparison provided moderate quality evidence for effectiveness outcomes (muscle strength and functional tests) (<a href="./full#CD003725-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the quality of evidence once because the risk of allocation bias was unclear in all studies that provided data for the analyses and for potential publication bias. Removal of a trial at high risk of bias did not substantially change the results of meta‐analyses. Two studies were not fully published or did not report results in a form suitable for reporting (<a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>; <a href="./references#CD003725-bbs2-0012" title="TodorovicSM . High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy. Muscle &amp; Nerve. 1998; Vol. 7 Suppl:72. ">Todorovic 1998</a>). <a href="./references#CD003725-bbs2-0002" title="BäckmanE , HenrikssonKG . Low‐dose prednisolone treatment in Duchenne and Becker muscular dystrophy. Neuromuscular Disorders1995;5(3):233‐41. [PUBMED: 7633189] ">Bäckman 1995</a> provided only adverse event data. </p> <p><a href="./references#CD003725-bbs2-0001" title="AngeliniC , PegoraroE , TurellaE , IntinoMT , PiniA , CostaC . Deflazacort in Duchenne dystrophy: study of long‐term effect. Muscle &amp; Nerve1994;17(4):386‐91. [PUBMED: 8170484] ">Angelini 1994</a> was a small two‐year study (n = 28) with design limitations, and a very high dropout rate at two years. Although the trial assessed prolongation of ambulation, the statistical technique used to analyse the data was not appropriate. The change in MRC index favoured deflazacort over placebo at two years, but timed function test results at 24 months were very imprecise, allowing for the possibility of effects in either direction. </p> </section> <section id="CD003725-sec-0192"> <h4 class="title">Weekend‐only versus daily prednisone</h4> <p><a href="./references#CD003725-bbs2-0006" title="EscolarD , McDonaldC , KornbergAJ , BertoriniT , NevoY , LotzeT . Randomized, double‐blind, controlled study to compare efficacy and tolerability of standard daily prednisone regime with a novel intermittent high dose regime in ambulant boys with Duchenne muscular dystrophy. Neurology2008; Vol. 70, issue 11 Suppl 1:A109‐10, Abstract no: S05.004. EscolarDM , HacheLP , ClemensPR , CnaanA , McDonaldCM , ViswanathanV , et al. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology2011;77(5):444‐52. [PUBMED: 21753160] ">Escolar 2011</a> (n = 64) was a year‐long equivalence trial comparing weekend‐only and daily dosing of prednisone. We judged the study to be at a low risk of bias other than for attrition and reporting bias. Results were very imprecise, producing a low quality of evidence for manual muscle testing (MMT), body mass index (BMI) and behavioural change. As CI fell within equivalence limits for muscle strength measured by quantitative muscle testing (QMT), 10‐metre walk and four‐stair climb, we considered the quality of evidence for these outcomes moderate (<a href="./full#CD003725-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD003725-sec-0193"> <h4 class="title">Deflazacort versus prednisone</h4> <p>For all assessed outcomes, the evidence comparing prednisone with deflazacort at one year was very low quality (<a href="./full#CD003725-tbl-0003">summary of findings Table 3</a>). Two newly included studies comparing different corticosteroids did not fully report data, making only limited analysis possible (<a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a>; <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a>). <a href="./references#CD003725-bbs2-0009" title="KarimzadehP , GhazaviA . Comparison of deflazacort and prednisone in Duchenne muscular dystrophy. Iranian Journal of Child Neurology2012; Vol. 6, issue 1:5‐12. ">Karimzadeh 2012</a> was at a high risk of bias in most domains and <a href="./references#CD003725-bbs2-0004" title="BonifatiMD , RuzzaG , BonomettoP , BerardinelliA , GorniK , OrcesiS , et al. A multicenter, double‐blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle &amp; Nerve2000;23(9):1344‐7. ">Bonifati 2000</a> was at unclear risk of selection bias and high risk of selective reporting. We downgraded evidence from these studies twice for serious limitations in trial design and implementation. <a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>, a large four‐arm study (n = 196) comparing two doses of deflazacort, prednisone and placebo, also represented a risk of publication bias, being available only as an abstract, providing little useful data. </p> </section> </section> <section id="CD003725-sec-0194"> <h3 class="title" id="CD003725-sec-0194">Potential biases in the review process</h3> <p>Searches were comprehensive, and studies we identified were consistent with other reviews of these interventions in DMD. We attempted to contact study authors for clarification or missing data; some responded but others did not. Methods have not substantially changed from previous versions of the review. We added some additional detail to comply with current Cochrane standards; however, the new trials presented few opportunities for meta‐analysis. </p> </section> <section id="CD003725-sec-0195"> <h3 class="title" id="CD003725-sec-0195">Agreements and disagreements with other studies or reviews</h3> <p>The American Academy of Neurology (AAN) produced practice guidelines on corticosteroid treatment of Duchenne muscular dystrophy (DMD) following a systematic review of the literature from January 2004 to July 2014, and identification of 34 studies (<a href="./references#CD003725-bbs2-0108" title="GlossD , MoxleyRTIII , AshwalS , OskouiM . Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology2016;86:465‐72. ">Gloss 2016</a>). The conclusions of this Cochrane review are compatible with the recommendations of the AAN committee, who found evidence that: </p> <p> <ul id="CD003725-list-0012"> <li> <p>prednisone and deflazacort should both be offered for improving muscle strength;</p> </li> <li> <p>prednisone and deflazacort are possibly equally efficacious in improving motor function;</p> </li> <li> <p>prednisone may be associated with greater weight gain than deflazacort;</p> </li> <li> <p>deflazacort may be associated with a higher risk of cataracts than prednisone;</p> </li> <li> <p>a weekend‐only regimen of prednisone 10 mg/kg/weekend day may be equivalent to prednisone 0.75 mg/kg/day over a 12‐month period; </p> </li> <li> <p>prednisone 0.75mg/kg/day is associated with significant risk of weight gain, hirsutism and cushingoid changes. </p> </li> </ul> </p> <p>The AAN guidelines also examined other outcomes ‐ cardiac and respiratory outcomes, and scoliosis that we did not address in this update. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003725-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003725-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003725-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.1 MRC ‐ Average muscle score after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.1 MRC ‐ Average muscle score after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.7 Nine‐metre walking/running time after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.7 Nine‐metre walking/running time after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.11 Four‐stair climbing time after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Glucocorticoid corticosteroids versus placebo, outcome: 1.11 Four‐stair climbing time after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Deflazacort versus prednisone, outcome: 3.1 Weight gain (%)." data-id="CD003725-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Deflazacort versus prednisone, outcome: 3.1 Weight gain (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 1 Change in MRC index (%) after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days." data-id="CD003725-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 1 Change in MRC index (%) after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 2 MRC ‐ Average muscle score after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 2 MRC ‐ Average muscle score after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 3 Change in MRC index (%) after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days." data-id="CD003725-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 3 Change in MRC index (%) after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 4 Lower limb muscle strength grade after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 4 Lower limb muscle strength grade after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 5 Lower limb muscle strength grade after 12 months of treatment ‐ prednisone." data-id="CD003725-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 5 Lower limb muscle strength grade after 12 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 6 Time taken to rise from floor after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 6 Time taken to rise from floor after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 7 Change in time taken to rise from floor after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days." data-id="CD003725-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 7 Change in time taken to rise from floor after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 8 Time taken to rise from floor after 12 months of treatment (daily prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 8 Time taken to rise from floor after 12 months of treatment (daily prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 9 Change in time taken to rise from floor after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days." data-id="CD003725-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 9 Change in time taken to rise from floor after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-10.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 10 9‐metre walking/running time after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 10 9‐metre walking/running time after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 11 Timed walk (assumed in seconds) ‐ after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days." data-id="CD003725-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 11 Timed walk (assumed in seconds) ‐ after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 12 10‐metre walking time 6 months post‐treatment (daily prednisone 0.75 mg/kg)." data-id="CD003725-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 12 10‐metre walking time 6 months post‐treatment (daily prednisone 0.75 mg/kg). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 13 10‐metre walk time 1 year post‐treatment (daily prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 13 10‐metre walk time 1 year post‐treatment (daily prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 14 Timed walk (assumed in seconds) ‐ after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days." data-id="CD003725-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 14 Timed walk (assumed in seconds) ‐ after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 15 Lifting weight (kg) after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 15 Lifting weight (kg) after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-16.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 16 Four‐stair climbing time after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 16 Four‐stair climbing time after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 17 Timed function: stair climb after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days." data-id="CD003725-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 17 Timed function: stair climb after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 18 Four‐stair climbing time after 12 months of treatment (daily prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 18 Four‐stair climbing time after 12 months of treatment (daily prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 19 Change in timed stair climb after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days." data-id="CD003725-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 19 Change in timed stair climb after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 20 Dynamometry ‐ total muscle force after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 20 Dynamometry ‐ total muscle force after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 21 Leg function grade after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 21 Leg function grade after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 22 Forced vital capacity after 6 months of treatment ‐ prednisone." data-id="CD003725-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 22 Forced vital capacity after 6 months of treatment ‐ prednisone. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 23 Quality of life after six months of treatment (daily prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 23 Quality of life after six months of treatment (daily prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 24 Quality of life after 12 months of treatment (daily prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 24 Quality of life after 12 months of treatment (daily prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 25 Mean % weight gain ‐ prednisone ‐ daily dose regimen." data-id="CD003725-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 25 Mean % weight gain ‐ prednisone ‐ daily dose regimen. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 26 Weight gain ‐ prednisone ‐ intermittent, given 1st 10 days every month." data-id="CD003725-fig-0032" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 26 Weight gain ‐ prednisone ‐ intermittent, given 1st 10 days every month. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 27 Mean % weight gain ‐ deflazacort 2 mg/kg alternate days." data-id="CD003725-fig-0033" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 27 Mean % weight gain ‐ deflazacort 2 mg/kg alternate days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 28 Body weight at 6 months (prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0034" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 28 Body weight at 6 months (prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 29 Body weight at 12 months (prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0035" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 29 Body weight at 12 months (prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 30 BMI at 6 months (daily prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0036" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 30 BMI at 6 months (daily prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 31 BMI at 12 months (daily prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0037" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 31 BMI at 12 months (daily prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 32 Excessive hair growth ‐ prednisone." data-id="CD003725-fig-0038" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 32 Excessive hair growth ‐ prednisone.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 33 Behavioural changes ‐ prednisone." data-id="CD003725-fig-0039" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 33 Behavioural changes ‐ prednisone.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 34 Cushingoid appearance ‐ prednisone." data-id="CD003725-fig-0040" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 34 Cushingoid appearance ‐ prednisone.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 35 Acne ‐ prednisone." data-id="CD003725-fig-0041" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 35 Acne ‐ prednisone.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 36 Increased appetite ‐ prednisone." data-id="CD003725-fig-0042" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 36 Increased appetite ‐ prednisone.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 37 Height at 6 months (daily prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0043" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 37 Height at 6 months (daily prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-001-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-001-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Corticosteroids versus placebo, Outcome 38 Height at 12 months (daily prednisone 0.75 mg/kg/day)." data-id="CD003725-fig-0044" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1 Corticosteroids versus placebo, Outcome 38 Height at 12 months (daily prednisone 0.75 mg/kg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-001-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 1 Muscle strength (change from baseline to 12 months)." data-id="CD003725-fig-0045" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 1 Muscle strength (change from baseline to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 2 Functional outcome measures (change from baseline to 12 months)." data-id="CD003725-fig-0046" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 2 Functional outcome measures (change from baseline to 12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 3 Change in mobility function (lower extremity score ‐ Vignos)." data-id="CD003725-fig-0047" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 3 Change in mobility function (lower extremity score ‐ Vignos). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 4 Change in mobility function (upper extremity score ‐ Brooke)." data-id="CD003725-fig-0048" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 4 Change in mobility function (upper extremity score ‐ Brooke). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 5 FVC % predicted." data-id="CD003725-fig-0049" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 5 FVC % predicted.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 6 FEV1 % predicted." data-id="CD003725-fig-0050" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 6 FEV1 % predicted.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 7 Maximal inspiratory pressure." data-id="CD003725-fig-0051" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 7 Maximal inspiratory pressure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 8 Maximal voluntary ventilation." data-id="CD003725-fig-0052" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 8 Maximal voluntary ventilation.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 9 Weight (BMI kg/m2)." data-id="CD003725-fig-0053" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 9 Weight (BMI kg/m2).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 10 Weight (kg)." data-id="CD003725-fig-0054" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 10 Weight (kg).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 11 Child Behavior Checklist: total problems (higher = more severe)." data-id="CD003725-fig-0055" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 11 Child Behavior Checklist: total problems (higher = more severe). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 12 Child Behavior Checklist: internalising." data-id="CD003725-fig-0056" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 12 Child Behavior Checklist: internalising. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 13 Child Behavior Checklist: externalising." data-id="CD003725-fig-0057" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 13 Child Behavior Checklist: externalising. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 14 Child Behavior Checklist: anxious/depressed." data-id="CD003725-fig-0058" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 14 Child Behavior Checklist: anxious/depressed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 15 Child Behavior Checklist: somatic complaints." data-id="CD003725-fig-0059" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 15 Child Behavior Checklist: somatic complaints. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 16 Child Behavior Checklist: withdrawn/depressed." data-id="CD003725-fig-0060" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 16 Child Behavior Checklist: withdrawn/depressed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 17 Child Behavior Checklist: attention problems." data-id="CD003725-fig-0061" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 17 Child Behavior Checklist: attention problems. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 18 Child Behavior Checklist: aggressive behaviour." data-id="CD003725-fig-0062" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 18 Child Behavior Checklist: aggressive behaviour. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 19 Osteoporosis: lumbar spine Z scores (DEXA)." data-id="CD003725-fig-0063" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 19 Osteoporosis: lumbar spine Z scores (DEXA). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 20 Height (m)." data-id="CD003725-fig-0064" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 20 Height (m).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Weekend‐only versus daily prednisone, Outcome 21 Mean growth in cm." data-id="CD003725-fig-0065" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Weekend‐only versus daily prednisone, Outcome 21 Mean growth in cm.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Deflazacort versus prednisone, Outcome 1 Weight gain (%)." data-id="CD003725-fig-0066" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Deflazacort versus prednisone, Outcome 1 Weight gain (%).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Deflazacort versus prednisone, Outcome 2 Adverse events at six months." data-id="CD003725-fig-0067" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Deflazacort versus prednisone, Outcome 2 Adverse events at six months.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003725-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/urn:x-wiley:14651858:media:CD003725:CD003725-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_t/tCD003725-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Deflazacort versus prednisone, Outcome 3 Adverse events at 1 year." data-id="CD003725-fig-0068" src="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Deflazacort versus prednisone, Outcome 3 Adverse events at 1 year.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/media/CDSR/CD003725/image_n/nCD003725-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003725-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Corticosteroids versus placebo for Duchenne muscular dystrophy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Corticosteroids versus placebo for Duchenne muscular dystrophy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with Duchenne muscular dystrophy<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> corticosteroids<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk or score/value with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk or score/value with corticosteroids</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolongation of time to loss of ambulation ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An outcome measure in one 2‐year trial (n = 28). The trial reported a 13‐month prolongation of walking with deflazacort among boys who became wheelchair‐dependent, but statistical analysis was flawed as it did not take account of participants still walking at study end </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in average muscle score: prednisone ‐ daily dose regimen (0.75 mg/kg/day)</p> <p>Assessed with: MRC scale (higher indicates stronger)</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in average muscle score was 4.73 units<sup>1</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in average muscle score in the intervention group was 0.52 units more (0.33 more to 0.71 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (3 RCTs)<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The average muscle score (MRC scale) also showed a clear difference in favour of corticosteroid at 0.3 mg/kg/day and 1.5 mg/kg/day. For other strength outcomes see text </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nine‐metre walking/running time: prednisone ‐ daily dose regimen (0.75 mg/kg/day)</p> <p>Assessed with: seconds</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean nine‐metre walking/running time was 9.1 seconds<sup>4</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean nine‐metre walking/running time in the intervention group was 2.73 seconds quicker (3.97 quicker to 1.50 quicker) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> <p>(3 RCTs)<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For other functional outcomes and corticosteroid doses, see text.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4‐stair climbing time: prednisone ‐ daily dose regimen (0.75 mg/kg/day)</p> <p>Assessed with: seconds</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean 4‐stair climbing time was 7.40 seconds</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean 4‐stair climbing time in the intervention group was 3.09 seconds quicker (4.33 quicker to 1.85 quicker) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> <p>(4 RCTs)<sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For other functional outcomes and corticosteroid doses, see text</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean % weight gain: prednisone ‐ daily dose regimen (0.75 mg/kg/day)<br/> Follow‐up: 6 months<sup>8</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % weight gain was 6.95 %</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean % weight gain in the intervention group was 9.27% more (6.87% more to 11.68% more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (2 RCTs)<sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For other prednisone doses, see text. 1.09% more weight gain reported with deflazacort (2 mg/kg alternate days) than with placebo (mean gain 25.5%) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavioural changes ‐ prednisone (0.75 mg/kg/day)</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>695 per 1000<br/> (470 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.39<br/> (0.94 to 2.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>For other doses, see text</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractures</p> <p>Follow‐up: 6 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 participant receiving deflazacort had a pathological fracture of tibia. An arm fracture occurred in the placebo group of a prednisone trial and a traumatic fracture of femur occurred in the placebo phase of a cross‐over prednisone trial </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies measured bone densitometry. A 6‐month trial is too short to adequately assess long‐term side effects. Other trials did not comment on the occurrence of fractures </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MRC</b> : Medical Research Council; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Mean of mean control group values.<br/> <sup>2</sup>Two additional trials (6 and 12 months' duration), which could not be included in the meta‐analysis, also demonstrated improvements in muscle strength over placebo with daily or intermittent prednisone 0.75 mg/kg/day ‐ see text for details (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>).<br/> <sup>3</sup>Single downgrading for unclear risk of allocation bias and possible publication bias.<br/> <sup>4</sup>Mean of the mean control group values at 6 months from <a href="./references#CD003725-bbs2-0007" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Prednisone in Duchenne dystrophy. A randomized controlled trial defining the course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Archives of Neurology1991;48(4):383‐8. [PUBMED: 2012511] ">Griggs 1991</a>, <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a> and <a href="./references#CD003725-bbs2-0010" title="MendellJR , MoxleyRT , GriggsRC , BrookeMH , FenichelGM , MillerJP , et al. Randomized, double‐blind six‐month trial of prednisone in Duchenne's muscular dystrophy. New England Journal of Medicine1989;320(24):1592‐7. [PUBMED: 2657428] ">Mendell 1989</a> (data are not provided in <a href="./references#CD003725-bbs2-0011" title="RahmanMM , HannanMM , MondolBA , BhoumickNB , HaqueA . Prednisolone in Duchenne muscular dystrophy. Bangladesh Medical Research Council Bulletin2001;27(1):38‐42. [PUBMED: 11692899] ">Rahman 2001</a> report).<br/> <sup>5</sup>Two additional trials (6 and 12 months' duration), which could not be included in the meta‐analysis, also demonstrated improvements in timed walk over placebo with daily or intermittent prednisone 0.75 mg/kg/day ‐ see text for details (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>).<br/> <sup>6</sup>An additional 6‐month trial, which could not be included in the meta‐analysis, also demonstrated improvements in 4‐stair climb over placebo with intermittent prednisone (0.75 mg/kg/day given for the first 10 days of every month for six months) ‐ see text for details (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>).<br/> <sup>7</sup>Two additional trials (6 and 12 months' duration), which could not be included in the meta‐analysis, monitored weight during daily or intermittent prednisone 0.75 mg/kg/day; no clear difference was present between groups at six months (intermittent dosing) or a year; however these results were imprecise ‐ see text for details (<a href="./references#CD003725-bbs2-0003" title="BeenakkerEA , FockJM , VanTolMJ , MauritsNM , KoopmanHM , BrouwerOF , et al. Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial. Archives of Neurology2005;62(1):128‐32. [PUBMED: 15642859] ">Beenakker 2005</a>; <a href="./references#CD003725-bbs2-0008" title="HuJ , YeY , KongM , HongS , ChengL , WangQ , et al. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China. Muscle &amp; Nerve2015;52(6):1001–7. [PUBMED: 25809413] ">Hu 2015</a>).<br/> <sup>8</sup>For details of other dosages and the deflazacort versus placebo comparison see the review text. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Corticosteroids versus placebo for Duchenne muscular dystrophy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003725-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Weekend‐only versus daily prednisone for Duchenne muscular dystrophy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Weekend‐only versus daily prednisone for Duchenne muscular dystrophy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with Duchenne muscular dystrophy<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> weekend prednisone<br/> <b>Comparison:</b> daily prednisone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Score/value with daily prednisone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Score/value with weekend‐only prednisone</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolongation of time to loss of ambulation ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not an outcome in the single included study for this comparison</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in muscle strength ‐ QMT arm score (lb)</p> <p>follow‐up: 12 months</p> <p>(higher indicates stronger)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in QMT arm score in the control group was 1.3 lb</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in QMT arm score in the intervention group was 0.6 lb lower (1.67 lower to 0.47 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Moderate</b> </p> <p><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in muscle strength ‐ QMT leg score (lb)</p> <p>follow‐up: 12 months</p> <p>(higher indicates stronger)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in QMT leg score in the control group was 3.4 lb</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in QMT leg score in the intervention group was 0.1 lb more (1.75 lower to 1.95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in muscle strength ‐ MMT score</p> <p>Follow‐up: 12 months</p> <p>(higher indicates stronger)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in MMT score in the control group was ‐0.6</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in MMT score in the intervention group was 4.6 higher (8.07 lower to 17.27 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>2</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in 10‐metre walking time</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 10‐metre walking time in the control group was 0.1 seconds</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 10‐metre walking time in the intervention group was 0 (0.21 quicker to 0.21 slower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Moderate<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in 4‐stair climbing time</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 4‐stair climbing time in the control group was ‐0.06 seconds</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in 4‐stair climbing time in the intervention group was 0 (0.22 quicker to 0.22 slower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Moderate<sup>3</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BMI (kg/m<sup>2</sup>) at end of study </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI (kg/m<sup>2</sup>) in the control group was 19.6 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean BMI kg/m<sup>2</sup> in the intervention group was 1.8 lower (3.74 lower to 0.14 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean % weight gain not reported. Mean difference in weight (kg) did not show a clear difference at 12 months, being 2.5 kg lower; 7.54 lower to 2.54 higher with weekend‐only dosing </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavioural changes<br/> assessed with Child Behaviour Checklist total problems (higher scores indicate more severe behavioural changes) </p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean behavioural change score in the control group was 48</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean behavioural change score in the intervention group was 1 higher (4.34 lower to 6.34 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractures ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No fractures reported. Change in lumbar spine Z scores favoured weekend‐only dosing (increase in the weekend group +0.26, compared with ‐0.30 decline with daily prednisolone </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>BMI</b> : body mass index; <b>CI:</b> confidence interval; <b>MMT</b> : manual muscle testing; <b>QMT</b> : quantitative muscle testing; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Trial authors defined equivalence limits (limits within which the regimens can be considered of equivalent efficacy) of ± 2 lb for QMT. We downgraded once as although serious imprecision is present, the CIs fall within the equivalence limits. </p> <p><sup>2</sup>We downgraded the quality of evidence twice for serious imprecision due to small sample size; trial authors defined equivalence limits (limits within which the regimens can be considered of equivalent efficacy) of ± 17 points and the CIs allow for the possibility of non‐equivalence. </p> <p><sup>3</sup>Trial authors defined equivalence limits (limits within which the regimens can be considered of equivalent efficacy) of ± 0.4 seconds for timed tests. We downgraded once; although serious imprecision is present, the CIs fall within the equivalence limits. </p> <p><sup>4</sup> We downgraded the evidence for very serious imprecision (due to small sample sizes, plus the CI includes appreciable differences in favour of either intervention). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Weekend‐only versus daily prednisone for Duchenne muscular dystrophy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003725-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Deflazacort versus prednisone for Duchenne muscular dystrophy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Deflazacort versus prednisone for Duchenne muscular dystrophy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with Duchenne muscular dystrophy<br/> <b>Setting:</b> outpatient<br/> <b>Intervention:</b> deflazacort<br/> <b>Comparison:</b> prednisone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk or score/value with prednisone or prednisolone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk or score/value with deflazacort</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prolongation of time to loss of ambulation ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the studies investigating this comparison assessed prolongation of time to loss of ambulation </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Muscle strength ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>One study measured summed MRC scores from 4 muscles at 3, 6, 9, and 12 months, but presented data graphically without measures of variability </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in 10‐metre walking time</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies (n = 43) reported composite scores of timed function tests, but did not report the scores for each test separately </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in 4‐stair climbing time</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two studies (n = 43) reported composite scores of timed function tests, but did not report the scores for each test separately </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain (%)</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean weight gain (%) was 21.48%</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean weight gain (%) in the intervention group was 9.52% lower (14.91 lower to 4.12 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2, 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavioural changes</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>500 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>445 per 1000 (160 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07 (0.53 to 2.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>1,2, 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractures</p> <p>Follow‐up: 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 traumatic fracture occurred after 4 months' deflazacort treatment in one study (n = 26). No other fractures reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>MRC</b> : Medical Research Council; <b>RCT</b> : randomised controlled trial; <b>RR:</b> risk ratio; <b>SD</b>: standard deviation </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded the quality of evidence twice for a high risk of bias in most domains.<br/> <sup>2</sup>We downgraded the quality of evidence once for possible publication bias ‐ a large study remains unpublished (<a href="./references#CD003725-bbs2-0005" title="BrookeMH . A randomised trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity. Neurology1996;46:A476. ">Brooke 1996</a>).<br/> <sup>3</sup>Analysis involved some statistical assumptions in calculating SD.<br/> <sup>4</sup>CIs include the possibility of both a large effect and a clinically unimportant effect (i.e. imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Deflazacort versus prednisone for Duchenne muscular dystrophy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003725-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Excluded non‐randomised studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Regimen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0031" title="DrachmanDB , ToykaKV , MyerE . Prednisone in Duchenne muscular dystrophy. Lancet1974;2(7894):1409‐12. ">Drachman 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 10.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 2 mg/kg/day for 3 months, then two‐thirds dose on alternate days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 weeks to 28 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events in 4 patients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0059" title="SiegelIM , MillerJE , RayRD . Failure of corticosteroid in the treatment of Duchenne (pseudo‐hypertrophic) muscular dystrophy. Report of a clinically matched three year double‐blind study. Illinois Medical Journal1974;145(1):32‐3. ">Siegel 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 5 mg/kg on alternate days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No benefit</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0025" title="BrookeMH , FenichelGM , GriggsRC , MendellJR , MoxleyRT3rd , MillerJP , et al. Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Archives of Neurology1987;44(8):812‐7. ">Brooke 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improvement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 dropouts</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0030" title="DeSilvaS , DrachmanDB , MellitsD , KunclR . Prednisone treatment in Duchenne muscular dystrophy. Long‐term benefit. Archives of Neurology1987;44(8):818‐22. ">DeSilva 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 to 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 2 mg/kg/day for 3 months, then two‐thirds dose on alternate days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 11 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Walking prolonged by 2 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excessive weight gain in 12 patients; cataracts in 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0035" title="FenichelGM , FlorenceJM , PestronkA , MendellJR , MoxleyRT3rd , GriggsRC , et al. Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology1991;41(12):1874‐7. ">Fenichel 1991b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stabilisation for 2 yrs Prednisone 0.56 mg/kg/day least effect dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataracts in 10 patients;<br/> glycosuria in 10 patients;<br/> significant weight gain </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0049" title="MesaLE , DubrovskyAL , CorderiJ , MarcoP , FloresD . Steroids in Duchenne muscular dystrophy ‐ deflazacort trial. Neuromuscular Disorders1991;1(4):261‐6. ">Mesa 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ 1 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improved up to 6 months, then stable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35% cushingoid; no significant weight gain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0056" title="SansomeA , RoystonP , DubowitzV . Steroids in Duchenne muscular dystrophy; pilot study of a new low‐dosage schedule. Neuromuscular Disorders1993;3(5‐6):567‐9. ">Sansome 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 to 14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day for 10 days/months (given 10 days on, 20 days off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>From 6 to 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Strength improved at 6 months; slow decline at 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fewer adverse events, but<br/> 26% of boys had more than 20% weight gain </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ 0.9 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8 (+/‐ SD 1.5) yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ambulation prolonged<br/> FVC preserved: mean % predicted FVC 72% in DFZ group; 35% in non‐treated group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cataracts in 30%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0032" title="DubowitzV , KinaliM , MainM , MercuriE , MuntoniF . Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low‐dosage prednisolone therapy. European Journal of Paediatric Neurology2002;6(3):153‐9. ">Dubowitz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 yrs 10 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day (given 10 days on, 10 days off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stabilisation of motor function for up to 5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability in 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0027" title="ConnollyAM , SchierbeckerJ , RennaR , FlorenceJ . High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscular Disorders2002;12(10):917‐25. ">Connolly 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open, historical controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 treated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 5 mg/kg twice weekly<br/> (every Friday and Saturday). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (+/‐ 1.5) months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improved strength over 6 to 12 months in majority</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability in 6. 2 stopped, 4 reduced prednisone dose</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0048" title="MerliniL , CicognaniA , MalaspinaE , GennariM , GnudiS , TalimB , et al. Early prednisone treatment in Duchenne muscular dystrophy. Muscle &amp; Nerve2003;27(2):222‐7. ">Merlini 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open, parallel‐group, double consent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 treated, 3 control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 to 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone<br/> 0.75 mg/kg for 2 weeks, then 1.25 mg/kg on alternate days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47 to 63 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ability to rise from floor prolonged; stairs and 10‐metre walking time similar</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Growth rate decline; irritability requiring niaprazine in 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0041" title="KinaliM , MercuriE , MainM , MuntoniF , DubowitzV . An effective, low‐dosage, intermittent schedule of prednisolone in the long‐term treatment of early cases of Duchenne dystrophy. Neuromuscular Disorders2002;12(Suppl 1):S169‐74. ">Kinali 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (including 2 patients from <a href="./references#CD003725-bbs2-0032" title="DubowitzV , KinaliM , MainM , MercuriE , MuntoniF . Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low‐dosage prednisolone therapy. European Journal of Paediatric Neurology2002;6(3):153‐9. ">Dubowitz 2002</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 yrs 10 months to 4.5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day (given 10 days on, 10 days off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 yrs to over 5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stabilisation of motor function for up to 5 yrs; loss of ambulation in 1 boy at age 9 yrs, after 5 yrs of treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bone mineral density on DEXA scans at 1 to 6 yrs of treatment was normal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0061" title="SilversidesCK , WebbGD , HarrisVA , BiggarDW . Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. American Journal of Cardiology2003;91(6):769‐72. ">Silversides 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study; patients refusing treatment formed control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (21 treated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.4 (+/‐2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ<br/> Start: 0.9 mg/kg/day<br/> (gradual decrease in dose with age) </p> <p>At 18 yrs: 0.59 +/‐0.15 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.1 (+/‐ 2.4) yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Walking prolonged, 48% ambulant at 14 +/‐ 2 yrs of age</p> <p>Mean % predicted FVC:<br/> 83% in treated, 41% control group </p> <p>Cardiomyopathy:<br/> 5% of DFZ vs 58% of controls </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Marked retardation of height gain; weight gain similar to controls; cataracts in 50% (asymptomatic) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0018" title="Luz AvilesC , GutiérrezC , NovoaF , GilE , StuardoA . Steroid treatment of Duchenne's muscular dystrophy [Tratamiento esteroidal en distrofia muscular de Duchenne]. Revista Chilena de Pediatra1982;53(3):187‐91. ">Aviles 1982</a> <br/> (Published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone<br/> 3 mg/kg on alternate days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0033" title="DubrovskyAL , DeVitoE , SuarezA , MesaLE , PessolanoF , SobrinoR , et al. Deflazacort treatment and respiratory function in Duchenne muscular dystrophy. Neurology1999;52 Suppl(2):A544. ">Dubrovsky 1999</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (compared to 59 age‐matched controls)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 to 21 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ<br/> 0.5 to 1 mg/kg/day. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 yrs to 9 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FVC significantly preserved in DFZ‐treated group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0064" title="TuncaO , KabakusO , HergunerA , KaradumanA , TopalogluH . Alternate day prednisone therapy in Duchenne muscular dystrophy. Neuromuscular Disorders2001;11:630. ">Tunca 2001</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 (compared with 22 historical controls)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5 to 11 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg on alternate days; Vit D</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 to 5 <br/> (mean 2.75) yrs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age at loss of ambulation ‐ prednisolone 10 yrs, controls 7.69 yrs); no scoliosis at a mean age of 11 .7 yrs </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0050" title="PandyaS , MyersG , MoxleyRT . Effect of daily prednisone on independent ambulation in patients with Duchenne dystrophy treated for up to 15 years. Neuromuscular Disorders2001;11(6‐7):630. ">Pandya 2001</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 independently ambulant patients from clinical Investigation group of Duchenne Dystrophy (CIDD) studies </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone<br/> 0.75 mg/kg/day,<br/> gradually decreased over time </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean age of loss of ambulation prolonged to 14.5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0054" title="ResendeMBD , ReedUC , EspindolaAA , FerreiraLG , CarvalhoMS , DiamentA , et al. Deflazacort in Duchenne muscular dystrophy: preliminary results in a Brazilian series. Neuromuscular Disorders2001;11:630. ">Resende 2001</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ 1 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15 treated for 12 to 43 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 of the 15 boys ambulant beyond 10 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>GI disturbances and depression needing discontinuation of treatment in 1 patient; cataracts in 2 patients </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0029" title="deGrootIJM . The effectiveness of prednisolone treatment (10 days on/10 days off) in the ambulatory phase of Duchenne muscular dystrophy: an open study. Neuromuscular Disorders2002;12(7‐8):737‐8. ">de Groot 2002</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 to 9 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day (given 10 days on,10 days off)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Functional ability improved"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Osteoporosois 2 ‐3 SD at the start, but did not change under treatment"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0013" title="AhlanderAC , KroksmarkAK , TuliniusM . Low‐dosage prednisolone in the long‐term treatment of Duchenne muscular dystrophy. Neuromuscular Disorders2003;13(7‐8):630. ">Ahlander 2003</a> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (15 not treated)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.35 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Up to 7.5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Authors perceived a prolongation of walking by 0.9 yrs, but the patient groups compared are from different eras and there may be confounding factors </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Behavioural problems; weight gain; dyspepsia; growth retardation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0022" title="BiggarWD , HarrisVA , EliasophL , AlmanB . Long‐term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders2006;16(4):249‐55. ">Biggar 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open cohort study; patients declining treatment formed comparison (control) group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 treated, 34 not treated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 to 18 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ 0.9 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean of 5.5 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ‐treated boys were able to rise from supine to standing walk 10 metres without aids, 3 to 5 yrs longer than boys not treated </p> <p>At 18 yrs, only 4/40 treated boys had scoliosis greater than 20 degrees, compared to 30/34 untreated boys </p> <p>At 18 yrs, 4/40 boys treated with DFZ had cardiac left ventricular ejection fraction of &lt; 45%, compared with 20/34 untreated boys </p> <p>Two of the 40 DFZ‐treated boys died by 18 yrs of age, compared with 12/34 boys in the untreated group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ‐treated boys were significantly shorter, but did not have excessive weight gain</p> <p>22/40 treated boys had asymptomatic cataracts</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0021" title="BiggarWD , PolitanoL , HarrisVA , PassamanoL , VajsarJ , AlmanB , et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscular Disorders2004;14(8‐9):476‐82. ">Biggar 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Description and comparison of 2 cohorts in open study of 2 DFZ protocols, in 2 different centres:<br/> 1. Naples protocol (retrospective); 2. Toronto protocol (<a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a> cohort) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 boys started on DFZ</p> <p>30 boys on DFZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 to 8 yrs</p> <p>6 to 8 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ 0.6 mg/kg/day for 1st 20 days every month, Vit D 880 iu &amp; Ca 1000 mg daily<br/> <br/> <br/> DFZ 0.9 mg/kg/day, Vit D 1000 iu &amp; Ca 750 mg daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 yrs +</p> <p>4 yrs +</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 15 yrs of age 25% able to walk 10 metres<br/> <br/> <br/> <br/> At 15 yrs of age 77% able to walk 10 metres </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No cataracts<br/> <br/> <br/> <br/> Cataracts in 30%. Shorter in height than the Naples study cohort </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0067" title="YilmazO , KaradumanA , ArasO , BasogluB , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. Neuromuscular Disorders2004; Vol. 14:581. YilmazO , KaradumanA , TopaloğluH . Prednisolone therapy in Duchenne muscular dystrophy prolongs ambulation and prevents scoliosis. European Journal of Neurology2004;11(8):541‐4. ">Yilmaz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort study with historical controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66 treated</p> <p>22 controls</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.8 ± 2.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg given on alternate days,<br/> Vit D 600 to 1200 iu daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.75 ± 1.1 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No scoliosis &gt; 24° in prednisolone‐treated group at end of study (mean age 10.8±1.2 yrs) </p> <p>7/22 in the historical controls had scoliosis &gt; 45° aged 11.7± 0.8 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duration of follow‐up limited with young mean age at end of study</p> <p>Scoliosis appears postponed as compared to historical controls, but potential for worsening in pubertal growth spurt in early teens remains </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0014" title="AlmanBA , RazaNS , BiggarWD . Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy. Journal of Bone and Joint Surgery. American Volume2004;86‐A(3):519‐24. ">Alman 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort study (same cohort as <a href="./references#CD003725-bbs2-0020" title="BiggarWD , GingrasM , FehlingsDL , HarrisVA , SteeleCA . Deflazacort treatment of Duchenne muscular dystrophy. Journal of Pediatrics2001;138(1):45‐50. ">Biggar 2001</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (30 treated) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 to 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ Start: 0.9 mg/kg/day<br/> (gradual decrease in dose with age) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 (5 to 8) yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scoliosis &gt; 20° developed in 5/30 DFZ group versus 16/24 in non‐treated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptomatic stress fractures in 3/30 in DFZ group<br/> <br/> Cataracts in 33% of DFZ group </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0019" title="BalabanB , MatthewsDJ , ClaytonGH , CarryT . Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long‐term effect. American Journal of Physical Medicine and Rehabilitation2005;84(11):843‐50. ">Balaban 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 49<br/> <br/> 18 prednisone‐treated </p> <p>12 DFZ‐treated<br/> <br/> 19 no drug treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 to 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone starting dose: 0.75 mg/kg/day<br/> <br/> DFZ starting dose:<br/> 0.9 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroid therapy for &gt; 2 yrs before loss of ambulation<br/> <br/> Mean duration of treatment was 5.49 yrs and 5.85 yrs in prednisone and DFZ‐treated groups, respectively </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Similar benefit for walking in both prednisone and DFZ‐ treated groups, with approximate prolongation of walking of 2 yrs as compared to non‐treated control group<br/> <br/> Markedly decreased need for scoliosis surgery in DFZ and prednisone groups </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dose decrease required in prednisone group because of excessive weight gain<br/> <br/> <br/> DFZ dose decreased in 3 boys because of hypertension, behavioural changes and vertebral fracture </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0057" title="ScharaU , MortierJ , MortierW . Long‐term steroid therapy in Duchenne muscular dystrophy‐positive results versus side effects. Journal of Clinical Neuromuscular Disease2001;2(4):179‐83. ">Schara 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 DFZ‐treated boys</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 to 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ starting dose 0.9 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More than 2 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All DFZ‐treated boys were able to walk independently during the study period to a mean age of 13 yrs (range 9.4 to 18.11 yrs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fourteen of the 19 DFZ‐treated boys developed cataracts; one patient's progressive cataracts lead to implantation of lenses after 56 months into the treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0043" title="KingWM , RuttencutterR , NagarajaHN , MatkovicV , LandollJ , HoyleC . Orthopedic outcomes of long‐term daily dose corticosteroid treatment in Duchenne muscular dystrophy. Neurology2007;68(19):1607‐13. ">King 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 143<br/> <br/> 75 prednisone or DFZ‐treated boys<br/> <br/> 68 non‐treated (or briefly treated, and therefore considered appropriate as controls) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean 16.9<br/> (6 to 30 yrs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily dose prednisone or DFZ</p> <p>Average "steroid" dose at last clinic review 0.55 mg/kg/day (range 0.1 ‐ 0.78)</p> <p>Corticosteroid‐treated boys were given Ca carbonate 350 mg 3 times daily, or a calcium tablet with vit D (750 to 1200 mg) daily </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 8 yrs (+/‐5.2 yrs, range 0.5 to 18 yrs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treated boys walked 3.3 yrs longer than the untreated group</p> <p>Lower prevalence (31% versus 91%) and severity (Cobb angle 11˚ versus 33˚) in the corticosteroid‐treated as opposed to the non‐treated boys </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vertebral compression fractures reported in 32% of the treated group (none in the steroid‐naïve group) </p> <p>Long‐bone fractures were 2.6 times greater in corticosteroid‐treated patients</p> <p>Eight of the 75 treated boys discontinued corticosteroid treatment because of adverse effects. Another 2 boys stopped treatment as it was thought that the maximum benefit had been achieved </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0028" title="DaftaryAS , CrisantiM , KalraM , WongB , AminR . Effect of long‐term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics2007;119(2):e320‐4. ">Daftary 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective,<br/> case‐control study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 35<br/> <br/> 10 prednisone or DFZ‐ treated<br/> <br/> 25 non‐treated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 to 21 yrs in the treated group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.75 mg/kg/day and DFZ at 0.9 mg/kg/day, were the starting doses</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 yrs<br/> (range 1 yr to 14 yrs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRLS model suggested that the corticosteroid‐treated group had higher peak cough flow values (27 L/min higher than the non‐treated group (95% CI 2 to 52 L/min; P = 0.0328) </p> <p>Longitudinal effect on peak cough flow could not be assessed because of the study design </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0042" title="KinaliM , MainM , EliahooJ , MessinaS , KnightRK , LehovskyJ . Predictive factors for the development of scoliosis in Duchenne muscular dystrophy. European Journal of Paediatric Neurology2007;11(3):160‐6. ">Kinali 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective study analysing predictive factors for scoliosis in DMD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 123<br/> <br/> 37 prednisolone‐treated </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All boys 17 yrs or older at time of study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day, 10 consecutive days/month<br/> <br/> (Prednisolone started at mean age of 9.5 yrs (range 7.7 to 12.4) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median 1 yr (range 2 months to 9 yrs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a positive relationship between age at scoliosis onset (later) and duration (longer) of prednisolone treatment (r = 0.44, P = 0.01, n = 36)<br/> <br/> There was no relationship between severity of scoliosis at 17 yrs and duration of prednisolone treatment (P = 0.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0051" title="ParreiraSL , ResendeMB , Della Corte PedutoM , MarieSK , CarvalhoMS , ReedUC . Quantification of muscle strength and motor ability in patients with Duchenne muscular dystrophy on steroid therapy. Arquivos de Neuro‐Psiquiatria2007;65(2A):245‐50. ">Parreira 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective single (treated) cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age at start of treatment: 5 yrs 8 months to 8 yrs 8 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg/day in an intermittent course of 10 days on, 10 days off<br/> or<br/> DFZ 1 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Focus of the study was to select an assessment protocol which could be applied in outpatient settings<br/> <br/> 8 boys stopped walking during the study period<br/> <br/> Muscle strength MRC score decreased over time, but there was some functional improvement in lifting weights, 9‐metre walking time </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 withdrew from treatment and 2 took it irregularly</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0044" title="MarkhamLW , SpicerRL , KhouryPR , WongBL , MathewsKD , CripeLH . Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatric Cardiology2005;26(6):768‐71. [10.1007/s00246‐005‐0909‐4] ">Markham 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective review</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n = 111<br/> <br/> Prednisone‐treated n = 29<br/> <br/> DFZ‐treated n = 19 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 to 11 yrs<br/> <br/> Treated 11 ± 4 yr<br/> <br/> Non‐treated 12 ± 5 yr </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean length of treatment was 3 ± 2.5 yr</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Article focuses on cardiac outcome and presents cross‐sectional echocardiographic data<br/> <br/> The shortening fraction was lower in the non‐treated group than in the corticosteroid‐treated group (30% ± 7% vs 36% ± 5%; P &lt; 0.001)<br/> <br/> In comparison with the corticosteroid‐treated boys, the non‐treated boys older than 10 yrs were 15 times more likely to have a shortening fraction less than 28% (P &lt; 0.01) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0040" title="HoudeS , FiliatraultM , FournierA , DubéJ , D'ArcyS , BérubéD , et al. Deflazacort use in Duchenne muscular dystrophy: an 8‐year follow‐up. Pediatric Neurology2008;38(3):200‐6. ">Houde 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study (patients declining to take corticosteroid or used for less than 6 months formed the control group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 treated</p> <p>42 untreated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean 13.1 +/‐3.2 yrs treated group</p> <p>Mean 9.5 +/‐2.9 yrs untreated group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DFZ started at 0.9 mg/kg</p> <p>Adjusted according to evolution or side effects (max 1 mg/kg)</p> <p>Mean dose at most recent visit 0.69 +/‐ 0.22 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean treatment 66 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Walking prolonged:</p> <p>mean age loss of ambulation 11.5 years treated versus 9.6 yrs control</p> <p>Muscle strength improved:</p> <p>63% of normal in DFZ group versus 32% of normal in control group</p> <p>FVC improved:</p> <p>66% DFZ versus 48% control</p> <p>Cardiomyopathy reduced:</p> <p>present in 32% DFZ versus 58% control</p> <p>Scoliosis reduced:</p> <p>present in 27% DFZ versus 67% control (43% of whom required surgery)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All fractures:</p> <p>43% DFZ versus 26% control</p> <p>At least 1 limb fracture:</p> <p>24% DFZ versus 26% control</p> <p>Vertebral fractures:</p> <p>20% DFZ versus 0% control</p> <p>Decline in bone density:</p> <p>Z‐score ‐1.8 after 1 yr DFZ and ‐4.5 after 7 yrs</p> <p>Weight excess:</p> <p>62% DFZ versus 55% control</p> <p>Mean height gain:</p> <p>3 times as much in controls versus DFZ group</p> <p>Cataracts:</p> <p>developed in 49% of DFZ group (1 required surgery)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0039" title="HenricsonEK , AbreschRT , CnaanA , HuF , DuongT , ArrietaA , et al. CINRG Investigators. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle &amp; Nerve2013;48(1):55–67. ">Henricson 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort study over 12 months of 3 groups:</p> <p>GC‐naïve (treated &lt; 1 month total or never),</p> <p>current GC users,</p> <p>past GC users (treated in past for &gt; 1 month but not currently receiving GC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>340 total</p> <p>82 GC‐naïve</p> <p>210 current GC</p> <p>48 past GC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age range 2 to 28 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Assessments performed over a 12‐month period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Better upper and lower extremity function in current GC group versus GC‐naïve P &lt; 0.001 </p> <p>Better functional milestones in GC users versus GC‐naïve P = 0.0022</p> <p>No significant differences in MMT scores although rate of decline slower than compared with historical GC‐naïve controls </p> <p>Requirement for surgical spinal stabilisation reduced in GC group versus GC‐naïve between ages 13 to 15 yrs P = 0.013 </p> <p>Better FVC in GC‐treated versus GC‐ naïve in ages 10 to 15 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractures:</p> <p>no significant differences between groups</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0063" title="TakeuchiF , YonemotoN , NakamuraH , ShimizuR , KomakiH , Mori‐YoshimuraM , et al. Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients. Journal of Neurology2013;260(12):3023‐9. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study of prednisolone‐treated (current and past) versus steroid‐naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>553 total</p> <p>242 prednisolone‐treated, 311 steroid‐naïve</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age range &gt; 5 to &lt; 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone (no data on dose, regimen or duration)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Review of registry data compiled from July 2009 to June 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased age at loss of ambulation:</p> <p>steroid‐naïve median 10.1 yrs</p> <p>prednisolone‐treated 11.0 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not examined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0055" title="RicottiV , RidoutDA , ScottE , QuinlivanR , RobbSA , ManzurAY , et al. NorthStar Clinical Network. Long‐term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery &amp; Psychiatry2013;84(6):698‐705. ">Ricotti 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective longitudinal observational study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age range</p> <p>3 to 15 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Daily versus intermittent GC regimens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean duration of treatment 4 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased age at loss of ambulation for daily regimen:</p> <p>median 12 yrs intermittent versus 14.5 yrs daily</p> <p>Slower decline in NSAA score after age 7 for daily versus intermittent regimen</p> <p>No difference in respiratory or cardiac outcomes between groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cushingoid features: 33% daily versus 15% intermittent</p> <p>Hyperactivity: 23% daily versus 15% intermittent</p> <p>GI symptoms: 14% daily versus 6% intermittent</p> <p>Hypertension: 22% daily versus 5% intermittent</p> <p>Excessive weight gain in both groups but greatest increase in overall BMI and shorter heights seen in daily regimen </p> <p>Low bone mineral density z scores &lt; 2.5 in 8% daily versus 5% intermittent</p> <p>Vertebral fractures: 8% daily versus 4% intermittent</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>BMI: body mass index; Ca: calcium; CI: confidence interval; DEXA: dual energy x‐ray absorptiometry; DFZ: deflazacort; FVC: forced vital capacity; GC: glucocorticosteroid; GI: gastrointestinal; IRLS: iteratively reweighted least squares; MMT: manual muscle testing; MRC: Medical Research Council; NSAA: North Star Ambulatory Assessment; SD: standard deviation; vit D: vitamin D; yr: year; </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Excluded non‐randomised studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/full#CD003725-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003725-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Corticosteroids versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Change in MRC index (%) after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MRC ‐ Average muscle score after 6 months of treatment ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 0.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.17, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.33, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.23, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in MRC index (%) after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Lower limb muscle strength grade after 6 months of treatment ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Hip flexion (right)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Knee extension (right)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Lower limb muscle strength grade after 12 months of treatment ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Hip flexion (right)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.74, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Knee extension (right)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.71, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Time taken to rise from floor after 6 months of treatment ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 0.75 mg/kg for 1st 10 days every month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.08 [‐2.51, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 0.3 mg/kg/ daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.59 [‐3.75, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 0.75 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.28 [‐3.12, ‐1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 1.5 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.74 [‐3.98, ‐1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in time taken to rise from floor after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Time taken to rise from floor after 12 months of treatment (daily prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Change in time taken to rise from floor after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 9‐metre walking/running time after 6 months of treatment ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 0.75 mg/kg for 1st 10 days every month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.68 [‐1.15, ‐0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 0.3 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.18 [‐2.65, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 0.75 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.73 [‐3.97, ‐1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 1.5 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.64 [‐4.45, ‐0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Timed walk (assumed in seconds) ‐ after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 10‐metre walking time 6 months post‐treatment (daily prednisone 0.75 mg/kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 10‐metre walk time 1 year post‐treatment (daily prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Timed walk (assumed in seconds) ‐ after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Lifting weight (kg) after 6 months of treatment ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 0.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.13, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.50, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.52, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Four‐stair climbing time after 6 months of treatment ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 0.75 mg/kg for 1st 10 days every month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.93 [‐3.56, ‐0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 0.3 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.68 [‐4.06, ‐1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 0.75 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.09 [‐4.33, ‐1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.4 1.5 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.05 [‐4.41, ‐1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Timed function: stair climb after 6 months of treatment ‐ deflazacort 2 mg/kg alternate days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Four‐stair climbing time after 12 months of treatment (daily prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Change in timed stair climb after 24 months of treatment ‐ deflazacort 2 mg/kg alternate days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Dynamometry ‐ total muscle force after 6 months of treatment ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Leg function grade after 6 months of treatment ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 0.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.79, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.73, ‐0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.93, ‐0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Forced vital capacity after 6 months of treatment ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 0.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [0.05, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.10, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.3 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.05, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Quality of life after six months of treatment (daily prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Child self report</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 Parent proxy‐report</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Quality of life after 12 months of treatment (daily prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Child self report</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.2 Parent proxy‐report</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Mean % weight gain ‐ prednisone ‐ daily dose regimen <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 0.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.21 [0.76, 7.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.2 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.27 [6.87, 11.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.3 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.78 [5.46, 12.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Weight gain ‐ prednisone ‐ intermittent, given 1st 10 days every month <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Mean % weight gain ‐ deflazacort 2 mg/kg alternate days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Body weight at 6 months (prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Body weight at 12 months (prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 BMI at 6 months (daily prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 BMI at 12 months (daily prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 Excessive hair growth ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 0.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.18, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.2 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [1.47, 4.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.3 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.32 [1.16, 4.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Behavioural changes ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 0.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.67, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.94, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.3 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.92, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 Cushingoid appearance ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 0.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.60, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.2 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [1.53, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.3 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.36 [2.04, 9.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Acne ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 0.3 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.18, 3.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.2 0.75 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [0.96, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.3 1.5 mg/kg/day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [0.84, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Increased appetite ‐ prednisone <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 0.3 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.2 0.75 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Height at 6 months (daily prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Height at 12 months (daily prednisone 0.75 mg/kg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Corticosteroids versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003725-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Weekend‐only versus daily prednisone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Muscle strength (change from baseline to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 MMT score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 QMT arm score, lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 QMT leg score, lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 QMT elbow flexors, lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 QMT elbow extensors, lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 QMT knee flexors, lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 QMT knee extensors, lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 QMT grip score, lb</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Functional outcome measures (change from baseline to 12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Time taken to rise from the floor (Gowers' time) (log seconds)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 10‐metre walking time (log seconds)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Four‐stair climb (log seconds)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in mobility function (lower extremity score ‐ Vignos) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change in mobility function (upper extremity score ‐ Brooke) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 FVC % predicted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 FEV1 % predicted <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Maximal inspiratory pressure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Maximal voluntary ventilation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Weight (BMI kg/m2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Child Behavior Checklist: total problems (higher = more severe) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Child Behavior Checklist: internalising <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Child Behavior Checklist: externalising <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Child Behavior Checklist: anxious/depressed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Child Behavior Checklist: somatic complaints <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Child Behavior Checklist: withdrawn/depressed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Child Behavior Checklist: attention problems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Child Behavior Checklist: aggressive behaviour <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Osteoporosis: lumbar spine Z scores (DEXA) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Height (m) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Mean growth in cm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Weekend‐only versus daily prednisone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003725-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Deflazacort versus prednisone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Weight gain (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 At 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.52 [‐14.91, ‐4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events at six months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Cushingoid appearance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Appetite increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Behavioural changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Gastric symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Hirsutism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events at 1 year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Cushingoid appearance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Appetite increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Behavioural changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Gastric symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Hirsutism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Deflazacort versus prednisone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003725-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded randomised studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Regimen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0034" title="FenichelGM , MendellJR , MoxleyRT , GriggsRC , BrookeMH , MillerJP . A comparison of daily and alternate‐day prednisone therapy in the treatment of Duchenne muscular dystrophy. Archives of Neurology1991;48(6):575‐9. ">Fenichel 1991a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 1.25 mg/kg/alternate day<br/> Prednisone 2.5 mg/kg alternate day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improved at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Similar adverse events on daily and alternate day regimens</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0037" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology1993;43(3 Pt 1):520‐7. ">Griggs 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.75 mg/kg/day<br/> Azathiaoprine 2.5 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months<br/> 12 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Strength and function improved</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No additional benefit of<br/> azathioprine </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0052" title="PradhanS , GhoshD , SrivastavaNK , KumarA , MittalB , PandeyCM , et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. Journal of Neurology2006;253(10):1309‐16. [DOI 10.1007/s00415‐006‐0212‐1] ">Pradhan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open controlled study with participants randomised in 2:1 proportion, to prednisolone (+ multivitamins) treatment group or control (multivitamins only)<br/> <br/> Note: Data from only a subgroup (15/44) of participants in the prednisolone‐treated group who did not drop out because of adverse effects and improved, were used for comparison with the control group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> <br/> (44 in prednisolone treatment group)<br/> <br/> <br/> <br/> (23 in control group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ages 8.8 and 8.1 yrs in prednisolone and control groups, respectively</p> <p>Participants were enrolled into the study when they had started falling several times during the day and had appreciable difficulty in rising from the floor (Gowers' sign time of more than 10 seconds) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 yrs or longer until completely wheelchair‐dependent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of the 44 participants in the prednisolone treatment group, 24 dropped out because of adverse effects and treatment was stopped in a further 5 participants because of no improvement in power. Of the remaining 19, only 15 participants in the treatment group could be followed up regularly for 2 yrs and then up to wheelchair‐dependent stage; data from only these 15 participants was used for comparison with the control group<br/> <br/> In this subgroup of 15 participants from the prednisolone group, the mean age of becoming wheelchair‐dependent was 169 ± 9 months compared to 132 ± 8 months in the control group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 of the 44 patients in the prednisolone group dropped out because of adverse effects; 14 dropped out because of excessive weight gain, 12 within the 3 months of starting treatment; 4 dropped out because of tuberculosis and 2 because of recurrent infections </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0053" title="ReitterB . Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain &amp; Development1995;17 Suppl:39‐43. ">Reitter 1995</a> <br/> (Data reported in <a href="./references#CD003725-bbs2-0094" title="DubowitzV . 75th European Neuromuscular Centre International workshop: 2nd workshop on the treatment of muscular dystrophy, 10‐12 December, 1999, Naarden, The Netherlands. Neuromuscular Disorders2000;10(4‐5):313‐20. ">Dubowitz 2000</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 until ambulant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.75 mg/kg/day<br/> DFZ 0.9 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Muscle function stabilised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excessive weight gain in prednisolone group; cataracts in 27% of DFZ group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0065" title="VasanthA , Gourie‐DeviM , RajaramP , TalyAB , VenkataramBS , RavishankarD , et al. Duchenne muscular dystrophy: therapeutic options and rehabilitation. European Journal of Neurology1996;3(Suppl 2):20. ">Vasanth 1996</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT of prednisone, ayurvedic drug and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone<br/> 1 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stability in prednisone group; deterioration in the other two groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"mild weight gain" in prednisolone group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0065" title="VasanthA , Gourie‐DeviM , RajaramP , TalyAB , VenkataramBS , RavishankarD , et al. Duchenne muscular dystrophy: therapeutic options and rehabilitation. European Journal of Neurology1996;3(Suppl 2):20. ">Vasanth 1996</a> <br/> (unpublished data provided by Dr AB Taly National Institure of Mental Health &amp; NeuroSciences, Bangalore) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised, non‐blinded trial comparing prednisone with a combination of ayurvedic drugs (participants who had been given placebo in the initial part of the study, were put on ayurvedic drug treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128<br/> <br/> (32 on prednisone treatment, and 96 on ayurvedic drug treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone<br/> 1 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 yrs<br/> <br/> (2‐yr follow‐up data available for only 18/32 participants in the prednisone group and 29/96 in the ayurvedic treatment group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Strength and function not statistically different in the 2 groups at 2 yrs</p> <p>Of the boys who lost walking ability, mean age of loss of ambulation in 13 boys in the prednisone group was 11.88 (SD 2.7) yrs and 10.97 (SD 2.2) yrs in the 42 boys in the ayurvedic treatment group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Most children had weight gain and developed striae"</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>DFZ: deflazacort: RCT: randomised controlled trial; SD: standard deviation; yr: year</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded randomised studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003725-tbl-0008"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded randomised studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>No. of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Regimen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Treatment period</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0034" title="FenichelGM , MendellJR , MoxleyRT , GriggsRC , BrookeMH , MillerJP . A comparison of daily and alternate‐day prednisone therapy in the treatment of Duchenne muscular dystrophy. Archives of Neurology1991;48(6):575‐9. ">Fenichel 1991a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 1.25 mg/kg/alternate day<br/> Prednisone 2.5 mg/kg alternate day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Improved at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Similar adverse events on daily and alternate day regimens</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0037" title="GriggsRC , MoxleyRT3rd , MendellJR , FenichelGM , BrookeMH , PestronkA , et al. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology1993;43(3 Pt 1):520‐7. ">Griggs 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 to 15 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.75 mg/kg/day<br/> Azathiaoprine 2.5 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 months<br/> 12 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Strength and function improved</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No additional benefit of<br/> azathioprine </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0052" title="PradhanS , GhoshD , SrivastavaNK , KumarA , MittalB , PandeyCM , et al. Prednisolone in Duchenne muscular dystrophy with imminent loss of ambulation. Journal of Neurology2006;253(10):1309‐16. [DOI 10.1007/s00415‐006‐0212‐1] ">Pradhan 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Open controlled study with participants randomised in 2:1 proportion, to prednisolone (+ multivitamins) treatment group or control (multivitamins only)<br/> <br/> Note: Data from only a subgroup (15/44) of participants in the prednisolone‐treated group who did not drop out because of adverse effects and improved, were used for comparison with the control group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> <br/> (44 in prednisolone treatment group)<br/> <br/> <br/> <br/> (23 in control group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ages 8.8 and 8.1 yrs in prednisolone and control groups, respectively</p> <p>Participants were enrolled into the study when they had started falling several times during the day and had appreciable difficulty in rising from the floor (Gowers' sign time of more than 10 seconds) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisolone 0.75 mg/kg daily</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 yrs or longer until completely wheelchair‐dependent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Of the 44 participants in the prednisolone treatment group, 24 dropped out because of adverse effects and treatment was stopped in a further 5 participants because of no improvement in power. Of the remaining 19, only 15 participants in the treatment group could be followed up regularly for 2 yrs and then up to wheelchair‐dependent stage; data from only these 15 participants was used for comparison with the control group<br/> <br/> In this subgroup of 15 participants from the prednisolone group, the mean age of becoming wheelchair‐dependent was 169 ± 9 months compared to 132 ± 8 months in the control group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 of the 44 patients in the prednisolone group dropped out because of adverse effects; 14 dropped out because of excessive weight gain, 12 within the 3 months of starting treatment; 4 dropped out because of tuberculosis and 2 because of recurrent infections </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0053" title="ReitterB . Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. Brain &amp; Development1995;17 Suppl:39‐43. ">Reitter 1995</a> <br/> (Data reported in <a href="./references#CD003725-bbs2-0094" title="DubowitzV . 75th European Neuromuscular Centre International workshop: 2nd workshop on the treatment of muscular dystrophy, 10‐12 December, 1999, Naarden, The Netherlands. Neuromuscular Disorders2000;10(4‐5):313‐20. ">Dubowitz 2000</a>) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 until ambulant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone 0.75 mg/kg/day<br/> DFZ 0.9 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 yrs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Muscle function stabilised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excessive weight gain in prednisolone group; cataracts in 27% of DFZ group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0065" title="VasanthA , Gourie‐DeviM , RajaramP , TalyAB , VenkataramBS , RavishankarD , et al. Duchenne muscular dystrophy: therapeutic options and rehabilitation. European Journal of Neurology1996;3(Suppl 2):20. ">Vasanth 1996</a> <br/> (published as abstract only) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT of prednisone, ayurvedic drug and placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone<br/> 1 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stability in prednisone group; deterioration in the other two groups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"mild weight gain" in prednisolone group</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD003725-bbs2-0065" title="VasanthA , Gourie‐DeviM , RajaramP , TalyAB , VenkataramBS , RavishankarD , et al. Duchenne muscular dystrophy: therapeutic options and rehabilitation. European Journal of Neurology1996;3(Suppl 2):20. ">Vasanth 1996</a> <br/> (unpublished data provided by Dr AB Taly National Institure of Mental Health &amp; NeuroSciences, Bangalore) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised, non‐blinded trial comparing prednisone with a combination of ayurvedic drugs (participants who had been given placebo in the initial part of the study, were put on ayurvedic drug treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128<br/> <br/> (32 on prednisone treatment, and 96 on ayurvedic drug treatment) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prednisone<br/> 1 mg/kg/day </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 yrs<br/> <br/> (2‐yr follow‐up data available for only 18/32 participants in the prednisone group and 29/96 in the ayurvedic treatment group) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Strength and function not statistically different in the 2 groups at 2 yrs</p> <p>Of the boys who lost walking ability, mean age of loss of ambulation in 13 boys in the prednisone group was 11.88 (SD 2.7) yrs and 10.97 (SD 2.2) yrs in the 42 boys in the ayurvedic treatment group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Most children had weight gain and developed striae"</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>DFZ: deflazacort: RCT: randomised controlled trial; SD: standard deviation; yr: year</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Excluded randomised studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003725.pub4/references#CD003725-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003725.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003725-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003725-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD003725-note-0001">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD003725-note-0011">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003725\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003725\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003725\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003725\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003725\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003725.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003725.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003725.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003725.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003725.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715302421"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003725.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715302425"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003725.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d83c6cbaef446',t:'MTc0MDcxNTMwMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 